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Abstract
URATE GENETIC ASSESSMENT IN ASIAN AND PACIFIC ISLANDER
SUBGROUPS OF PREGNANT WOMEN: IMPLICATIONS FOR PERSONALIZED
MEDICINE AND MEANS TO REDUCE HEALTH DISPARITIES
By Ali Yaseen Alghubayshi
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science, Pharmacotherapy and Outcomes Science at Virginia Commonwealth
University
Virginia Commonwealth University, 2021
Major Director: Youssef Roman
Pharm.D., Ph.D., Pharmacotherapy and Outcomes Science
Background
Gout is one of the most common rheumatological conditions and appears to have a
higher prevalence in certain populations Risk factors for gout and its precursor,
hyperuricemia, are also significant risk factors for preeclampsia, a major pregnancyrelated morbidity. We hypothesized that uric acid (UA) allele frequencies are associated
with certain populations and the development of preeclampsia. This project aimed to
assess UA risk allele frequencies across a diverse cohort of pregnant individuals and to
determine if UA risk allele are associated with risk factors for preeclampsia.
Methods
A retrospective cross-sectional study was conducted on pregnant women from different
ethnicities who 100% reported their ethnicities from the Asian Pacific Islander
population. Numerous UA genes and clinical conditions were addressed, and all study
details were reviewed and exempted by the University of Hawaii human Studies
Program (Protocol Number: 2018-00225). The biospecimens repository at the
University of Hawaii provided DNA samples, medical information, and demographic
data on study participants. These samples were collected after receiving written consent.
DNA was extracted from cord blood samples, and genotyping was performed at the
Cancer Center's Genomics and Bioinformatics Shared Resource (Honolulu, HI).
ix

Our primary outcome was to assess the frequencies of the eight UA risk alleles provided
by the biospecimens repository across the Asian, Native Hawaiian, and Pacific Islander
populations compared to European (EUR) ancestry. All UA risk alleles and genotypes
for EUR were estimated from the Ensembl genome browser. Our secondary outcome
was to assess the role of both UA risk alleles and other factors involving age/BMI
contributing to CMDs in Filipino and Samoan subgroups. We estimated the proportion
of UA genotype in the presence and absence of the CMDs. Moreover, we tested for
association between CMDs and both age and BMI. Finally, we compared mean BMI
among different UA genotypes across the Filipino and Samoan populations.
Results
In this study, 1059 pregnant women aged 18 or older self-reported their race and
ethnicity, including Asian, Native Hawaiian, and Pacific Islander populations. The UA
risk alleles frequencies amongst our participants differed from EUR. Compared to EUR,
8/8 UA risk alleles were found in Japanese, 6/8 in Korean, 6/8 in Filipino, 8/8 in
Samoan, 6/8 in Hawaiian, and 6/8 in Marshallese. The HU/gout risk alleles indices were
8, 5, 6, 5, 4, and 4 in Japanese, Koreans, Filipinos, Samoans, Marshallese, and
Hawaiians, respectively. Out of the eight SNPs, the risk alleles associated with HU/gout
in Japanese and Filipino were 100%, followed by 83.5% in Korean. In addition, we
found alleles at the ABCG2 gene to be associated with increased risk of diabetes
mellitus in the Filipino population under both additive and recessive genetic models, p
<0.05. Under the recessive genetic model, we found that SLC22A11 alleles were
trending towards a significant association with the development of chronic hypertension
(p=0.085) and gestational diabetes mellitus (p=0.063) in the Samoan subgroup.
Using logistic regression analysis. we found both age and BMI were associated with
increased risk of chronic hypertension across the Filipino subgroup (OR= 1.06, 95%
x

CI= 0.99- 1.13, p= 0.06 (BMI), and (OR= 1.11, 95% CI= 1.02- 1.22, p=0.013 (Age)).
Moreover, age factor was associated with gestational diabetes mellitus development
across the Samoan population (OR=1.15, 95% CI 1.06- 1.25, p=0.0006). Finally,
ANOVA test showed lower mean BMI in both Filipino and Samoan subjects carrying
risk genotypes compared to wild-type genotype.
Conclusion
Our study found that Asian pregnant women had a higher prevalence of UA risk alleles
compared to the EUR population. The Asian population is at high risk of
cardiometabolic disorder prevalence, and we found UA risk alleles may be associated
with developing CMDs across the Asian population. This is the first study of its type to
look at the genetics of uric acid in ethnicities who are underrepresented in studies. This
research is considered the first report to estimate the UA risk allele and nongenetic
factors (age and BMI) and their role in CMDs across different ethnicities. We
recommend that further studies be conducted on large sample sizes and in different
locations to validate our findings.
Keywords: Gout, Hyperuricemia, Uric acid, Cardiometabolic diseases, Single nucleotide
polymorphisms, European ancestry, Asian, Native Hawaiian, Pacific Islander,
Pregnancy
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Chapter 1: Introduction of hyperuricemia and gout disease
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Hyperuricemia and Gout definitions
Gout is an inflammatory arthritic condition characterized by precipitation of
monosodium urate (MSU) crystals in or around joints due to chronic elevation of serum urate
(SU), exceeding saturation point.1 Several factors could lead to gout, including both genetic
and non-genetic risk factors.2 Hyperuricemia (HU) resulted due to excessive production or
under excretion of uric acid.3 Genetic, comorbidities and environmental factors are major
contributors to HU 4, which is defined as serum uric acid levels of more than 7 mg/dl in men
and 6 mg/dl in women (Table 1.1).1
Epidemiology of hyperuricemia and gout
Gout is one of the most frequent inflammatory arthritis. It is critical to evaluate its
prevalence patterns in order to prepare for adequate health care resources. Unfortunately,
epidemiologic data is limited, variable, and without a standard approach to diagnosis. A
systematic review that aimed to collect data from different regions around the world to
estimate the differentiation in gout prevalence and incidence reported that the data indicating
gout distribution globally is unclear due to the lack of standardized methods used to diagnose
gout in developed and developing countries.5
The prevalence and incidence of gout and hyperuricemia are more common in
developed rather than developing countries. The prevalence of gout has remained high since
ancient times, but it has more than doubled over the last 20 years.6,7 Globally, reports
indicate that the prevalence of gout ranges from 0.1% to about 10%, with an incidence rate
ranging from 0.3 to 6 cases per 1,000 person-years.5
On the one hand, the prevalence of gout in developed countries estimated >1% in countries
like North America and Europe. Furthermore, Europe, Greece has the highest gout
prevalence of about 4.75% among the adult community8, whereas in Portugal (about 0.3%)
among adults.9 A previously published survey reported that the Japanese and South Korean
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populations had the lowest incidence of gout, which is 0.51% (2003) and 0.4% (2008),
respectively, using the health insurance database. Moreover, Taiwan, Hong Kong, and
Singapore reported a much higher prevalence of gout. The Hong Kong population aged 45–
59 was shown to have a 5.1% prevalence, while those older than 60 years had a gout
prevalence of 6.1%. In Singapore and Taiwan, the prevalence was reported as 4.1% and
4.92%, respectively, in 2004.5 Other study has reported that gout incidence in South Korea
increased by 25% between 2009 and 2015.10
In the USA, the National Health and Nutrition Examination Survey (NHANES) from
2015 to 2016, combined with data from 5467 subjects consisting of both men and women in
the United States (US), has reported that the gout prevalence is approximately 3.9% among
the US adult population, affecting roughly 9.2 million persons, with men having a higher
gout prevalence rate than women [5.2% (5.9 million) versus 2.7% (3.3 million)].11 In
addition, the means that serum urate levels were 6.0 mg/dl in men and 4.8 mg/dl in women.
Hence, the prevalence of hyperuricemia was 20.2% and 20.0% in men and women,
respectively (Table 1.2).11
On the other hand, a community-oriented program for the control of rheumatic diseases
(COPCORD) survey was conducted among 15 developing countries to estimate the
prevalence of gout. The prevalence of gout in Central and South America was low, with a
rate of 0.3% to 0.4% in Mexico, Cuba, and Venezuela 12,13, compared with Asian countries
such as Indonesia, which had a gout prevalence of 1.7%, and Kuwait, which had a gout
prevalence of 0.8%, while other Asian countries reported gout prevalence of less than 0.5%.5
A limited diagnosis tool or absence of gout flare symptoms impact the gout disease
reports. For instance, asymptomatic hyperuricemia is common in some countries but goes
undiagnosed. Aside from this, a study conducted in Saudi Arabia which interviewed 487
Saudi participants in 14 primary care clinics in Riyadh over seven months from September
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1998 to March 1999 indicated that up to 8.2% of people (males and females) had high SU,
but none of them had symptoms of gout.14 Thus, it is clear that the prevalence of gout is
highest in developed countries, whereas data is lacking for some parts of the developing
world, particularly Africa and South America.15
In summary, gout prevalence varies globally, with the highest prevalence reported in
Oceanic countries, particularly in indigenous and South Pacific Island populations, and the
lowest prevalence in the developing world. In addition to the previously reported increasing
prevalence of gout in Europe and the USA, there is evidence of increasing prevalence in
Australia (self-reported), Canada, China, and South Korea.15

Pathophysiology of Gout
Physiologically, HU occurs via increased catabolism of purine substances or under
excretion of UA from the body. These mechanisms could result from different circumstances,
as motioned before16 Purine production could occur through endogenous or exogenous
pathways. Nucleic acid degradation, known as the endogenous process, HU could also occur
by exogenous due to numerous factors, which eventually convert to uric acid.17
Physiologically, enzymes dysfunction, mainly those responsible for the balance of
endogenous purine production, could cause increased activity of 5’-ribosyl-1’-pyrophosphate
(PRPP) synthetase and a decrease in hypoxanthine phosphor-ribosyltransferase enzyme
(HPRT). Hence, these enzyme defects may result in excessive purine production.18 In
addition, several clinical conditions, including rhabdomyolysis, hemolysis, and tumor lysis
syndrome, are prime examples of cell turnover and significant purine sources, which
eventually lead to increased urate production.3
Once purine is converted to UA and exceeds the normal range, that leads to the
formation of monosodium urate (MSU) crystals that precipitate in the synovial fluid and soft

4

tissues, causing signs and symptoms of acute gout flares.11 MSU deposits trigger the
inflammatory pathways through the activation of macrophages, which have a role in releasing
inflammatory cytokines, such as interleukin (IL-1β). This chemical release leads to the onset
of acute gout flare that is characterized by erythema, swelling, and severe pain, in addition to
neutrophil-activated proinflammatory mediators, such as arachidonic acid, prostaglandins
(PGE), leukotriene (LTB), and NLRR3 inflammasome. NLRR3 is an innate immune system
component that may trigger a range of cellular damage and the release of proinflammatory
cytokines such as IL-1B/IL-18.19 (Figure 1.1)20
The renal system eliminates two-thirds of uric acid generated in the body and the gut
excretes the remaining one-third. Thus, changes in renal function may impact uric acid
removal from the body through increased absorption or decreased excretion.3 On the other
hand, impairment of kidney function is not always the main reason for uric acid under
excretion. Uric acid under excretion may be due to genetic defects or variations in renal uric
acid transporter genes, such as the ATP binding cassette subfamily G (ABCG2), glucose
transporter 9 (SLC2A9), and others.21
Genetics of hyperuricemia and gout
The interaction between genetic variants and environmental factors can explain the
development of hyperuricemia and its progression to gout. Urate heritability has been
estimated to be between 45% and 73%.22 One of the largest genome-wide association studies
(GWAS) conducted in over 110,000 people of European and other ancestries discovered 28
loci associated with urate.23 These loci are dominated by genes encoding the uric acid
transporters in the kidney and the gastrointestinal system (SLC2A9/GLUT9, ABCG2,
SLC22A11/OAT4, SLC22A12/URAT1, SLC17A1/NPT1, and the scaffolding protein gene
PDZK1).22 (Figure 1.2)24
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Several genes were reported to influence the excretion or reabsorption of uric acid.25 For
example, the ATP-binding cassette transporter is located in the apical membrane in the renal
proximal tubule and is responsible for urate excretion. ABCG2 is a gene transporter for UA in
the proximal tubular cells of the kidney and the gastrointestinal (GI) tract. The ABCG2 gene
encodes an ATP transporter, so the presence of polymorphisms may cause clinical
consequences, either a higher or lower risk of HU/gout. The ABCG2 gene possesses a high
capacity and affinity for uric acid excretion and is expressed in different tissues, including the
kidneys, intestines, and liver. Therefore, this gene’s polymorphism could lead to decreased
urate excretion 26 and an inadequate response to medication, such as the urate-lowering
therapy allopurinol.27
A meta-analysis conducted in Aotearoa, New Zealand, demonstrated that a
particular ABCG2 gene, rs2231142 polymorphism, is associated with the adequate response
levels of allopurinol. The missenses variant of ABCG2 141K could increase allopurinol
concentration in the kidney tubules and decrease concentration in the tubular fluid. This can
result in reduced or inhibited SU excretion from the kidneys, causing inadequate allopurinol
response. 27 Another example is the SLC2A9 (GLUT9) gene, which has a high-affinity urate
transporter. It has a role in SU re-absorption and might lead to renal hypouricemia due to loss
of function.28’29 Meanwhile, genetic polymorphisms of some genes, such as inhibin beta C
(INHBC), a transforming growth factor (TGF)-β gene product in the super-family of proteins,
could lead to an increase in the risk for gout flares through numerous cellular processes.30
SLC17A1 and SLC17A3 transportome genes are involved in the urate transporter and
located in the apical side of the kidneys. Other genes involved in regulating SU include the
SLC22A11, GCKR, LRRC16A, and PDZK1 genes.31’32 The prevalence of hyperuricemia and
gout across a given population is also associated with race and ethnicity. These differences
may make some ethnicities more susceptible to the diseases, gout in particular, than others.
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For example, African-American (AA) groups have more gout risk compared to their
European counterparts (EUR).33 Asian populations, including Japanese and Han-Chinese, are
also at high risk of gout relative to EUR ancestry.34 This research confirms that the
prevalence of hyperuricemia and gout among people varies across different populations.
Moreover, several risk factors could be both genetic and non-genetic in regard to an
individual’s susceptibility to HU/gout development as previously mentioned. Genetically
many single nucleotide polymorphisms (SNPs) in genes involved in uric acid regulation play
an important role in distinguishing the frequency and incidence of gout amongst ethnic
groups. According to a study conducted in 2014 by Sakiyama et al. in which the ethnic
differences of polymorphism of the ABCG2 gene among three populations were examined, it
was shown that differences with respect to ABCG2 rs2231142 polymorphism, which causes
variations in uric acid regulation and drug response, do exist among three ethnicities, namely
Japanese, Caucasian, and African-American.35

Risk factors of hyperuricemia and gout
Several risk factors are associated with developing HU/gout, and these factors are
classified into modifiable and non-modifiable factors.36 Non-modifiable risk factors include
age, sex, race, and genetic polymorphisms in the UA transportome. In contrast, lifestyle and
some dietary habits involve alcohol consumption, purine-rich foods, fructose/sugarsweetened beverages, and other dietary aspects, which contribute to an increase in the risk of
HU/gout. These factors can be avoided to reduce the risk of HU/ gout development.
Depending on gender, men are generally at a higher risk of gout than women of all ages. The
main reason for the difference in uric acid levels between men and women is the uricosuric
action of the estrogen hormone, which helps enhance uric acid excretion in females.
However, the risk of gout increases in postmenopausal women, which could be mitigated by
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using hormone replacement therapy.37,38 The biological function of organs such as kidneys
declines with increased age, suggesting that age could be a risk factor in the development of
HU/gout since two-thirds of SU is eliminated by the renal system.39
Genetic risk factors constitute a large part of developing hyperuricemia and gout either
through rare monogenic disorders or urate transporter polymorphisms. Lesch-Nyhan
Syndrome is an example of a monogenic disease caused by the deficiency of HPRT, which
may result in HU with hyperuricosuria.18 So far, genome-wide association studies (GWAS)
have reported many UA genes related to HU/gout development. These studies were
performed amongst different populations, and specifically targeted UA genes such as
ABCG2, SLC2A9, and SLC22A12. The loss of function of these genes may lead to a higher or
lower risk of gout. For example, among multiple populations, including White, African, and
Asian groups, a significant association was found between rs2231142 SNP and increased SU
(due to a 53% reduction in ABCG2 function), resulting in a decrease in uric acid efflux.4
Other types of risk factors that have been identified as having the potential to induce
HU/gout include alcohol consumption, protein/purine-rich food, and beverages containing
fructose/sugar, as well as other lifestyle choices. Consuming a high amount of alcohol is
associated with an increased risk of HU/gout due to the ethanol catabolism mechanism.
Ethanol catabolism leads to purine degradation, resulting in the formation of lactic acidosis,
which affects renal UA excretion.40 Diets including a high amount of purine, such as seafood,
red meat, and foods with high carbohydrate levels have also been linked with the increased
incidences of HU/gout.41
Additionally, current studies have found a strong relationship between fructose intake
and ongoing hyperuricemia and gout. In a study conducted by Martin Underwood in 2008, it
was shown that “consuming two servings a day of any sugar-sweetened soft drink will
increase the risk of developing gout by 85%” (relative risk 1.85, 95% confidence interval [CI]
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1.08–3.16).42 Consumption of high-fructose corn syrup could increase the risk of gout
through elevated uric acid production by a prompted breakdown of ATP.43 Additionally,
obesity, in which the body mass index registers 30 kg/m2 or more, could interact with other
factors, causing an increase in the possibility of the incidence of gout44, whereas consuming
low-fat dairy products, coffee, and vitamin C supplements might be beneficial for minimizing
the risk of gout.45’44
Comorbidities diseases and gout
The relationship between gout and comorbidities, such as cardiovascular conditions,
renal impairment, and metabolic syndrome, may be exacerbated by high uric acid levels.46
Since the late 19th century, cardiovascular disease (CVD) has been recognized as one of the
several chronic disorders that may appear as part of diseases associated with HU. However,
this relationship is still the subject of debate, although the risk of CVD development has been
shown to increase among patients with serum uric acid levels of more than 6 mg/dl.47,48
Physiologically, HU could increase the production of reactive oxygen species (ROS), which
then leads to a decrease in nitric oxide (NO) bioavailability. Decreasing the NO may lead to
endothelial dysfunction, causing vasoconstriction and cardiac dysfunction. Likewise,
decreasing NO activates the renin-angiotensin system (RAS), which may increase the
possibility of cardiovascular damage.49 Moreover, gout was shown to be strongly correlated
with a risk of chronic kidney disease (CKD) up to three-fold in older people aged 65–74
years with a hazard ratio (HR) of 3.05 (95% CI 2.99–3.10).50 HU may contribute to
decreasing kidney function by activation of the nucleotide-binding domain, leucine-rich
repeat (NALP3) inflammasome, which leads to stimulation of interleukin (IL)-1β and IL-18
and other pro-inflammatory cytokines and contributes to CKD progression.49
High uric acid levels contribute to hyperinsulinemia and insulin resistance (IR) via
stimulation of mitochondrial oxidative stress, which plays an essential role in causing a
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decrease in insulin signaling. Moreover, HU inhibits signaling enzymes, such as protein
kinase B (AKT) and adenosine monophosphate (AMP), activated protein kinase (AMPK)
phosphorylation that influences the glucose metabolic pathway. The inhibition
phosphorylation of these enzymes might result in decreased hepatic glucose production,
ultimately causing IR.52 IR can lead to other complications, such as type 2 diabetes (T2DM),
which is recognized as one of the most common clinical syndromes due to the development
of impaired insulin-mediated glucose transport 4 (GLUT4).53 Other metabolic syndrome
subsets, such as dyslipidemia and hypertension, could occur, causing an increased risk of
cardiovascular disease risks.54 (Figure 1.3)55
These biological observations beg the question of whether urate-lowering therapy (ULT)
in patients that have hyperuricemia could assist in improving metabolic syndrome and
increasing insulin sensitivity. A few studies reported that ULT could support a reduction in
IR, hence patients who have already used benzbromarone have a significantly lower risk of
developing diabetes than other hyperuricemia patients, as shown by data from the Taiwan
National Health Insurance Program (HR = 0.86; 95% CI 0.79–0.94).56 A more recent analysis
of a US cohort heavily enriched for stroke found that hyperuricemia was associated with
stroke (HR 1.42, 95% CI 1.12-1.80), but this association seemed primarily mediated by the
effect of treatment-resistant hypertension (full adjustment HR 1.17, 95% CI 0.87-1.56).57
Other reported gout associations with co-morbidities, including macular degeneration58,
erectile dysfunction59, atrial fibrillation60, and thrombo-embolism61, are an attestation to the
complexities that rheumatologists and other providers caring for gout have to consider when
making treatment decisions (Table 1.3)62
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Medication-induced hyperuricemia
HU could occur as a result of a particular medication's side effects. Many
pharmacological classes have been reported as being associated with inducing HU. For
instance, diuretics, anti-tubercular drugs, immunosuppressant agents, nicotinic acid, low-dose
aspirin, cytotoxic chemotherapy, non-glucose carbohydrate, lactate infusion, and testosterone
can all promote uric acid production or inhibit uric acid excretion.63
Diuretics are commonly prescribed medications that improve outcomes in patients with
cardiovascular diseases.64 Diuretic pharmacotherapy increases the risk of HU by
approximately 6% to 21%.63 Loop and thiazide-diuretic, for example, may induce HU due to
the inhibition of SU excretion in the proximal renal tubule through causing alterations in such
transporters, like organic anion transporters (OAT)1 and 3 and human sodium phosphate
transporter (NPT)-4.63,65 Furthermore, loop diuretics such as furosemide induced a high level
of lactic acidemia that interacts with urate elimination.66
Anti-tubercular drugs, such as pyrazinamide and ethambutol, have been associated with
an increase in SU, which could lead to HU and acute gout flares. Studies have proposed a
strong relationship between the use of pyrazinamide and developing gout. Pyrazinamide
inhibits urate excretion up to 80% due to extensive urate retention in a therapeutic dose of
300 mg/day.67 Ethambutol also alters SU by reducing the fractional excretion of uric acid.
Hence, 43% to 100% of patients who receive ethambutol may develop HU.63,65
Calcineurin inhibitors are a group of medications that inactivate immune cells; they are
used after an organ transplant to reduce tissue rejection.68 Certain immunosuppressant agents
should be used after tissue transplant, including cyclosporine, tacrolimus, and mizoribine, all
of which may increase uric acid levels.69 Cyclosporine is extensively used post-transplant of
organs, including kidney, heart, and liver. Cyclosporine induces HU and acute gout flare due
to an increase in urate reabsorption, mainly when administered with diuretics due to arteriolar
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vasoconstriction that leads to a decrease in glomerular function.63 Cyclosporine has been
found to produce a more significant effect regarding inducing HU compared to other immune
suppression agents, such as azathioprine (84% versus 30%, respectively, p-value < 0.0001).70
Tacrolimus immune suppressive agent is similarly causing an increased incidence of
HU, but a recent study demonstrated that Tacrolimus has fewer effects on SU levels than
cyclosporine with a mean (+/- standard deviation) level of uric acid (303±75 μmol/L versus
344 ± 62 μmol/L; P= 0.006.71 Nevertheless, some studies have concluded that there is an
insignificant difference between either agent in inducing hyperuricemia.72
Mizoribine is another type of immunosuppressant agent used with transplant patients,
mainly in the Asian population. Also, other clinical uses of mizoribine are in patients who
suffer from lupus nephritis, rheumatoid arthritis, and nephrotic syndrome.73 Mizoribineinduced HU is primarily due to the inhibition of guanine nucleotides synthesis.63
Nicotinic acid, identified as niacin or vitamin B3, has been used since 1955 to improve
neurological function.74 HU could result at therapeutic doses of 3 to 6 g of nicotinic acid.63
This effect is most likely due to uric acid elimination reduction, since nicotinic acid increases
urate reabsorption by the kidneys in addition to OAT10 transporter exchange with nicotinic
acid, thus leading to HU. Moreover, niacin may simulate the uricase enzyme that leads to
elevated SU levels.63,75
In patients with stroke, atherosclerosis, and angina, aspirin is often given as secondary
prevention. Consequently, aspirin users have lower ischemic stroke numbers than non-aspirin
users (OR: 0.83, 95% CI: 0.74–0.93; P = 0.45).76’77 Aspirin has a unique biphasic mechanism
that acts on uric acid levels. A low dose of salicylate (1-2 g/day) competes for SU excretion,
causing urate retention resulting in increased uric acid levels. Conversely, a high dose of
salicylates (>3g/day) hinders urate reabsorption, resulting in decreased SU, an indication that
a high dose has a uricosuric effect.78
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Cytotoxic chemotherapy is associated with tumor lysis syndrome (TLS). TLS results in
the formation of excessive nucleic acids due to cell breakdown. The nucleic acids are then
converted into hypoxanthine and xanthine to form uric acid, resulting in HU.79 As a result,
HU is one of the most common complexities associated with cancer medications and might
pose a serious threat to acute uric acid nephropathy. Different types of tumors such as NonHodgkin’s lymphoma, solid tumors, acute myeloid leukemia, and acute lymphocytic
leukemia are the most well-known malignancies associated with increased TLS and hospital
mortality about 21%.80
Fructose metabolism could lead to elevated uric acid levels and gout risk due to purine
nucleotide degradation or denovo purine synthesis. Also, fructose at a high concentration
leads to lactic acid formation, causing blockages in urate elimination, resulting in HU. Thus
there is an overt indication that the severity of HU-related fructose is dose-related.36,81
Genetically, the variants in GLUT9, which is responsible for fructose transport, could
increase the risk of gout flare in different multi-ethnicities.82
Sodium lactate infusion is administered to critically ill patients and yields benefits
resulting in organ function improvement, specifically heart and brain, in ischemic
situations.83 Nonetheless, lactate infusion could cause HU at high doses due to decreases in
urinary fractional excretion of uric acid.84
Testosterone replacement therapy (TRT) is used for treating men who have gender
identity disorder (GID) due to hypogonadism. TRT has shown several beneficial anabolic
impacts on biological functions, including metabolism, cardio-protection, and enhanced bone
and muscle cells synthesis.85,86 A recent study reported that dose-dependent TRT increases
SU after three months of treatment (intramuscular injection of testosterone enanthate), with a
29% to 43.4% increase after using 125 and 250 mg every two weeks.87 In addition, numerous
studies have found that TRT induces gout disease 88. Hormonal replacement therapy could
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affect gene expression. Hence, the therapy changes the level of urate transporters, causing
HU due to a reduction in renal uric acid elimination. Additionally, because muscle is the
major source of purine, increasing muscle mass during the early phases of therapy is linked to
HU.63
There are also a variety of miscellaneous agents that could contribute to high uric acid
levels, inducing HU and gout flare. Examples of these agents include acitretin, didanosine,
ritonavir, filgrastim, L-dopa, omeprazole, peg-interferon, ribavirin sildenafil, teriparatide,
ticagrelor, and topiramate. These agents have different mechanisms inducing HU, either
through increasing uric acid production or decreasing urate elimination. Meanwhile, other
agents such as teriparatide could lead to HU by creating an imbalance in endocrine function
and thereby increasing serum parathyroid hormone levels, which are significantly associated
with hyperuricemia (OR: 1.045; 95%CI: 1.017–1.075; P = 0.002).63,89
In short, several medications are associated with HU and gout flares due to different
mechanisms of action. Additional studies are required to classify these pharmacological
classes according to their severity in increasing uric acid levels from baseline to mild,
moderate, and severe.
Management of hyperuricemia and gout
It is usually accepted to define hyperuricemia when the uric acid level is above 7.0
mg/dl. Meanwhile, the presence of HU without signs or symptoms of MSU crystal deposition
is called asymptomatic hyperuricemia, linked to metabolic syndromes developments. 90 The
goal of gout management is to prevent acute flare and prevent the complications that HU
could cause. There are numerous pharmacological agents used in gout management, either in
acute gout flare or in long-term management. These agents include nonsteroidal
inflammatory drugs (NSAIDs), steroids, colchicine, and urate-lowering therapy (ULT).
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Moreover, diet and social lifestyle changes could contribute to mitigating hyperuricemia
complications and gout flare.91
Management of acute gout flare
Acute gout flare is characterized by severe pain due to the deposition of MSU crystals
in the joints.20 The primary purpose of treating acute gout is to reduce and resolve the pain
associated with the flare. The drug choices used in clinical practice to manage gout flares
consist of anti-inflammatory drugs, including non-steroid anti-inflammatory drugs (NSAIDs),
colchicine, glucocorticoids (intra-articular, intramuscular, intravenous), as well as the
incorporation of local ice therapy to decrease flare severity.92 Ibuprofen, indomethacin, and
naproxen, classified as NSAIDs used to help relieve gout flare symptoms by inhibiting cyclooxygenase enzyme (COX). Therefore, until the flare resolves, these drugs should be taken at
the FDA-approved doses. Moreover, some NSAIDs, such as indomethacin, can also reduce
SU due to uricosuric effects.93 Using NSAIDs in the long term may cause gastrointestinal
bleeding in some patients; proton pump inhibitors could help minimize these side effects.94
Colchicine is one of the effective medications used for an acute gout flare. Initiation of
colchicine should be with a loading dose at 1.2 mg, followed by a 0.6 mg single dose after
one hour, then continuous use of prophylactic doses of 0.6 mg once or twice a day, but not
exceeding 1.6 mg/day to avoid toxicity.95 Colchicine is a cytochrome P450 and Pglycoprotein substrate. As a result, it can interact with various drugs, including antineoplastic,
macrolide antibiotics, and calcium channel blockers, potentially increasing colchicine toxicity
(Table 1.4).96
Other options that could be used to treat an acute flare and decrease pain severity are
steroids, either via intravenous or intra-articular administration. These options should be
given with caution so as to avoid any complications related to steroid usage.97 Steroids such
as oral prednisone, at a daily dose of 30 mg/d for 7 days, have been shown to be effective98

15

and are recommended by the ACR and EULAR panels as potential first-line therapy in the
management of gout flares.99 Steroids are best administered in patients contra-indicated for
NSAIDs or colchicine (i.e. CKD patients). When not contraindicated, co-prescription a low
dose (0.5–1 mg/d) of colchicine may help prevent uncommon inflammation relapses after
steroid discontinuation.20
Open-label studies also suggest that adrenocorticotropic hormone (ACTH) can relieve
gout inflammation.100 Intra-articular steroid injections appear to be very effective and are
recommended by both the ACR and the EULAR in the management of mono or polyarticular flares, despite the lack of randomized clinical trials (RCT). Open-label studies of the
IL-1 receptor antagonist anakinra support its off-label use in patients who are resistant or
have a contraindication to NSAIDs, colchicine, and steroids. 101’102
Canakinumab agent is a long-acting antibody to IL-1 beta that is approved by the
European Medical Agency following two RCT trials against intramuscular triamcinolone
acetonide.103 The EULAR recommends considering IL-1 blockers for the management of
gout flares in patients with frequent flares contraindicated to NSAIDs, colchicine, and
steroids (oral or injectable).20
Long-term management of gout
Urate lowering therapy (ULT) agents are used in long-term gout management to reach
target uric acid levels within the normal range. The American College of Rheumatology
(ACR) strongly recommends administering ULTs such as allopurinol for all patients with the
presence of frequent acute flare at least once per year, chronic kidney disease stage 3 or
higher, or history of nephrolithiasis in patients diagnosed with gout arthritis. Furthermore, it
has been recommended that following a restricted diet and social life habits could help in
gout management.104
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Allopurinol and its active metabolite, oxypurinol, are xanthine oxidase enzyme
inhibitors that reduce uric acid production. The half-life of both allopurinol and oxypurinol
are 1-2 and 15 hours, respectively, and both are excreted renally.105 When initiating ULT, it is
important to provide gout prophylaxis to prevent ULT-induced gout flares. When the uric
acid levels start to fall, the crystallization in the joints could shift, and this shift in the crystals
may cause an acute gout flare. Thus, it is essential to continue gout prophylaxis for three to
six months to avoid gout flares during UTL treatment. 106,107 Allopurinol dosage is
determined on kidney function; thus, patients with normal kidney function should start at 100
mg daily (but not more than 300 mg), with dose titration up to 50 mg every two to four weeks
until the target uric acid level is achieved.105 Patients who suffer from renal function decline
should be started on allopurinol 50 mg, followed by a titration up to 50 mg every two to five
weeks until the uric acid levels reach the normal range.96
Although allopurinol hypersensitivity syndrome is uncommon, it could occur in some
patients, notably in the elderly with renal impairment, patients using a thiazide diuretic, and
some Asian groups with HLA-B* 5801 genotypes. Thus, ACR recommends using alternative
ULTs in the Asian ethnic population who have tested positive for the HLA-B* genotype so as
to avoid allopurinol hypersensitivity syndrome, leading to Stevens-Johnson syndrome or
toxic epidermal necrolysis. These major adverse effects are characterized by vasculitis,
hepatocellular and acute kidney injury, fever, leukocytosis, and eosinophilia. Therefore, the
initial dose in normal and decreasing renal function patients should be less than 100 mg and
50 mg, respectively, to reduce the risk of allopurinol hypersensitivity. 105,108
The FDA approved Febuxostat in February 2009 for the treatment of chronic gout
patients. Febuxostat is a non-purine selective xanthine oxidase inhibitor. The half-life of
febuxostat is about five to eight hours, and it is metabolized mainly by the liver and
eliminated by renal and hepatic routes.109 Compared to allopurinol, with respect to its safety
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profile, febuxostat is associated with increased cardiovascular-related mortality; therefore, the
FDA recommends minimizing its use only in patients who do not derive any benefits from
allopurinol or who have serious side effects from allopurinol use. Therefore, before switching
from allopurinol to other xanthine oxidase inhibitor agents, allopurinol should be titrated to
the maximum tolerable dose possible.110
Febuxostat is a once-daily pill available in multiple doses, available in 40 and 80 mg
doses in the USA and 80 and 120 mg doses in Europe. Febuxostat is a more effective ULT
than allopurinol at dosages of 80 and 120 mg/d (maximum levels authorized in the United
States and Europe, respectively). 111 Febuxostat is contraindicated in patients diagnosed with
CVD, including ischemic heart disease and congestive heart failure. In addition, febuxostat is
more costly than allopurinol.96 Moreover, febuxostat is associated with elevated liver
enzymes compared with allopurinol, and it can cause adverse drug reactions such as nausea,
arthralgia, and rashes.109
Uricosuric medications such as probenecid and benzbromarone are pharmacological
agents used to facilitate uric acid excretion in order to achieve the target urate levels.
Probenecid is an appropriate adjunctive or second-line therapy for preventing acute flare by
inhibiting the renal excretion of organic anions in the proximal renal tubule and reducing
tubular urate reabsorption.96 The use of probenecid is recommended as a ULT in gout if
allopurinol is ineffective or contraindicated. Using probenecid as a ULT monotherapy is rare.
However, the use of probenecid in combination with allopurinol results in a significant
reduction in uric acid levels.112 Benzbromarone is more effective than probenecid uricosuric
agent, but it is infrequently used due to hepatotoxicity. Thus, it is restricted only to patients
who cannot tolerate other ULT agents.113 Furthermore, patients who suffer from kidney
stones, renal impairment, or who indicate the presence of uricosuria (higher than 700 to 800
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mg/24 hours) must avoid these uricosuric agents.92 Other pharmacological agents including
losartan and fenofibrate show a uricosuric effect, but it is not a class-wide effect.114
Pegloticase is another option that could be used for the treatment of chronic tophaceous
gout cases. It can be used if the patient cannot take the available conventional urate-lowering
drugs such as allopurinol, febuxostat, or probenecid. Pegloticase is a potent ULT and could
improve the quality of life in patients with tophaceous gout by reducing the size and severity
of urate tophi.115 From a pharmacological perspective, pegloticase is a human recombinant
enzyme that helps to convert uric acid into allantoin, which is more soluble and easier to
excrete.116 However, pegloticase has several adverse drug reactions, including anaphylactic
symptoms related to infusion administration.117 Moreover, pegloticase is contraindicated in
special ancestral groups such as Africans and Middle Easterners with glucose-6 phosphate
dehydrogenase (G6PD) deficiency.118
In summary, in this chapter, we have discussed the whole prospective of HU/gout
prevalence. Published reports afford us multiple opportunities to investigate other reasons for
HU/gout prevalence between different races. Therefore, we decided to assess the urate
transportome genetic polymorphism across the different societies in the US. The main goal is
to take the first step into personalized medicine in order to minimize health inequalities
between population groups.
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Table 1.1: Uric acid normal range1
Gender

mg/dl

Males, postmenopausal women

3.5 – 7.2

Premenopausal women

2.6 – 6.0

Table 1.2: Prevalence of hyperuricemia (HU)/ Gout in USA,
NHANES 2015-201611
Category

Gout
Prevalence
% (95% CI)

Hyperuricemia
Prevalence %
(95% CI)

Persons
with gout
(N)

All

3.9 (3.2, 4.7)

20.1 (17.8, 22.4)

9.2 million

Male

5.2 (4.4, 6.2)

20.2 (16.6,24.3)

5.9 million

Female

2.7 (2.0, 3.8)

20.0 (17.8, 22.4)

3.3 million

Caucasian

4.0 (3.1, 5.3)

21.4 (18.1, 25.1)

6.13 million

African American

4.8 (3.8, 6.0)

22.6 (20.9, 24.3)

1.3 million

Hispanic

2.1 (1.4, 2.9)

14.9 (12.6, 17.5)

0.73 million
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Table 1.3:Gout Comorbidities 62
Organ system

Clinical condition

Cardiovascular

Hypertension
Coronary heart disease
Atherosclerosis
Stroke
Heart failure
Peripheral vascular disease
Atrial fibrillation
Thromboembolism

Renal/genitourinary

Chronic kidney disease
Nephrolithiasis
Erectile dysfunction

Metabolic

Diabetes
Metabolic syndrome
Osteoporosis

Neurological

Alzheimer’s disease
Vascular dementia
Parkinson’s disease

Ophthalmological

Macular degeneration

Rheumatological

Osteoarthritis
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Table 1.4: Common drugs that interact with colchicine 96
Strong CYP3A4 inhibitors
Clarithromycin
Cobicistat
Diltiazem
Itraconazole
Ketoconazole
Ritonavir
Telithromycin
Voriconazole

Moderate CYP3A4
inhibitors
Cimetidine
Ciprofloxacin
Cyclosporine
Erythromycin
Fluconazole
Fluvoxamine
Imatinib
Verapamil

Figure 1.1: Pathogenesis of Acute Gouty Inflammation20
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P-glycoprotein inhibitors
Amiodarone
Carvedilol
Clarithromycin
Itraconazole
Quinidine
Ranolazine
Ritonavir
Verapamil

Figure 1.2: Uric Acid Transportome Genetics24
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Figure 1.3: Uric acid and cardio metabolic diseases55

(NAFLD): Non-alcoholic fatty liver disease, (RAAS): Renin-Angiotensin-Aldosterone
system
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Abstract
Background:
Gout, an inflammatory condition, is characterized by the precipitation of monosodium
urate crystals (MSU) in or around joints. The latter is caused by chronic hyperuricemia
(HU) - high urate levels in the blood. Genetic variations in urate transporters play a
significant role in regulating urate levels within the human body, rendering some racial
and ethnic groups more susceptible to developing HU or gout. This study aims to
estimate the frequencies of HU and gout risk alleles in Asian, Native Hawaiian, and
Pacific Islander subgroups using biorepository DNA samples. Urate allele frequencies
in Japanese, Korean, Filipino, Native Hawaiian, Samoan, and Marshallese were then
compared with Europeans (EUR).

Methods:
The biospecimens repository center at the University of Hawaii provided DNA samples
of consented post-partum women. The DNA was extracted from the cord blood and
genotyped at the Genomics and Bioinformatics Shared Resource, Cancer Center
(Honolulu, HI). Nine urate genes: ABCG2, SLC2A9, SLC16A9, GCKR, SLC22A11,
SLC22A12, LRR16A, PDZK1, and SLC17A1, were selected due to their significant
association with HU and gout risk. Hardy-Weinberg equilibrium (HWE) for genotype
frequencies was assessed using the Chi-Square test with p<0.05 for statistical
significance. Allele frequencies in our study were compared to EUR from the 1000
Genomes Project Phase 3 database, using the Chi-square or Fisher exact test as
appropriate. Bonferroni correction for multiple comparisons was used, with p<0.006 for
statistical significance.
Results:
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Our study involved 1095 post-partum women 18-year-old or older who self-reported
their respective race and ethnicity, including Asian and Pacific Islander ancestry. Asian
groups involved Korean, Japanese, and Filipino. Besides, the Pacific Islander group
includes Native Hawaiian, Marshallese, and Samoan. None of the study participants had
a history of gout. We excluded the PDZK1 gene from the final analysis due to its
deviation from HWE (p<0.05) across all the populations. Compared to EUR, the genetic
polymorphism frequencies were significantly different-8/8 in Japanese, 6/8 in Korean,
6/8 in Filipino, 8/8 in Samoan, 6/8 in Hawaiian, and 6/8 in Marshallese. The total count
of HU and gout risk alleles between our participants and EUR were 8, 5, 6, 5, 4, and 4
in Japanese, Korean, Filipinos, Samoans, Marshallese, and Hawaiians, respectively. The
percentage of cumulative risk alleles was 100% in Japanese and Filipino followed by
83.5% in Korean.
Conclusions:
Compared to EUR, Asian subgroups, particularly Japanese, Filipinos had the highest
percentage of UA risk alleles at 100%, followed by Koreans at 83.5%. These results
could partly explain that some individuals of Asian descent are at an increased risk of
developing HU or gout.
Keywords: Gout, Hyperuricemia, Health Disparities, Genetics, Asian Ancestry, Native
Hawaiians, Pacific Islanders, Single nucleotide polymorphisms, Pregnancy
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Introduction
Gout is an inflammatory arthritic condition characterized by the precipitation of
monosodium urate crystals (MSU) in or around distal joints.1 Chronically elevated
serum urate (SU), a condition known as hyperuricemia (HU), is the culprit of
developing gout. Acute gout flares affect monoarticular joints (e.g., knees, ankles, and
metatarsophalangeals), causing severe inflammation marked with excruciating pain,
swelling, erythema, and reduced mobility.20 The prevalence of gout in developed
countries is higher than the developing ones. In the United States (U.S.), gout
prevalence is up to 3.9%, affecting about 9.2 million people.11 Gout and hyperuricemia
prevalence varies by sex and age groups. Also, specific racial and ethnic subgroups
have distinct HU and gout prevalence, ushering the notion of population-specific risk
and suggesting distinct HU and gout risk allele frequencies across different racial and
ethnic groups.36
Many factors play significant roles in regulating SU levels and might lead to HU
and gout.119 Genetic polymorphisms in uric acid transporters, mainly single nucleotide
polymorphisms (SNPs), have been implicated in developing HU or gout. Numerous
studies have ascertained the role of the genetic variation of urate transporters, and
estimate the heritability of urate is up to 73%.22 One of the largest genome-wide
association studies (GWAS) metanalysis, involving more than 110,000 participants
from different racial backgrounds, discovered 28 loci associated with SU levels.23 These
loci are predominately in genes encoding urate transporters, including SLC2A9, ABCG2,
SLC22A11, SLC22A12, SLC17A1, and the scaffolding protein-encoding gene PDZK1.22
Indeed, the prevalence of and HU gout varies among people and countries. Along with
differences in the genetic background, several demographic and environmental
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characteristics such as diet and lifestyle, smoking, alcohol consumption, or beverages
containing high amounts of fructose may increase prevalence.120
Studies published in 2015 and thereafter showed substantial increase in gout
incidence over recent decades in the U.S., Canada, Denmark, Sweden, and South Korea,
confirming greater incidence in men relative to women, and increased incidence in later
life decades. Besides, recent studies in North America and Scandinavia found a 1.5–2fold increase in gout incidence over the past two to three decades.116,121–125 Gout
incidence in South Korea increased by 25% between 2009 and 2015.10 A recent study
reported that the Maori and Pacific Islanders groups in New Zealand have a gout
prevalence of 7.6%.126 These trends indicate that gout incidence increased in many
countries over recent decades and that the aging population in these countries may drive
this increased gout incidence. Gout prevalence varies globally, with Oceanic countries
having one of the highest prevalence worldwide, particularly in indigenous and South
Pacific Island populations. Along with the earlier reported increasing prevalence of gout
in Europe and the US, there is evidence of increasing prevalence in Australia (selfreported), Canada, China, and South Korea as well.15 According to the U.S. Census
Bureau, Chinese and Filipino communities are considered the largest Asian subgroups.
Similarly, Native Hawaiians and Samoans are the largest Pacific Islander subgroups.127
Amongst all the ethnic subgroups in the U.S., populations with Asian ancestry are
approximately three times more likely to develop gout than Europeans (EUR).128
Despite the correlation between genetic polymorphisms in urate disposition and
incidence of gout amongst different ethnic groups, the frequencies of HU and gout risk
alleles in a low admixed subgroups remain unknown. Therefore, the purpose of this
study is to estimate the frequencies of selected SNPs in essential urate genes across
diverse populations rarely represented in genetic or clinical research (Filipino, Japanese,
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Korean, Samoan, Marshallese, and Native Hawaiian) compared with EUR. With the
growing need for racial diversity in genomic research, this study will further our
understanding of the genetics of HU and gout in underrepresented minorities.
Furthermore, to establish the genetic basis between ethnicity and gout prevalence. We
hypothesized that the risk allele frequencies of HU and gout significantly differ between
the Asian, Native Hawaiian, and Pacific Islander subgroups compared to European
(EUR) population.
Methods
Study participant and urate genes
Participants included in this study were pregnant women who are 18-year-old or
older. All participants self-reported 100 % of their respective race/ethnicity, indicated
by both biological parents and four grandparents being of the same race/ethnicity. We
excluded any participants age <18 years old, with a history of cancer or organ
transplant, and poor DNA quality in the final analysis. The uric acid gene/SNPs were:
SLC17A1 (rs1183201), PDZK1 (rs12129861), SLC22A11 (rs17300741), ABCG2
(rs2231142), SLC16A9 (rs2242206), SLC22A12 (rs505802), SLC2A9 (rs734553),
LRRC16A (rs742132), GCKR (rs780094).
Sample procurement and genotyping
DNA samples along with medical and demographics information of study
participants were provided by the University of Hawaii biospecimens repository.
Historically, these samples were collected after obtaining the written consent. The
placenta and umbilical cord of the participants were collected as part of the routine care.
DNA extraction was from cord blood samples and genotyping was carried out at the
Genomics and Bioinformatics Shared Resource, Cancer Center (Honolulu, HI). A
customized TaqMan genotyping assay panel was run on the Quant Studio 12K Flex
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Real-Time PCR system (Applied Biosystems). All study details were previously
published.129 All study material were reviewed and exempted by the University of
Hawaii Human Studies Program (protocol Number: 2018-00225).
Statistical analysis
The data analysis was conducted utilizing SPSS Statistics for Windows, version 23
(IBM SPSS, IBM Corp., Armonk, N.Y., USA). Shapiro – Wilk test was used to
evaluate normal distribution for continuous variables. Demographic characteristics were
expressed as means (+/- standard deviation and minimum-maximum) for parametric
data and number (%) for categorized data. Allele frequencies in our data were compared
with EUR, using Chi-square or Fisher’s exact test, when appropriate. Bonferroni
correction was used for multiple comparisons with p <0.006 for statistical significance.
Deviation from Hardy-Weinberg Equilibrium in our selected genetic polymorphisms
was assessed using Chi-square test with P<0.05 for statistical significance. Ensemble
genome browser was used to estimate the allele and genotype frequencies of EUR
population (Reference). In our study, the risk allele was defined as the allele associated
with the baseline or higher risks of developing HU and/or gout.
Results
Study participants characteristics and demographics in this study, 1059 participants
were included. Demographic characteristics of all participants are shown in Table 2.1.
The participant’s age ranged from 18 to 47 years with a means of 29 years. The
gestational age ranged from 24 to 41 weeks with a means of 38 weeks, of which 82.2%
(n= 871) were full term and 17.3% (n= 182) were pre-term. Using the pregravida
weight, the body mass index (BMI) ranged from 24.5 to 30.1 kg/m2, with mean of 26.3
kg/m2, of which 43.4% (n= 400) were classified as having normal weight, 26.9% (n=
248) were classified as obese, 22.9% (n =211) were classified as overweight, and 6.8%
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(n= 63) were classified as underweight. It is worth mentioning that Asian and Asian
Americans are at high risk of obesity at lower BMI than in whites.130 Our study
consisted of 21.5%. (n= 229) Filipinos, 19.8% (n= 210) Japanese, 18.9% (n= 200)
Samoans, 15.1% (n= 160) Marshallese, 14.7% (n=156) Hawaiian, and 9.8% (n= 104)
were Koreans. No subjects reported a history of gout.

Genetic Analysis and Quality Control
As a measure of quality control, genetic results were assessed for Hardy-Weinberg
Equilibrium (HWE), using chi-square with p<0.05 for significance (Table 2.6). SNPs
call rates were evaluated and reported for each ethnic group and for the overall study
cohort (n=1059 participants). Overall SNPs call rate were 97.4% in SLC22A12, 95.1%
in SLC17A1, 96% in SLC16A9, 96.9% in ABCG2, 94.3 in SLC22A11, 91% in PDZK1,
96.1% in SLC2A9, 96.4% in LRRC16A, and 96.7% in GCKR (Table 2.7).
Hyperuricemia and Gout Risk Alleles Frequencies
Risk alleles and genotype frequencies of all nine uric acid genes/SNPs in all ethnic
subgroups are summarized in Table 2.3 & Table 2.4. Due to deviation from the HWE,
we excluded the rs12129861 C>T in PDZK1 from the final analysis. In the Japanese
group, eight out of the eight uric acid SNPs were significantly different from EUR
(Table 2.5). All these eight alleles (100%) were prevalent in the Japanese population
from EUR and were considered risk alleles. These risk alleles included: rs1183201 T>A
in SLC17A1, rs2231142 G>T in ABCG2, rs2242206 G>T in SLC16A9, rs505802 C>T
in SLC22A12, rs734553 G>T in SLC2A9, rs17300741 A>G in SLC22A11, rs742132
A>G in LRRC16A, and rs780094 C>T in GCKR.
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In the Korean group, six out of the eight uric acid SNPs were significantly different
from EUR (Table 2.5). Five out of the six alleles (83.5%) were more prevalence in
Koreans than EUR and were considered risk alleles. These risk alleles genes/SNPs
included: rs1183201 T>A in SLC17A1, rs2242206 G>T in SLC16A9, rs505802 C>T in
SLC22A12, rs734553 G>T in SLC2A9, rs17300741 A>G in SLC22A11.
In the Filipino group, six out of the eight uric acid SNPs were significantly different
than those of EUR (Table 2.5). All these six SNPs in Filipino were more prevalent
(100%) than EUR. These genes/SNPs included: rs1183201 T> A in SLC17A1,
rs2231142 G>T in ABCG2, rs2242206 G>T in ABCG2, rs2242206 G>T in
SLC16A9, rs505802 C>T in SLC22A12, rs734553 G>T in SLC2A9, and rs17300741
A>G in SLC22A11.
In the Marshallese group, six out of the eight uric acid SNPs were significantly
different in the Marshallese population than those of EUR (Table 2.5). Among those six
SNPs, the Marshallese population had four uric acid alleles significantly more prevalent
(66.5%) than EUR. These genes/SNPs included: rs2231142 G>T in ABCG2, rs2242206
G>T in SLC16A9, rs505802 C>T in SLC22A12, and rs734553 G>T in SLC2A9.
In the Samoan population, eight out of the eight urate SNPs were significantly different
from EUR (Table 2.5). Among those eight SNPs, five uric acid alleles (62.5%) had a
higher prevalence in the Samoan population than EUR. These genes/SNPs
included: rs2231142 G>T in ABCG2, rs505802 C>T in SLC22A12, rs734553 G>T in
SLC2A9, rs17300741 A>G in SLC22A11, rs1183201 T>A in SLC17A1.
In the Native Hawaiian group, six out of the eight uric acid SNPs were
significantly different from EUR (Table 2.5). Four out of six alleles (66.5%) were more
prevalence in Native Hawaiian population than EUR and were considered risk alleles.
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These genes/SNPs include: rs505802 C>T in SLC22A12, rs734553 G> T in SLC2A9,
rs17300741 A> G in SLC22A11, and rs1183201 T>A in SLC17A.
Among all our studied population subgroups, Asian subgroups of Japanese,
Koreans, and Filipinos had the highest HU and gout risk allele indices of 8, 5, and 6,
respectively. The percentages of risk alleles were 100% in Japanese and Filipino,
followed by 83.5% in the Korean subgroup. Pacific Islander subgroups were 66.5% in
Native Hawaiians and Marshallese, followed by 62.5% in Samoan (Table 2.5).
Discussion
Our study found that the population of Asian ancestry had a higher prevalence of
HU and/or gout risk alleles compared with the EUR population. Uric acid associated
alleles found in the Asian subgroup were significantly different from the EUR
population and were all considered HU and/or gout risk allele. These results could
partially explain the differential prevalence of hyperuricemia and gout across different
ethnic and racial groups based on their genetic makeup. Therefore, a discussion on the
role of these various genes/alleles in developing HU and/gout is warranted.
ABCG2 gene encodes the ATP-Binding Cassette G-protein transporter located in the
apical membrane in the proximal renal tubule, and it is also expressed in the
gastrointestinal tract and liver. ABCG2 is a major urate excretion transporter.131 Genetic
polymorphisms in the ABCG2 gene were reported to contribute to elevated urate levels
leading to hyperuricemia and gout. The SNP rs2231142 G>T (Q131K) in ABCG2 is
associated with increased urate levels in the presence of the T-allele.131 Therefore,
individuals with the TT genotype are at high risk of HU and gout than GG counterparts.
A recent study reported that T-allele presence is 3- times higher in East Asians than
EUR. This suggests that East Asian populations are at higher risk for developing HU
and gout.132
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Similarly, our findings showed that the prevalence of the T allele of the rs2231142
(G>T) was 9.4% in EUR, 45.8% in Filipinos, 27.8% in Koreans, and 25.6% in Japanese
(Table 2.3). In our Korean cohort, however, the rs2231142 (G>T) deviated from the
HWE (p=0.0407) (Table 2.6). In the Native Hawaiian and Pacific Islander (NHPI)
subgroups, the frequencies of the T allele of the rs2231142 (G>T) were 31.1%, 17.6%,
and 12.7% in Samoan, Marshallese, and Native Hawaiian subgroups, respectively. The
genetic polymorphism rs22131142 (G>T) in ABCG2 is significantly associated with
urate levels and increased risk for HU and gout among different populations.34,133,134
A study conducted in the Korean population showed that the rs22131142 G>T is
strongly associated with gout risk (Odds ratio [OR] 3.32; 95% confidence interval [CI]:
2.11 to 5.20).135 Also, in a study of 6881 Koreans identified that the genetic
polymorphism rs2231142 (G>T) was associated with increased SU levels (Effect size =
0.220, p=2.06E-29).136 Consistent with our results, a previous study reported that the
minor allele frequency (MAF) of the T risk allele of the genetic variant rs2231142
in ABCG2 was high in Japanese and Koreans compared to Caucasians (0.29, 0.28, vs.
0.11).137 Additionally, a meta-analysis conducted on a multi-ethnic cohort reported that
the T allele of rs22131142 G>T in ABCG2 was strongly associated with HU and gout
across populations, and the severity is affected by gender and ethnicity.138
Overall, the genetic polymorphism rs2231142 (G>T) of the ABCG2 gene is considered
the most significant gene polymorphism related to the increased risk of HU and/or gout
in selected minorities compared with other risk alleles. Sun et al. studied the association
between 11 genetic loci of which ABCG2 rs2231142 (G>T) was one of the genes
associated with serum urate concentrations in the Chinese population.139 Also, Zhang et
al. reported that the SNP rs2231142 of the ABCG2 gene was associated with
hyperuricemia in the American population consisting of EUR Americans, African
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Americans, Mexican Americans, and Indian Americans.140 Our finding provides that
the genetic variants in ABCG2 rs2231142 (G>T) may increase urate levels and gout risk
in Asian, Native Hawaiian, and Pacific Islander subgroups compared to EUR.
SLC2A9 encodes the GLUT9 transporter, which has a high-capacity transporter for
urate, fructose, and glucose. It is known to be strongly associated with urate regulation
in the human body.141 It is mainly expressed in the kidneys and liver, but it is also
expressed in human articular cartilage.142 The intronic polymorphism rs734553 (G>T)
in SLC2A9 is associated with increased HU risk and gout resulting from a change in
transporter affinity for urate.143 This genetic variation strongly affects SU levels in
EUR ancestry and could significantly affect SU in women (Effect size = 0.315,
p=5.22x10-201).32 Reginato Am et al. have identified that polymorphism rs734553 of
the SLC2A9 gene is linked to SU levels and gout in the Islandic Polynesian
population.144
Our analysis has shown that the T-allele's prevalence in Asian and Pacific Islander
populations was higher than in the EUR population. Specifically, the frequency of
rs734553 (G>T) was 99.5% in Japanese, 98.8% in Filipinos, and 98.3% in Koreans
compared to 75.5% in EUR (p<0.0001). Additionally, the frequency of rs734553 (G>T)
was 100% in Marshallese, 98.3% in Samoans, and 90.9% in Hawaiians compared to
75.5% in EUR (p<0.006) (Table 2.3). Our results suggest that carrying the T -allele will
likely increase the risk of elevated SU in both the Asian and NHPI subgroups.
SLC17A1 encodes the voltage-gated human sodium-dependent phosphate co-transporter
type 1 protein (NPT1), located in the proximal tubule's apical side in the kidney and
works as renal urate efflux transporter. Decreased SU Levels were found to be
associated with the genetic polymorphism rs1183201 (T>A) in SLC17A1 (Effect size =
-0.062, 95% CI: -0.078; -0.459) with the effect of allele A as the protective allele of
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EUR descent. Therefore, intronic SNP rs1183201 (T>A) of SLC17A1, the A allele, was
associated with decreased SU level with a prevalence of 48.2% in EUR descent. In the
intronic SNP rs1183201 (T>A) of SLC17A1, the A allele was associated with decreased
SU level with a prevalence of 48.2% in EUR descent.32 The polymorphism rs1165205
of SLC17A3 has strong linkage disequilibrium r2=0.966 with rs1183201of SLC17A1
and has shown an association with gout and SU in Korean population with a MAF of T
allele of 0.137.137
Our analysis found that the prevalence of A allele in both Asian and Pacific
Islander populations was lower than EUR descent except in Marshallese, where it was
57.2% vs. 46.1% (p=0.002). Amongst the Asian population, the frequency of A allele
for rs1183201 (T>A) was 2-3-folds lower than that observed in EUR (14.6%, 17.1%,
and 20.9% for Koreans, Japanese, and Filipinos respectively vs. 46.1% p<0.00001)
(Table 2.3). The significant differences in A allele frequency across minorities covered
in our study suggest that some ethnicities could be genetically predisposed to high urate
levels.

SLC22A12 encodes for URAT1, a protein found on the kidney's apical side of the
proximal tubules. This transporter is responsible for the majority of the urate
reabsorption from the kidneys and a primary target for urate-lowering therapies.145 A
previous study reported that the loss of activity in URAT1 had been found to cause
hypouricemia in Japanese populations, suggesting that URAT1 plays an essential role in
regulating the renal tubular reabsorption of urate.146 The intergenic polymorphism
rs505802 (C>T) in SLC22A12 was observed to reduce urate levels in EUR ancestry.
Specifically, the T- allele correlates with lower SU levels in women and men (Beta
effect -0.073, -0.047, respectively) in EURs.32
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Jang et al. reported that the T6092C genetic variant of SLC22A12 was also
significantly associated with SU concentration amongst the male Korean population.147
The T6092C at rs1529909 of SLC22A12 was found in linkage disequilibrium (LD= 1, r2
=1) with rs505802 of SLC22A12. However, the prevalence of the T-allele in our
population subgroups was lower than EUR population (p<0.00001). Our results found
that the prevalence of T-alleles was 3-4-folds lower in both Asian and NHPI
populations (Table 2.3), which suggests a higher baseline line urate levels in the Asian
and NHPI population subgroups compared with EURs. Furthermore, our findings
showed that the C-allele frequency was higher in both subgroups of targeted
populations compared with EUR. Particularly, the frequency of the C allele in
Marshallese was more than three times than EUR (95% vs. 29.3%, p<0.00001). These
results propose a higher risk for HU and/or gout in our studied populations and suggest
a possible implication in the response to treatments targeting URAT1 transporter in
Asian and NHPI subgroups.

SLC22A11 is predominantly expressed in the proximal tubule's apical side in the
kidney and encodes the organic anion transporter 4 (OAT4). The Organic anion
transporter 4 (OAT4) is associated with regulating UA reabsorption, like URAT1, and a
target for urate-lowering therapy.148 The intronic variant rs17300741 (A>G) in the
SLC22A11 gene was associated with renal urate under excretion type gout in the
Japanese population (p=0.049).149 Kolz et al. have reported a significant association
between the polymorphism in OAT4/SLC22A11 rs17300741 A>G and UA levels in
individuals of Caucasian descent (p = 6.7×10−14).32 Our analysis found that the Aallele prevalence was higher across selected minorities than EUR. The A allele
frequency in the Asian subgroups of Koreans, Filipinos, and Japanese, was about 2-fold
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higher than EUR (89.6%, 85.3%, and 84.7%, respectively vs. 46.2% in EUR
(p<0.00001). Furthermore, the A allele frequency was higher in Samoan, Native
Hawaiian, and Marshallese compared with EUR (78.5%, 72.3%, and 70%, respectively,
vs. 46.2% in EUR (p<0.00001). Our analysis of the rs17300741 A>G in SLC22A11
suggests a higher genetic risk for higher baseline urate levels or gout in Asian and NHPI
compared with EUR. Hence, our results are consistent with the previous literature
confirming the association of rs17300741 A>G with the prevalence of gout, which is
two-fold higher in non-EURs relative to EURs.150 Collectively, our study shows that the
frequencies of risk alleles C and A in both loci SLC22A12 and SLC22A11,
respectively, were significantly higher in Filipino, Korean, Japanese, Samoan,
Marshallese, and Native Hawaiian relative to EUR (Table 2.3). Notably, the prevalence
of risk alleles rs505802 (C>T) of SLC22A12 and rs17300741 (A>G) of SLC22A11
genes were highest in Asian subgroups compared with the NHPI population.

SLC16A9 encodes for monocarboxylic acid transporter protein across the cell
membrane (MCT9). It is located on the proximal tubule's apical side of the kidney and
responsible for urate excretion. A missense variant rs2242206 (G>T) in the SLC16A9
has been reported to dysregulate urate level. Nonetheless, Nakayama et al. have found a
significant relationship between the rs2242206 G>T (K258T) in SLC16A9, and gout
(p = 0.012), with an odds ratio (OR) of 1.28 in a Japanese population.151 Our cohort
analysis showed that the frequency of T allele across minority subgroups was
significantly higher than that of EUR ancestry (Table 2.3).
Remarkably, the Asian subgroup (Koreans, Japanese, and Filipinos) had the
highest prevalence of T allele, which is approximately two times higher vs. EUR
(59.2%, 55.5%, and 45%, respectively, vs.26.6%, p<0.00001). Additionally, the
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prevalence of risk allele T in Native Hawaiians (45.1%), Marshallese (44.5%), and
Samoans (39.3%) were significantly higher compared with EUR (26.6%) (p<0.00001).
However, the polymorphism rs2242206 (G>T) in the SLC16A9 was not in HWE in
Samoans and Hawaiians (Table 2.6). These findings suggest that individuals of Asian
descent, carrying the polymorphism in rs2242206 (G>T) in SLC16A9 could be at higher
risk for and an increase the susceptibility to gout, especially in individuals of Japanese,
Korean, and Filipino descent.

GCKR is a protein that encodes glucokinase regulatory protein (GCKR), which has
a role in developing the metabolic syndrome, involving triglyceride regulation and
glucose metabolism.152,153 Several studies have shown the relationship between urate
levels and metabolic syndrome-related traits such as insulin resistance and hypertension
through oxidative stress and inflammatory pathway.32 The intronic variant rs780094
(C>T) of the GCKR gene has shown a strong association with gout in the male HanChinese population.154 Furthermore, the T- allele of Intronic polymorphism
of rs780094 C>T has been associated with UA concentration regulation in EUR
ancestry.32 Meanwhile, the MAF of the C allele was higher in the Korean group
compared with Caucasian ancestry (0.47, vs. 0.42).137
In our analysis, the frequency of T-allele was higher in the Japanese subgroup than
EUR (58% vs. 41.1%, p<0.00001) and lower in Samoans than EUR (30.6 vs. 41.1%,
p=0.0005) (Table 2.3). This signifies that allele is associated with less risk for HU
and/or gout. There was no significant difference between Filipinos and Koreans
compared to EUR, although the T-allele frequency was higher in Asian subgroup
ancestry. Overall, these results found that the Japanese subgroup could be predisposed
to developing HU and gout compared with other subgroups in the study. Noteworthy,
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GCKR protein is associated with modulating the metabolic activities; hence, this finding
might partially suggest a biological mechanism between genetic variations and the
development of cardiometabolic disorders, including HU and gout, which may
contribute to the health disparities seen in gestational diabetes and hypertension in
pregnant women.

PDZK1 has been identified in the kidney and acts as a scaffolding protein for
different transporter proteins associated with SU levels baseline.155 The Intergenic
variants rs12129861 (C>T) of PDZK1 protein have shown an association with reducing
the risk of gout in the male Han-Chinese population (OR = 0.727, P =0.015).155 Kolz et
al. have identified the role of scaffolding PDZK1 protein in SU baseline regulation.32
It should be noted that we found a deviation when we conducted the Hardy-Weinberg
equilibrium investigation PDZK1 rs12129861 (C>T) genotypes across all minorities
addressed in the study (p<0.05) (Table 2.6). In this case, further studies having a larger
sample size and different ethnic backgrounds are needed to investigate the prevalence of
risk alleles to validate our results. Hence, we excluded this protein from the results of
this study to avoid any conflicts in our findings. In genetic science, the Hardy
Weinberg equilibrium principle applies to estimate if the allele and genotype
frequencies remain constant from generation to the next. Several factors may influence
HWE, and the technical issues in the genotyping sequencing consider one of them.156 In
our dataset, the PDZK1 across the whole population deviated from HWE, and we
assume a lab error happened during genotyping.

LRR16A is expressed in the apical side of proximal tubules in the kidneys, which
encodes a protein called capping protein ARP2/3 and myosin-I linker (CARMIL). This
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protein has a role in urate transportome formation, which mediates urate
reabsorption.32,157 Hiraka Ogata et al. have found a significant association between
intergenic variant homozygote AA in rs742132 A>G of LRRC16A and risk of gout
disease among Japanese males.158
The genetic polymorphism rs742132 in LRRC16A is associated with increased SU in
EUR ancestry.32 Notably, a GWAS study conducted on East Asian groups, including
Koreans, showed that the rs742132 in LRRC16A is associated with elevated urate
levels.159 Our analysis showed that Japanese had a higher frequency of the Aallele compared to EUR (78.2%, vs. 69%, p=0.0009). However, the frequency of the Aallele in the Filipinos was indifferent compared with EUR (69.7% vs. 69, p=0.836). In
addition, Koreans had an insignificantly different A-allele frequency compared with
EUR (78%, vs. 69, p=0.017). On the other hand, in NHPI groups, there was a deviation
from Hardy-Weinberg equilibrium in the Native Hawaiians p<0.05 (Table 2.6). Also,
although the prevalence of A-allele in Marshallese was higher than EUR, it was not
statistically significant (70%, vs. 69%, p=0.819) (Table 2.3). Moreover, Samoans had a
lower frequency of the A-allele compared with EUR (51.7%, vs. 69%,
p<0.00001) (Table 2.3). Asian subgroups of Japanese and Koreans had the highest Aallele frequency as compared to the other subgroups in this study, and this is consistent
with other results in the literature.160 Our findings suggest that the genetic
polymorphism in rs742132 of LRRC16A may explain the differential prevalence of
HU/gout across different population’s subgroups.
Collectively, our results have shown that the frequency of HU and/or gout risk
alleles in several population subgroups significantly differs from EUR (p<0.006). We
found out that the Asian subgroups had the highest prevalence of HU and/or gout risk
alleles as compared to the NHPI populations. These results are consistent with the
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patient claims data in the ambulatory care clinics that gout diagnosis in the Asian
population living in the U.S. is about three times more than EUR (reference).
Consistent with the previously published reports , our results provide more evidence
that populations of Asian descent have a higher risk of developing HU and/or gout than
EUR.34,161,162

Limitations
We have several limitations in this study. First, this study was retrospective, and
the participants were selected from one location. Hence the sample size may not be
representative of all populations. In addition, in retrospective studies, the medical
records system provides information, and those datasets are obtained in a pre-designed
form that may not match the study's purposes. Therefore, some data would constantly be
missing. Furthermore, certain variables that can influence the result may have gone
unseen.
Hence a more representative sample of the population is needed in future studies to
validate our findings. Hyperuricemia and gout are polygenic conditions, so other
genes/SNPs are also involved in urate disposition. We believe that multiple genes/SNPs
are associated with the development of HU and gout. Nevertheless, our study had a
limited number of genes/SNPs selected from GWAS conducted in EUR.
Other factors that may also influence urate levels, including older age, smoking, diuretic
use, dietary and social lifestyle factors. Nonetheless, we provide primary knowledge
that could help clinical practitioners understand the pathophysiology of diseases in some
understudied population subgroups. Further replication in different ethnic subgroups
with larger population samples is needed because genetic and epigenetic factors vary
across the population, which could influence disease prevalence.
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Some other factors such as dietary habits, older age, and male sex contribute to HU
and gout. Our results might partially be associated with gout pathophysiology besides
other factors. Furthermore, study participants did not have levels of SU measured to
conduct association analysis between genotype and phenotype. Also, in some
subgroups, the sample size was not enough to estimate the exact prevalence of risk
alleles, leading to a deviation from HWE.
Conclusions
Our analysis suggested that HU and gout risk alleles were significantly more
frequent in the Asian subgroup, Korean, Japanese, and Filipino, than EURs. These
findings are consistent with previous reports suggesting that Japanese and Han-Chinese
populations having the highest prevalence of gout/HU risk alleles than EUR. Hence, our
findings may partially explain the three-time higher risk of gout diagnosis in Asian
subgroups living in the US than EUR. Meanwhile, consistent with the epidemiology of
gout, child-bearing age women are unlikely to develop gout, despite having the genetic
risk. This the first report of its kind to investigate the genetics of uric acid in populations
that are minimally and rarely represented in research.
Future Perspective
Personalized medicine based on individual genetic profiles could play a crucial role in
predicting and addressing some health inequalities across different racial and ethnic
groups. Our research proposes that genetic data may assess in the clinical practice by
predicting disease risk, selecting an appropriate drug, and reducing the risk of new
disease onset. This study is the first genetic investigation focusing on several urate
genes/SNPs pairs and multiple underserved populations involving Asian and NHPI
pregnant women. Furthermore, this investigation could help future research assess the
role of HU and gout-risk-alleles in pregnant women to identify patients at higher risk of
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maternal comorbidities such as gestation diabetes and gestation hypertension, which are
associated with preeclampsia.
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Table 2.1: Demographic Characteristics across populations
Characteristics

Total sample
population
(n=1059)
28.8±6.3

Filipino
(n= 229)

Japanese
(n= 210)

Samoan
(n= 200)

Marshallese
(n= 160)

N. Hawaiian Korean
(n= 156)
(n= 104)

29.8±6.1

33.4±5.2

26.3±5.7

25.1±4.6

26.2±5.5

31.3±5.2

Gestational age
(weeks)
Gestational age
category

38.0±2.2

37.8±2.2

2.6±37.6

2.0±38.4

38.0±2.0

38.2±2.0

38.3±2.4

Preterm (<37 weeks)
Full term (≥37
weeks)
Body mass index
(kg/m2)
Body mass index
categories
Underweight (<18.5
kg/m2)
Normal weight (18.5
– 24.9 kg/m2)
Overweight (25 –
29.9 kg/m2)
Obese (≥30 kg/m2)

182 (17.3%)
871 (82.2%)

44 (19.4%)
183 (80.63%)

50 (23.8%)
160 (76.2%)

27 (13.5%)
173 (86.5%)

29 (18.4%)
129 (81.6%)

21 (13.5%) 11 (10.8%)
135 (86.5%) 91 (89.2%)

26.3±6.9

25.0±6.0

24.4±5.6

30.1±7.5

25.18±6.2

28.19±7.3

24.51±7.2

63 (6.8%)

18 (9.0%)

20 (10.4%)

5 (2.9%)

10 (7.8%)

-

10 (11.5%)

400 (43.4%)

94 (46.8%)

93 (48.4%)

44 (25.3%)

68 (53.1%)

58 (41.4%)

43 (49.4%)

211 (22.9%)

56 (27.9%)

46 (24.0%)

38 (21.8%)

18 (14.1%)

30 (21.4%)

23 (26.4%)

248 (26.9%)
151.2±46.5

33 (16.4%)
132.7±28.4

33 (17.2%)
127.2±26.0

87 (50.0%)
203.7±44.7

32 (25.0%)
142.5±41.9

52 (37.1%)
166.9±47.9

11 (12.6%)
133.6±34.5

Mother’s age (years)

Pre- gravida weight
(Ibs)
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Table 2.2: Gene (SNP) and Function Summary
Gene
(Protein)

Protein Function

SNP (Class)

SNP Effect

References

ABCG2
(ABCG2)

Protein coding gene for ATP-binding
cassette transporter responsible for
urate excretion.

rs2231142 (G>T)
(Missense variant)

Reduction in ABCG2-mediated
urate transport by 50%, urate
under-excretion, and
hyperuricemia is caused by Glu
141 Lys amino acid substitution.

32

SLC2A9
(GLUT9)

SLC2A9 is a High-capacity urate,
fructose, and glucose transporter
located on both sides of the kidney's
apical and basolateral membrane. This
protein is expressed in liver, kidney,
and chondrocytes tissues. Also strongly
associated with increase serum UA.

rs734553 (G>T)
(Intronic variant)

Increases risk for gout through
altering urate transporter affinity.

32,163

Monocarboxylic acid transporter
protein located in the apical side of
kidneys, responsible for urate
excretion.

rs2242206 (G>T)
(Missense variant)

SLC16A9
(MCT9)

Beta effect= 0.315

47

Reported to substantially increase
the risk of ROL gout (p = 0.012),
with an odds ratio (OR) of 1.28.

151

SLC17A1
(NPT1)

Uric acid transport protein localized at
the apical membrane of the renal
proximal tubule which contributes to
urate efflux.

rs1183201(T>A)
(Intronic variant)

Known to be associated with
decreased urate levels and the A
allele seems to be the protective
allele in the EUR population.
Effect size= -0.062

32

SLC22A11
(OAT4)

SLC22A11 is expressed in the kidney
and encodes the organic anion
transporter 4 (OAT4), responsible for
urate reabsorption regulation.

rs17300741(A>G)
(Intronic variant)

It is linked to renal underexcretion of UA in EUR descent.
Beta effect= 0.062

32,149

SLC22A12
(URAT1)

SLC22A12 is Protein encodes for urate
transporter (URAT1), located on the
apical side of proximal tubules and
responsible for reabsorption of UA.

rs505802 (C>T)
(Intergenic variant)

It is associated to decrease SU
levels in the EUR population.
Effect size= -0.056

32

GCKR
(GCKR)

Glucokinase regulator protein has a role rs780094 (C>T)
in metabolic syndromes that may be
(Intronic variant)
associated with urate concentrations.

It is associated with glucose
metabolism, lipid regulation, SU
levels, and gout disease risk. Beta
effect= 0.052

32,152,153
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PDZK1
(PDZ)

Known as Scaffolding protein located
rs12129861(C>T)
in the apical side of the proximal tubule (Intergenic variant)
in the kidneys, which has a role in
maintaining the balance of urate levels
through the formation of urate
transportome.

LRRC16A
LRR16A is expressed in the apical side
(CARMIL1) of proximal tubules in the kidneys,
which encodes a protein called capping
protein ARP2/3 and myosin-I linker
(CARMIL). This protein has a role in
urate transportome formation, which
mediates UA reabsorption.

rs742132 (A>G)
(Intronic genetic
variation)
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It is associated with lower serum
urate levels among people of
EUR ancestry. Effect size= -0.06

32,164

A risk allele related to increased
risk of gout in Europe.
Beta effect= 0.054

32,157

Table 2.3: Uric acid risk allele frequencies comparisons Asian and Native Hawaiian and Pacific Islanders
Gene (SNP)

SNP
Type

Allele

EUR
% (n)

Filipino
% (n)

Korean
% (n)

Japanese
% (n)

Hawaiian
% (n)

Marshallese
% (n)

Samoan
% (n)

ABCG2
(rs2231142 G>T)
SLC2A9
(rs734553 G>T)
SLC17A1
(rs1183201T>A)
SLC16A9
(s2242206 G>T)

Missense

G
T
G
T
A
T
G
T

90.6 (911)
9.4 (95)
24.5 (246)
75.5 (760)
46.1 (464)
53.9 (542)
73.4 (738)
26.6 (268)

54.2 (194)*
45.8 (164)
1.2 (4)*
98.8 (348)
20.9 (73) *
79.1 (277)
55.0 (197) *
45.0 (161)

72.2 (133)*
27.8 (51)
1.7 (3)*
98.3 (183)
14.6 (26)*
85.4 (152)
40.8 (75) *
59.2 (109)

74.4 (278) *
25.6 (96)
0.5 (2)*
99.5 (368)
17.1 (63)*
82.9 (305)
44.5 (163)*
55.5 (203)

87.3 (253)
12.7(37)
9.1 (26)*
90.9 (260)
34.0 (98)*
66.0 (190)
54.9 (158)*
45.1 (130)

82.4 (201)*
17.6 (43)
0 (0)*
100 (242)
57.2 (135)*
42.8 (101)
55.5 (132)*
44.5 (238)

68.9(251)*
31.1 (113)
1.7 (6)*
↑
98.3 (358)
28.4 (103)* ↓
71.6 (259)
60.7 (221)* ↓
39.3 (143)

GCKR
(rs780094 C>T)
SLC22A11
(rs17300741 A>G)

Missense

C
T
A
G

58.9 (593)
41.1 (413)
46.2 (465)
53.8 (541)

55.1 (197)
44.9 (161)
85.3 (297)*
14.7 (51)

58.2 (107)
41.8 (77)
89.6 (163)*
10.4 (19)

42 (156) *
58 (216)
84.7 (305)*
15.3 (55)

65.9 (190)
34.1 (98)
72.3 (201)*
27.7 (77)

64.5 (156)
35.5 (86)
70.0 (167) *
30.0 (73)

69.4 (254* ↑
30.6 (112)
78.5 (281)* ↑
21.5 (77)

SLC22A12
(rs505802 C>T)
LRRC16A
(rs742132 A>G)

Intergenic T
C
Intronic
A
G

70.7 (711)
29.3 (295)
69.0 (694)
31.0 (312)

21.6 (79)*
78.4 (287)
69.7 (251)
30.3 (109)

20.4 (38)*
79.6 (148)
78.0 (142)
22.0 (40)

18.3 (68)*
81.7 (304)
78.2 (291)*
21.8 (81)

37.6(109)*
62.4 (181)
58.6 (171)*
41.4 (121)

2.1 (5) *
97.9 (230)
70.0 (168)
30.0 (72)

31.5(116)*
68.5 (252)
51.7(188)*
48.3 (176)

↓

39.3 (106)* 39.5 (90)*
60.7 (164) 60.5 (138)

46.5 (159*
53.5 (183)

↓

Intronic
Intronic
Intronic

Intronic

PDZK1
Intergenic C
54.1 (544) 44.7 (151)* 56.8 (92)
48.9 (178)
(rs12129861 C>T)
T
45.9 (462) 55.3 (187)
43.2 (70)
51.1 (186)
The bolded letter refers to the risk allele linked to HU/gout
* Indicates statistical significance p<0.006 between minorities and comparator group (EUR)
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Gout/
Urate
Effect (↑↓)
↑

↑

Table 2.4: Uric acid Genotype frequencies comparisons Asian, Native Hawaiian, and Pacific Islanders
Gene (SNP)

Genotype

EUR
% (n)

Filipino
% (n)

Korean
% (n)

Japanese
% (n)

ABCG2
(rs2231142 G>T)

GG
GT
TT

82.3 (414)
16.5 (83)
1.2 (6)

28.5 (51)
51.4 (92)
20.1 (36)

56.5 (52)
31.5 (29)
12.0 (11)

SLC2A9
(rs734553 G>T)

GG
GT
TT

5.6 (28)
37.8 (190)
56.6 (285)

2.3 (4)
97.7 (172)

SLC17A1
(rs1183201 T>A)

AA
AT
TT

23.1 (116)
46.1 (232)
30.8 (155)

SLC16A9
(rs2242206 G>T)

GG
CT
TT

GCKR
(rs780094 C>T)
SLC22A11
(rs17300741A>G)
SLC22A12
(rs505802 C>T)

Marshallese
% (n)

Samoan
% (n)

56.7 (106)
35.3 (66)
8.0 (15)

Native
Hawaiian
% (n)
75.5 (110)
23.1 (33)
1.4 (2)

68.0 (83)
28.7 (35)
3.3 (4)

48.9 (89)
40.1 (73)
11.0 (20)

3.2 (3)
96.8 (90)

1.1 (2)
98.9 (183)

1.4 (2)
15.4 (22)
83.2 (119)

100 (121)

3.3 (6)
96.7 (176)

4.0 (7)
33.7 (59)
62.3 (109)

1.1 (1)
27.0 (24)
71.9 (64)

3.8 (7)
26.6 (49)
69.6 (128)

11.8 (17)
44.4 (64)
43.8 (63)

29.7 (35)
55.0 (65)
15.3 (18)

6.6 (12)
43.7 (79)
49.7 (90)

54.9 (276)
37.0 (186)
8.1 (41)

32.9 (59)
44.1 (79)
23.0 (41)

15.2 (14)
51.1 (47)
33.7 (31)

16.9 (31)
55.2 (101)
27.9 (51)

34.7 (50)
40.3 (58)
25.0 (36)

31.9 (38)
47.1 (56)
21.0 (25)

33.0 (60)
55.5 (101)
11.5 (21)

CC
CT
TT
AA
AG
GG

33.6 (169)
50.7 (255)
15.7 (79)
23.5 (118)
45.5 (229)
31.0 (156)

31.8 (57)
46.4 (83)
21.8 (39)
73.6 (128)
23.5 (41)
2.9 (5)

35.9 (33)
44.6 (41)
19.5 (18)
80.2 (73)
18.7 (17)
1.1 (1)

18.8 (35)
46.3 (86)
34.9 (65)
71.7 (129)
26.1 (47)
2.2 (4)

41.7 (60)
48.6 (70)
9.7 (14)
54.0 (75)
36.7 (51)
9.3 (13)

41.3 (50)
46.3 (56)
12.4 (15)
53.3 (64)
32.5 (39)
14.2 (17)

48.1 (88)
42.6 (78)
9.3 (17)
62.6 (112)
31.8 (57)
5.6 (10)

CC
CT

9.9 (50)
38.8 (195)

61.2 (112)
34.4 (63)

63.4 (59)
32.3 (30)

67.7 (126)
28.0 (52)

35.8 (52)
53.1 (77)

90.9 (110)
8.3 (10)

48.9 (90)
39.1 (72)

51

TT
51.3 (258) 4.4 (8)
LRRC16A
AA
48.3 (243) 48.9 (88)
(rs742132 A>G)
AG
41.4 (208) 41.7 (75)
GG
10.3 (52)
9.4 (17)
PDZK1
CC
30.4 (153) 42 (71)
(rs12129861 C>T)
CT
47.3 (238) 5.4 (9)
TT
22.3 (112) 52.6 (89)
The bolded letter refers to the risk allele linked to HU/gout

4.3 (4)
60.4 (55)
35.2 (32)
4.4 (4)
54.3 (44)
4.9 (4)
40.8 (33)
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4.3 (8)
62.4 (116)
31.7 (59)
5.9 (11)
47.8 (87)
2.2 (4)
50.0 (91)

11.1 (16)
30.2 (44)
56.8 (83)
13.0 (19)
36.3 (49)
5.9 (8)
57.8 (78)

0.8 (1)
51.7 (62)
36.7 (44)
11.6 (14)
37.7 (43)
3.5 (4)
58.8 (67)

12.0 (22)
25.2 (46)
52.8 (96)
22.0 (40)
42.2 (72)
8.7 (15)
49.1 (84)

Table 2.5: Summary of Total Risk Alleles across Asian, Native Hawaiian, and Pacific Islanders
EUR
Alleles significantly different from EUR
HU or/gout risk allele index*

Reference (8 SNPs)

Percentage of risk allele*

Japanese

Korean

Filipino Marshallese Hawaiian

Samoan

100%
(8/8)

75%
(6/8)

75%
(6/8)

75%
(6/8)

75%
(6/8)

100%
(8/8)

8

5

6

4

4

5

100%
(8/8)

83.5%
(5/6)

100%
(6/6)

66.5%
(4/6)

66.5%
(4/6)

62.5%
(5/8)

*Indicates the risk allele that contributes to hyperuricemia or gout.
EUR: European
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Table 2.6: Hardy Weinberg Equilibrium (HWE) Assessment of Targeted SNPs
Gene/SNP

Filipino

Japanese

SLC17A1
0.7789
0.4036
(rs1183201)
PDZK1
0.0000
0.0000
(rs12129861)
SLC22A11
0.4439
0.9076
(rs17300741)
ABCG2
0.6376
0.3044
(rs2231142)
SLC16A9
0.1473
0.1129
(rs2242206)
SLC22A12
0.8183
0.3809
(rs505802)
SLC2A9
0.8788
0.9410
(rs734553)
LRRC16A
0.8602
0.3476
(rs742132)
GCKR
0.3981
0.4903
(rs780094)
** Indicates for deviated from HWE p<0.05

Samoan

Marshallese

Hawaiian

Korean

0.3326

0.1743

0.9035

0.4449

0.0000

0.0000

0.0000

0.0000

0.4465

0.0109**

0.3224

0.9926

0.3942

0.8952

0.7880

0.0407**

0.0275**

0.6046

0.0250**

0.5789

0.2042

0.1753

0.1123

0.9398

0.8211

0.0000

0.4077

0.8743

0.4492

0.1642

0.0384**

0.8089

0.9620

0.9112

0.3209

0.4184
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Table 2.7: SNPs Call Rate (%)

Filipino
Japanese
Korean
Native
Hawaiian
Marshallese
Samoans
Overall

SLC22A12
(rs505802)
96.3
98.4
97.9
99.3

SLC17A1
(rs1183201)
92.1
97.3
93.6
98.6

SLC16A9
(rs2242206)
94.2
96.8
95.9
98..6

ABCG2
(rs2231142)
94.2
98.9
96.8
99.3

SLC22A11
(rs17300741)
91.5
95.2
95.7
95.2

PDZK1
(rs12129861)
88.9
96.2
85.2
92.4

SLC2A9
(rs734553)
92.6
97.8
97.8
97.9

LRRC16A
(rs742132)
94.7
98.4
95.7
98.6

GCKR
(rs780094)
94.7
98.4
96.8
98.6

93.8
98.4
97.4

91.4
96.7
95.1

92.2
97.3
96

94.6
97.3
96.9

93
97.3
94.3

88.3
91.4
91

93.7
97.3
96.1

93
97.3
96.4

93.7
97.8
96.7
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Table 2.8: Abbreviations
SU
HU
SNP
NHANES
GWAS
EUR
NHPI
HD
CVD
IR
CKD
PE
MAF
HWE

Serum urate
Hyperuricemia
Single nucleotide polymorphism
National Health and Nutrition Examination Survey
Genome-Wide Association Studies
European
Native Hawaiian and Pacific Islander
Health Disparities
Cardiovascular Disease
Insulin Resistance
Chronic Kidney Disease
Preeclampsia
Minor Allele Frequency
Hardy-Weinberg Equilibrium
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Chapter 3: Assessment of Cardiometabolic Risk Factors among selected Pregnant
Asian-Pacific Islander groups.

57

Abstract
Background
Preeclampsia (PE), known as severe new onset of the hypertensive disorder
occurring after 20 weeks of gestation, can lead to maternal and fetal defects. Several
risk factors are associated with developing PE. The most common risk factors include
the history of comorbid conditions, advanced/younger age, high body mass index
(BMI), or history of chronic kidney disease (CKD). Hyperuricemia (HU) was found to
be an independent risk factor for developing cardiovascular diseases. Biologically,
dysfunctional urate transporters due to genetic polymorphisms could lead to clinical
consequences associated with increased or decreased serum urate (SU) levels. HU has
been reported as a significant risk predictor of developing cardiometabolic diseases
(CMDs). Examples of CMDs include chronic hypertension (CHTN), gestational
hypertension (GHTN), diabetes mellitus (DM), and gestational diabetes mellitus
(GDM). CMDs are considered major risk factors associated with developing PE.
Therefore, this study focuses on assessing the genetics of uric acid disposition and other
non-genetic factors in developing CMDs across selected pregnant Asian-Pacific
Islander groups.
Methods
The biospecimens repository at the University of Hawaii provided DNA samples
of consenting post-partum women. The DNA was extracted from the cord blood and
genotyped at the Genomics and Bioinformatics Shared Resource, Cancer (Honolulu,
HI). Nine urate genes—ABCG2, SLC2A9, SLC16A9, GCKR, SLC22A11, SLC22A12,
LRR16A, PDZK1, and SLC17A1—were selected due to their significant association with
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HU and gout risk. Age and BMI were selected as non-genetic risk factors associated
with developing CMDs.
The Hardy-Weinberg Equilibrium (HWE) for genotype frequencies was
assessed using the Chi-Square test with p<0.05 for statistical significance.
The association between genotype and CMDs phenotypes (CHTN, GHTN, DM, and
GDM) were assessed using chi-square or Fisher exact test as appropriate at p<0.05 in
different genetic assumption models (Additive, Dominant, and Recessive). Then a
logistic regression analysis test was used after conducting a global hypothesis test to
determine the association between age, BMI, and CMDs phenotype. Finally, the
univariate statistical analysis (ANOVA) was used to ascertain the association between
BMI and different UA genotypes.
Results
This study involved 429 post-partum pregnant women aged 18 years or older
who self-reported their respective race and ethnicity. Specifically, we chose the Filipino
group as the Asian subgroup and the Samoan population as the Pacific Islander
subgroup. No one of the participants reported a history of gout disease. Based on the
HWE results, we excluded some UA gene/SNPs in Filipino and Samoan sample
populations. All UA risk alleles were consistent with HWE (p>0.05), except PDZK1
(rs12129861 C>T) in both groups, and SLC16A9 (rs2242206 G>T) in the Samoan group
(p =0.0275). Using a chi-square test, we found a significant association between UA
genotype and diabetes mellitus in the Filipino group. These genotypes were ABCG2
(rs2231142 G>T) in both additive and recessive models 75% vs. 18.9% (p=0.016,
0.026, respectively).
Meanwhile, in the Samoan group, we found trending toward significant
differences between the recessive genetic model of UA genotype of SLC22A11
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(rs17300741 A>G) in the CHTN and GDM. The proportion of UA AA genotypes
trended significantly higher in the presence of CHTN (100%) versus (61.2%) in
participants without (p=0.085). The proportion of the UA genotype AA of SLC22A11 in
the presence of GDM was trending toward a significantly higher, around (80.9%) vs.
(60.2%) in the Samoan population without GDM (p=0. 063). In performing a logistic
regression analysis, we found age associated with developing CHTN (OR=1.11, 1.0261.225 95% CI, p=0.0139) in the Filipino population. Moreover, we found a trending
toward a significant association between BMI and CHTN in the Filipino cohort
(OR=1.08, 0.99- 1.13 95% CI, p= 0.06). Furthermore, age also associated with
developing GDM in the Samoan population (OR=1.15, 1.063- 1.254 95% CI, p=
0.0006).
In a univariate analysis test in the Filipino sample population, our results found a
significant difference in the mean BMI among ABCG2 (rs2231142 G>T) within the
dominant model (mean of GT+ TT= 24.14 relative to GG (reference)= 26.88, (p= 0.04).
In the Samoan population, we found a trending toward significant under the additive
model of GCKR (rs780094 C>T) (mean of TT= 26.56 compared to 29.72 of CC
(reference), (p = 0.08). Moreover, significant differences in mean BMI have been
shown in the Samoan population under the additive and recessive model
of LRRC16A (rs742132 A>G). Under the additive model, the mean BMI of AA
(genotype risk) was lower, 27.47 relative to 28.65 of GG (reference) p=0.03. Moreover,
under the recessive model, the mean BMI of AA (genotype risk) was lower, 27.47
compared to 30.3 of AG+GG (reference) p=0.031).
Conclusion
The UA risk alleles were associated with the development of diabetes mellitus
among the Filipino group. In contrast, they were trending toward an association
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between UA risk alleles and gestational diabetes and chronic hypertension in Samoan
ancestry. Age risk factors have shown an association with CMDs developments in both
Filipinos and Samoans. Moreover, BMI has shown an association with CHTN in the
Filipino population. Our statistical analysis results are consistent with a previous study
that confirms the Asian population had the highest prevalence of UA risk alleles relative
to the Pacific Islander population. In addition, these results are consistent with current
studies showing that the Asian population has the highest prevalence of CMDs
compared to the Pacific Islander population.
Key Words: Asian-Pacific Islanders, Gestational Diabetes, Chronic Hypertension,
Gestational Hypertension, Preeclampsia, Filipinos, Samoans, Uric acid, Single
Nucleotide Polymorphisms
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Introduction
Preeclampsia (PE) is a new onset of the hypertensive disorder occurring after 20 weeks
of gestation, potentially leading to maternal and fetal defects. This condition affects up
to 8% of pregnant women in the world. Additionally, in the US, severe PE risk
increased up to six-fold between 1980 and 2003, which increased the burden and costs
on the health care system.165 Several risk factors are related to developing PE, including
family history, multiple pregnancies, maternal comorbidities such as diabetes, CVD,
CKD, genetic predisposition, and in some population such as African and AfricanAmerican ancestry (odds ratio [OR]: 3.70, 95% CI: 2.19–6.24) compared to white
women.166–168 Nakagawa et al. found the prevalence of PE in the under-represented
population of Hawaii to be higher among the Asian and Pacific Islander populations.169
Several studies have suggested the association between UA during pregnancy and PE
causing severe maternal and fetus complications.170
Chemically, uric acid (UA) is the final product of purine metabolism.171 Placental
ischemia enhances xanthine oxidase (XO) activation, further activating uric acid
formation.172 The first discovered association between high serum uric acid (SU) and
PE in pregnant women was in 1934.173 In 2008, a large-scale prospective multi-center
study was conducted by Paula et al., wherein it was pointed out that SU level correlated
with the perinatal prognosis of patients with hypertensive disorders of pregnancy
(HDP).174
Hyperuricemia (HU) potentiates PE by stimulating inflammation, endothelial
dysfunction, and oxidative stress.175 Multiple studies reported the association between
SU and adverse maternal outcomes. Maternal gout, for instance, was found to be
associated with an increased risk of low birth weight, preterm birth, Cesarean delivery,
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and PE pathology.176,177 A recent study reported a correlation between hypertension and
UA levels, as well as the predictive capability of UA levels in severe PE.178
Additionally, some studies suggest that HU could be an essential indicator for
pregnancy-related disorders, including HDP development, PE, and preterm birth.177
Hyperuricemia could lead to hypertension and proteinuria, which are clinical markers
commonly used to diagnose PE.179 Women with PE have elevated SU, representing an
equally effective marker to proteinuria in detecting perinatal risk in gestational
hypertensive women.180’181 Relative to women with PE and normal SU, women with PE
and hyperuricemia have a higher risk of adverse perinatal outcomes.180,181 Nonetheless,
a correlation between hyperuricemia and maternal and fetal morbidity pointing to its
diagnostic value in predicting PE development has been reported.182
Hyperuricemia could be utilized as a predictor of fetal outcome in women with
PE. Studies have found that women with hyperuricemia occurring before 35 weeks of
gestation often have deliveries with adverse consequences, such as intrauterine growth
restriction (IUGR) and intrauterine death (IUD).183 A recent study reported that 72% of
newborns of mothers with hyperuricemia had low birth weights. In comparison, 62% of
newborns from women with normal uric acid levels had average birth weights.184
Despite these promising findings, it is unclear whether UA could be used as a
marker for PE or adverse maternal outcomes.182 Opposing studies have suggested that
high SU was not related to negative maternal effects. Moreover, SU may not be
involved in PE development, and thereby might not be a reliable marker for predicting
the incidence of adverse pregnancy outcomes.185 Studies investigating the effects of SU
on pregnancy and its potential as a marker for various maternal outcomes were
inconsistent.
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HU has the potential to inhibit trophoblast invasion of the placenta, resulting in
reduced blood supply and oxygen for the fetus.186 Biologically, HU could also reduce
nitric oxide (NO) production in endothelial cells, contributing to poor trophoblast
invasion187. This mechanism could imply the role of HU in PE pathogenesis.175
PE can happen due to several risk factors involving coexisting comorbidities,
most of which could be associated with HU/gout. Furthermore, several risk factors may
increase the risk of PE, such as diet and social factors, socioeconomic status, and
psychological disorders. Additionally, some ethnic groups—for instance, African
Americans—have a significantly higher risk of PE.188,189
Genetic polymorphism of the urate transportome may lead to clinical disorders
such as hyperuricemia. An example of the UA genes is SLC22A12 (URAT1), ABCG2,
which showed a strong association with chronic renal injury. 190’139 Interestingly,
reports showed significant association between various UA risk alleles, single
nucleotide polymorphisms (SNPs), and PE among pregnant South African women. A
case-control study demonstrated a strong association between the human urate
transporter SCL22A12/ rs502802 (URAT 1) and PE, specifically late-onset PE versus a
control group of pregnant women (OR=1.73, 95% CI=1.258- 2.442, p=0.028).191
The results of that previous study may highlight a possible role of UA risk
alleles in the development of chronic metabolic diseases. The link between HU/gout and
chronic complications, such as cardiovascular diseases (CVD), renal impairment, and
metabolic syndromes, may be exacerbated by HU. HU is implicated in the progress of
many metabolic diseases, as previously mentioned.192 Clinically, several risk factors
have been associated with the development of PE disease. According to the National
Institute for Health and Care Excellence (NICE) guidelines, these risk factors are
classified into high and moderate levels. If the pregnant women had a history of
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hypertension in their last pregnancy or suffered from gestational diabetes, kidney
disorders, or autoimmune diseases, they were classified at a high risk of PE.
Additionally, some other clinical factors like the woman’s age (≥ 40-years) or body
mass index (BMI) ≥ 35 kg/m2, as well as other risks, were classified as moderate
clinical determinants.193 Pregnant women diagnosed with diabetes mellitus as well as
those who develop gestational diabetes are at a two- to four-fold risk of being diagnosed
with preeclampsia.194
In this study, we hypothesized that UA genetic polymorphisms and non-genetic
factors including age and BMI may contribute to metabolic disorder development,
which are major risk factors for maternal outcomes in the Asian and Pacific Islander
subgroups. This study proposed to look at the impact of several UA gene/SNP pair
variations among selected pregnant women, variations that had been shown to cause
cardiometabolic syndromes such as diabetes mellitus (DM), gestational diabetes
mellitus (GDM), chronic hypertension (HTN), and gestational hypertension (GHTN).
Finally, this analysis aimed to assess the association between genetic/non-genetic risk
factors contributing to cardiometabolic disorders, which a major risk factors of PE
disease.
Methods
Preliminary Statistical analysis
Previously, we aimed to test an association between cardiometabolic diseases
and UA risk alleles using simple and multiple logistic regression analysis, adjusting for
other covariates, including age and body mass index (BMI), across the entire sample
population of the Asian and native Hawaiian-Pacific Islander populations.
Unfortunately, the results were uninterpretable because they were biologically and
directionally inconsistent with some UA genes associated with cardiometabolic
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diseases. We postulated that inconsistency might partly be due to the low frequency of
the outcomes and population heterogeneity. All previous statistical analyses appear
in the appendix section.
As a follow-up, we decided to focus our analysis only on Filipino and Samoan
groups using logistic regression analysis. Although the logistic regression results were
uninterpretable with some genes, it pointed to the possibility of specific non-genetic risk
factors associated with developing CMDs. We describe the process in the appendix
section.
Frist, we used chi-square and Fisher exact tests at p<0.05 to compare the
prevalence of comorbidities in the Asian population versus native Hawaiians and
Pacific Islanders. We summarize all the results in Table 3.3. Figure 3.1
In addition, we compared the same comorbidities conditions among Filipino relative to
the Samoan population, as well we compare the prevalence of each ethnicity to the
overall population. We summarized all findings in the Table 3.2., Figure 3.2.
To minimize the heterogeneity within the population, while considering the sample size
and the frequency of the outcome of interest, we decided to focus our analysis only on
Filipino and Samoan populations to run genetic and non-genetic factors models. We
assessed the association between CMDs and the prevalence of HU genotypes, using chisquare or Fisher exact test p<0.05. In addition, we used multiple logistic regression
models to test the association between non-genetic risk factors (age/BMI) and
cardiometabolic diseases. Moreover, a univariate analysis test (ANOVA) was used to
analyze the differences among mean BMI between different genotypes of UA genes.
We reported the results of the exploratory analysis of the entire cohort combined in the
appendix section.
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Study participant and urate genes
Participants in this study were pregnant women ≥18 years old. All of them selfreported as having Asian or Pacific Islander subgroups ancestry (Filipino and Samoan).
Age, gestational age, BMI, and other demographic information were provided. In Table
3.1, we summarize all demographic characteristics. Blood samples were collected from
participants for DNA extraction. The uric acid genes addressed in this study include
SLC17A1 (rs1183201), PDZK1 (rs12129861), SLC22A11 (rs17300741), ABCG2
(rs231142), SLC2A9 (rs734553) G>T, SLC164A9 rs2242206, SLC22A12 (rs505802),
CARMIL1, LRRC16A rs742132, and GCKR (rs780094). It should be noted that the
University of Hawaii provided all data we mentioned.
Following HWE analysis results and other quality assessments across the
selected population groups, we excluded PDZK1, SLC2A9 in both groups, and
SLC16A9 genes in the Samoan population. Social risk factors such as a history of
smoking and alcohol use were reported in the demographic information (Table 3.2).
Maternal medical conditions, including gestational hypertension, chronic hypertension,
gestational diabetes, diabetic mellitus, Preeclampsia, and premature labor, were also
reported and appear in Table 3.2. Participants’ younger than18 years of age or having a
history of cancer and/or organ transplants were excluded.
Sample procurement and genotyping
Genotype, medical, and demographical information were provided by the University of
Hawaii biospecimens repository. Post-partum women gave consent to donate their
placentas and umbilical cords. The DNA was extracted from the blood and genotyped at
the genomics and Bioinformatics Shared Resource, Cancer center (Honolulu, HI). A
customized TaqMan genotyping assay panel was run on the Quant Studio 12K Flex
Real-Time PCR system (Applied Bio systems). All study details were previously
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published.129 All study materials were reviewed and exempted by the University of
Hawaii Human Studies Program (protocol Number: 2018-00225).

Statistical analysis
Data obtained during the study were analyzed utilizing R software Version
1.3.1073. We assessed our data with Hardy-Weinberg Equilibrium at P <0.05 across our
selected population (Table 3.6). Chi-square statistical analysis and Fisher exact tests
were used to estimate the associations between gene variations and cardiometabolic
phenotypes across all three genetic models (additive, dominant, and recessive) at
p<0.05. The phenotypes of interest were presence and absence of gestational
hypertension, gestational diabetes, chronic hypertension, and diabetic mellitus. Other
risk factors, including age and BMI, were assessed in relationship to cardiometabolic
diseases using multiple logistic regression analysis tests and reported odds ratios (OR),
95% CI and p-value <0.05 for statistical significance. The association of BMI amongst
the different genotypes of UA genes was determined using one-way ANOVA.
Results
Our previous study concluded that the Asian population had the highest
prevalence of UA risk alleles as compared to native Hawaiians and Pacific Islanders
(Table 2.5). Moreover, our results show that the Asian population had a significantly
higher prevalence of cardiometabolic disorders as compared to native Hawaiian and
Pacific Islanders (Table 3.3) (Figure 3.1). Consistently, the current study has shown that
Filipinos have the highest prevalence of cardiometabolic diseases relative to the
Samoans (Table 3.2, Figure 3.2). The demographic, clinical, and social characteristics
across selected population ancestry is summarized in Table 3.1. Among all uric acid
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gene/SNPs, some deviated from HWE, and those deviations are summarized in Table
3.6.
Hardy-Weinberg Equilibrium and quality control
We used a chi-square statistical test analysis to perform HWE principle in order to
check all genes/ SNPs for deviation or consistency in regard to HWE across selected
populations. In both Filipino and Samoan populations, all UA risk alleles were
consistent with HWE, except PDZK1 (rs12129861 C>T) in both subgroups, and
SLC16A9 (rs2242206 G>T) in the Samoan population p =0.0275 (Table 3.6). In
addition, we excluded SLC2A9 (rs734553 G>T) in both groups due to a lack of GG
frequency.

Association of UA Genotypes (Additive, Dominant, and Recessive models) and
Cardiometabolic Diseases amongst Filipino and Samoan Subgroups
Based on the overall dataset, the prevalence of comorbid diseases, and the
largest sample size across Asian, native Hawaiians, and Pacific Islanders, we selected
the Filipino and Samoan population groups to determine the association between
genotypes and phenotypes. All UA genotype risk alleles were included in the Filipino
population except PDZK1, due to its deviation from HWE (Table 3.6). In the Samoan
population, we excluded PDZK1 and SLC16A9 out of a total of nine UA genes, also due
to their deviation from HWE (Table 3.6).
In the Filipino cohort, we found a trending toward significant differences
between SLC16A9 (rs2242206 G>T) and CHTN. The proportion of the TT risk allele of
SLC16A (rs2242206 G>T) was lower (0%) in the presence of CHTN, relative to
(24.4%) in participants without CHTN in both additive (TT vs. GT vs. GG (reference))
and recessive (TT vs. GT+TT (reference)) models (p=0.09, 0.07), respectively.
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Moreover, our analysis has not shown any statistical significance among the rest of UA
genes and chronic hypertension in Filipinos (Table 3.5). Meanwhile, in the Samoan
group, there was trending toward a significant relationship between SLC22A11
(rs17300741 A>G) and CHTN. Under the recessive model (AA vs. AG+GG
(reference)), the proportion of AA risk alleles were higher (100%) in participants who
were diagnosed with CHTN compared to (61.2%) in participants without. (p=0.08).
(Table 3.4).
Across the Filipino population, for those with diabetes mellitus (DM), there was
a significantly higher prevalence of genotype risk alleles of ABCG2 (rs2231142 G>T)
and diabetes mellitus in both additive and recessive genetic models. (Table 3.5). The
proportion of TT risk allele of ABCG2 (rs2231142 G>T) in the additive model (TT vs.
GT vs. GG (reference)) and recessive model (TT vs. GT+TT (reference)) was
significantly higher in the presence of DM (75%) as compared to the absence of DM
(18.9%) (P=0.016, 0.026), respectively. (Table 3.5).
In contrast, within the Samoan group, our analysis found a significantly lower
proportion of TT risk genotype of SLC17A1 (rs1183201 T>A) in the presence of DM
than in its absence (p<0.05) (Table 3.4). Our statistical analysis results have not shown
any significant differences between UA genotypes and gestational hypertension
phenotype in both Filipino and Samoan groups (Table 3.4 & Table 3.5).
In gestational diabetes mellitus (GDM), our analysis did not show any statistical
differences in the proportion of UA genotype and phenotype across the Filipino
population. However, in the Samoan population, we saw a trending toward a significant
association between SLC22A11 (rs17300741 A>G) and GDM. Under the recessive
model (AA vs. AG+GG (reference)) of SLC22A11 (rs17300741 A>G), the proportion of
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AA genotype was higher (80.9%) in participants who had been diagnosed with GDM
compared to (60.2%) in Samoan participants without (p=0.06). (Table 3.4).
Association of Cardiometabolic Diseases (CHTN, DM, GHTN, and GDM) and nongenetic risk factors (BMI and age) amongst Filipino and Samoan population
We used multiple logistic regression analysis models for both global and
secondary hypothesis to estimate age and BMI, which are considered non-genetic risk
factors associated with the development of cardiometabolic diseases. We found what we
determined to be an odd ratio, 95% CI, and p-value of multiple logistic regression
analysis, which has been summarized in Table 3.7.
Results of the analysis show higher odds significantly associated between
CHTN and age in the Filipino subgroup [(OR=1.11, 95% CI= 1.026- 1.225,
p= 0.0139)], as well as a trending toward significant in BMI [(OR=1.06, 95% CI=
0.991- 1.135, p= 0.06)] (Table 3.7). No significant association was found to exist
between age, BMI, and diseases such as DM, GDM, and GHTN in the Filipino
population. (Table 3.7). In contrast, for the Samoan population, the statistical analysis
showed a significant association between age and GDM [(OR=1.15, 95% CI= 1.061.25, p= 0.0006)]. (Table 3.7).
The differences in the mean BMI amongst UA genotypes in Filipino and Samoan
population
In this part of the analysis, we tested the differences in the mean BMI across the
different genotypes of UA genes in all three genetic models (additive, dominant, and
recessive). I started to test the assumption of variance using Bartlett’s test to decide on
using equal/unequal ANOVA. The statistical analysis showed a significant difference in
the mean BMI of ABCG2 (rs2231142 G>T) under the dominant model (GT+TT vs. GG
(reference)) across the Filipino population. Thus, the mean BMI of GT+TT of the
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dominant model was lower relative to the mean of the GG (reference) genotype (mean=
24.14 vs. 26.88, p=0.04), respectively. (Table 3.8) (Figure 3.3)
However, in the Samoan subpopulation, a trending toward significant was found
between mean of BMI and TT genotype of the additive model (TT compared to CC)
of GCKR (rs780094 C>T) (mean BMI of TT genotype was 26.56 relative 29.72 of CC
(reference) genotype (p=0.08). (Table 3.9) (Figure 3.4). Moreover, in the Samoan
population, significantly lower differences were found under additive (GG (reference)
vs. AG+GG) and recessive (AG+GG (reference) vs. AA) genetic models of LRRC16A
(rs742132 A>G). The mean BMI of AA was 27.47 is in contrast to the reference GG=
28.65, (p=0.03) in the additive model (Figure 3.5), while in the recessive genetic model,
the mean BMI of AA= 27.47 was lower than the reference AG+GG= 30.31 at (p=0.03)
(Figure 3.6). Furthermore, no significant differences were found in the remaining genes
and BMI across both populations (Table 3.9).
Discussion
Hypertension is considered one of the most common diseases in the Asian/Pacific
Islander populations.195 Pregnant women with a history of CHTN are considered more
susceptible to a higher risk of PE.193 Among many risk factors, UA is associated with
the development of cardiovascular diseases. Genetic polymorphisms of urate
transporters could cause an imbalance between urate excretion and reabsorption, which
could lead to metabolic disorders. Therefore, a high UA level could be an independent
predictor of several complications, such as hypertension.22 In our Filipino cohort, the
proportion of most UA genotypes were higher in participants that had CHTN versus
participants without CHTN, but there was not enough evidence to suggest a statistically
significant association (P>0.05). (Table 3.5). An example of UA risk alleles associated
with CVD is GCKR (rs780094 C>T) gene polymorphism, which is related to
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triglyceride and other cardiovascular risks.196 Our data analysis shows an insignificantly
higher proportion of T risk allele of the GCKR (rs780094 C>T) in the presence of
CHTN in all three genetic models (additive, dominant, and recessive) (36.4% vs.
20.7%, and 72.8% vs 67.4% vs. 36.4, and 20.7%, respectively, (p>0.05) (Table 3.5). At
this point, our results are inconsistent with available literature; therefore, further studies
should be conducted on a large enough sample size in order to validate the existing
results.
On the other hand, in the same Filipino group, the proportion of T risk allele
of SLC16A9 (rs2242206 G>T) trended significantly lower in women who had CHTN
compared to those without CHTN (0% vs. 24.4% p=0.090 in additive model (GT+TT
vs. GG (reference) and 0% vs. 24.4% p=0.069 in the recessive model (TT vs. GT+GG
(reference)) (Table 3.5). The results we found conflict with the physiological function
of SLC16A9 and its metabolic trait association. SLC16A9 codes for a monocarboxylic
acid protein (MCT9), which has a role in carnitine transportation and UA excretion
from the intestine. Carnitine is mostly excreted through the glomerular tubules of the
kidney. Based on kidney function, carnitine is a competitive substrate in regard to UA.
If it is not excreted well, carnitine could cause renal overload gout due to high UA,
causing cardiovascular dysfunctions and other metabolic traits.197
By contrast, in the Samoan subgroup, the study analysis results show a trend toward a
significantly higher proportion of AA genotype of SLC22A11 (rs17300741 A>G) under
a recessive genetic model (AG+GG (reference) vs. AA) in regard to the presence of
CHTN relative to non-CHTN. The proportion of AA genotype (100%) relative to
AG+GG (61.2%) p=0.0851). (Table 3.4). Flynn et al. have found that the SLC22A11
(OAT4) is strongly associated with UA and gout in the Pacific Islander population.198
Apart from this, we found that in our cohort, the prevalence of the A risk allele is
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significantly higher in both the Asian and native Hawaiian and Pacific Islander
populations than EUR.
Additionally, ABCG2 (rs2231142G>T), LRRC16A (rs742132 A>G), and GCKR
(rs780094 C>T) genotypes were insignificantly associated with increased risk of CHTN
in the Samoan population. Conversely, SLC22A12 (rs505802 C>T) and SLC17A1
(rs1183201 T>A) UA risk alleles were insignificantly lower in CHTN risk development
p >0.05 across the Samoan population. (Table 3.4).
Gestational hypertension (GHTN) can occur during pregnancy, causing an
elevation in blood pressure. During the first quarter of pregnancy, if the UA levels are
about 3.15 mg/dl it can be indicative of GHTN, which is classified as a decisive risk
factor of PE development. Hence, UA level is one of the predictive factors for
cardiometabolic diseases.199 Our analysis showed that Filipino-American population
groups in Hawaii had an insignificant association between UA gene polymorphisms and
GHTN. In the Filipino subgroup, UA genotypes of SLC22A11 (rs17300741 A>G),
SLC17A1 (rs1183201 T>A), ABCG2 (rs2231142 G>T), SLC16A9 (rs2242206 G>T),
and LRRC16A (rs742132 A>G) were insignificantly higher in the proportion of the risk
allele in the presence of GHTN (Table 3.4). It should be noted that Filipino-Americans
tend to have a higher risk of developing cardiometabolic conditions due to numerous
risk factors.200 Further studies are needed to explore the role of genetic factors
associated with heart-related diseases in the Filipino-American group.
On the other hand, our results have not shown any significant association
between UA gene polymorphisms and GHTN development in the Samoan subgroup.
Most UA genotypes had an insignificantly higher proportion in the presence of GHTN
relative to absence status p>0.05 in the Samoan population. These alleles include
SLC22A12 (rs505802 C>T), SLC17A1 (rs1183201 T>A), SLC22A11 (rs17300741
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A>G), and GCKR (rs780094 C>T) in all three genetic models, while ABCG2
(rs2231142 G>T) only appeared in dominant genetic model (Table 3.4). Although our
results may not be statistically significant, they are consistent with the biological
function of the association between UA gene polymorphisms and CMDs
development.197 The T risk allele of GCKR (rs780094 C>T) is an example of a
polymorphism that is biologically associated with the cardiometabolic trait.201
However, the AA genotype of LRRC16A (rs742132 A>G) was insignificantly lower in
proportion in regard to the presence of GHTN as compared to Samoan pregnant women
without GHTN in both dominant and recessive models p>0.05 (Table 3.4). What’s
more, LRRC16A genes have a biological role in metabolic traits, and our cohort results
show the opposite physiological direction in the Samoan population. We can hence
conclude that not only genetic factors contribute to metabolic diseases across the
different populations; indeed, there may be many other factors. This explanation leads
us to focus on other risk factors such as BMI and study their relationship to metabolic
traits. Lee et al. have reported that BMI over 21 kg/m2 and obesity are associated with
coronary heart disease at a level of approximately 58% in Samoan-Americans.202
Conversely, In the Filipino cohort, our analysis showed that the prevalence of AA
genotype of LRRC16A (rs742132 A>G) was higher in proportion in the presence of
GHTN relative to pregnant women without GHTN, but there was no evidence to fully
support that association (P>0.05) (Table 3.5).
Diabetes mellitus (DM) is a metabolic disorder resulting in reduced insulin
secretion, causing an elevation of the blood glucose level, leading to hyperglycemia.203
A history of DM, either type 1 or 2, among pregnant women increases the risk of PE as
well as gestational diabetes.194 Biologically, there is a potential association between
urate transporters’ heritability and metabolic disorder development.197 Hence, we
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conducted our analysis toward detecting an association between diabetes, gestational
diabetes, and UA genetic polymorphisms across Filipino and Samoan subgroups.
SLC22A12 (rs505802 C>T) is encoded for urate transporter 1 (URAT1), a major
transporter responsible for urate reabsorption. In addition, SLC22A12 has a role in
phosphorylation enzyme called phosphokinase-c (PKC), which contributes to activating
phosphoinositide inositol-3 kinase (PI3K), which is associated with insulin secretion
and glucose uptake. Reduced function in this protein reduces insulin secretion from the
beta cell, causing insulin resistance and DM. 197 Although the prevalence of the CC
genotype of SLC22A12 (rs505802 C>T) has been shown to be higher in the presence of
DM than in non-DM Filipino pregnant women in an additive model (TT (reference) vs.
CC)) 75% vs. 60.9%, respectively, our analysis did not show any significant association
(p=0.10) (Table 3.5). In addition, another genetic model had also found a nonsignificantly higher proportion of the C risk allele SLC22A12 (rs505802 C>T) in
participants with DM as compared to the non-DM p>0.05 across the Filipino cohort
(Table 3.5).
In the same Filipino cohort, the proportion of TT genotype of ABCG2
(rs2231142 G>T) shows a significantly higher association that contributed to DM
relative to women without DM in both additive and recessive genetic models (75% vs.
18.9% p 0.01627 and 75% vs. 18.9 p= 0.02611, respectively) (Table 3.5). It is well
established that ABCG2 is highly associated with hyperuricemia and gout across
different populations, and that it possibly contributes to cardiometabolic illnesses such
as diabetic mellitus.204
As previously mentioned, SLC16A9 codes for a protein monocarboxylic acid
transporter 9 (MCT9), which has a role in carnitine transporter that assists in insulin
secretion improvement; thus, lack of SLC16A9 function is associated with many
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conditions such as type 2 DM and cardiovascular disorders.197 Our analysis has found a
non-significantly higher proportion of the TT genotype of SLC16A9 (rs2242206 G>T)
under a dominant model (GT+TT vs. GG (reference)) across Filipino participants that
had DM relative to participants without (75% vs.66.8%, respectively, p=1). Other
genetic models also resulted in higher proportions but were not considered statistically
significant (Table 3.5). Furthermore, the analysis has found a higher proportion in both
genotypes of SLC22A11 (rs17300741 A>G) and GCKR (rs780094 C>T) in regard to
those with DM within the Filipino cohort, but these proportions were statistically
insignificant (p>0.05) (Table 3.5). Our final analysis showed an association between
UA genotypes and developing DM across Filipino pregnant women, supporting that
hyperuricemia may be considered a predictor of the risk factor for CMD.
In the Samoan subgroup, our analysis found a non-significantly higher proportion
of the AA risk genotype of SLC22A11 (rs17300741 A>G) across pregnant women who
had DM (75%) as compared to those without DM (62.3%), P>0.05. The remainder of
the genes—including SLC22A12 (rs505802 C>T), ABCG2 (rs2231142 G>T), SLC16A9
(rs2242206 G>T), LRRC16A (rs742132 A>G), GCKR (rs780094 C>T)—have zero
prevalence of UA risk genotypes, which has an effect on the results (Table 3.4). These
results lead us to look for other risk factors related to DM, such as obesity and age of
the pregnant woman, as well as other demographic characteristics.
Gestational diabetes mellitus (GDM) is a subtype of DM, and it occurs most often
in the mid-phase of pregnancy. Relating to PE, GDM increases the risk of PE by about
30%; it can also have negative effects on both the mother and her fetus.205 The analysis
shows trending toward a significant association between the AA genotype
of SLC22A11 (rs17300741 A>G) and GDM across the Samoan population. Under the
recessive model (AG+GG (reference) vs. AA), the proportion of AA was higher
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(80.9%) of the pregnant Samoan with GDM compared to (60.2%) in those without
GDM (p=0.06) (Table 3.4). This indicates that the prevalence of GDM amongst the
Pacific Islander population was very high, particularly in the Samoan subgroup.206
In both subgroups, our results did not find any significant association between
remaining UA SNPs risk alleles and GDM (p>0.05) (Table 3.4 & Table 3.5). In fact,
along with UA genetic risk factors, GDM might occur through different causes, and
maternal obesity is considered a major one of those causes.207
In summary, this cohort analysis aimed to detect a genetic association between
UA genotypes and CMDs among the Asian/Pacific Islander population, specifically
those in the Filipino and Samoan subgroups. Genetically, the Samoan population is at
risk of developing CHTN and GDM due to UA risk alleles of SLC22A11. Meanwhile,
the Filipino subgroup has shown a high risk of CMDs, mainly DM, due to genetic
polymorphism in ABCG2. Overall, from a genetic perspective of urate heritability, we
would argue that both Filipino and Samoan populations are at a higher risk of
developing cardiometabolic disorders. These findings are partially consistent with our
previous results that found Asian subgroups and the Filipino population to have the
highest prevalence of UA risk alleles and cardiometabolic disorders relative to the
population cohort and its subgroups of native Hawaiian and Pacific Islanders (Table
2.5& Table 3.4).
Non-genetic risk factors (Age, BMI) and development of comorbid Diseases (CMDs)
The logistic regression analysis test was used amongst Filipino and Samoan
subgroups to determine nongenetic risk factors involving the mother age and BMI
associated with CMDs progression. All associations between nongenetic risk factors
and CMDs were summarized in the Table 3.7. Across the Asian-Pacific community,
obesity is associated with an increased risk of comorbid diseases.208 Along with the
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relationship between CMDs and PE, obesity and advanced maternal age could be
classified as moderate risk factors associated with PE.193
Our analysis has shown an association between age and CHTN in Filipino
pregnant women (OR = 1.11, 95% CI = 1.026- 1.225, p = 0.0139 *). In addition, BMI
has been shown to be associated with CHTN in the Filipino population (OR=1.06, 95%
CI= 0.99-1.13, p=0.06). (Table 3.7). This result is consistent with other data published
in 2018 that reported that those Filipinos of an older age and those with a BMI greater
than 23kg/m2 were considered to be at risk for developing hypertension.209
Whereas Linhart et al. have reported that obesity and an increased BMI rate are
strongly associated with hypertension across the Samoan population210, the global
hypothesis test results of age/BMI covariates related to CHTN was insignificant
(p>0.05), which did not show an association between BMI and GHTN in the Samoan
population (Table 3.7).
Sugiyama et al. have reported that Pacific Islander pregnant women who are 30
years or older and have a BMI ≥ 30 kg/m2 are at a higher risk of GDM and maternal
consequences such as high weight infants and fetal death as compared to women
without GDM.211 Moreover, the severity of perinatal outcomes due to GDM vary across
ethnicities. The multiple logistic results show that age is considered a significant highrisk factor for development of GDM in the Samoan population (OR= 1.15, 95% CI =
1.06- 1.25, p = 0.0006 ***). Although the odds of BMI were positive in GDM in the
Samoan cohort, there was no evidence to suggest that association p>0.05 (Table 3.7).
This analysis shows that age and BMI could be contribute to cardiometabolic disorders,
which may negatively impact both mothers and fetuses. A previous study reported that
infants of Filipino mothers had twice the risk of developing macrosomia than other
Pacific Islander subgroups in the US.212
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The mean body mass index (BMI) between different genotypes of UA genes
Hyperuricemia has been reported to be associated with obesity metabolic traits
such as dyslipidemia.213 Urate genetic polymorphism could contribute to that
association. A recent study has found an association between GCKR (rs780094 C>T)
and multiple types of lipids, which may cause obesity and several other metabolic
complications.152 We utilized a univariate analysis ANOVA test to assess the
differences of mean BMI across the UA genes in different genetic models (additive,
dominant, and recessive). In the Filipino cohort, the analysis showed carriers risk of TT
genotype had a higher mean BMI relative to CC genotype (reference) of GCKR (780094
C>T), but these results were not statistically significant. (P>0.05). (Table 3.8).
Conversely, in the same Filipino cohort, we found a significant difference in mean BMI
under the dominant model (GG (reference) vs. GT+TT) of ABCG2 (rs2231142 G>T).
The participant carriers GT+TT had a lower mean BMI of 24.14 relative to GG
(reference) 26.88. (p=0.04). (Table 3.8). These results were in conflict with the
published literature, as previous studies have found a loss of function in ABCG2
(rs2231142 G>T) variant associated with gout in obese male compared to nonobese
females in a subset of Taiwanese patients.214 On the other hand, in the Samoan
population cohort, our analysis found a trend toward significant in the mean BMI of
GCKR (780094 C>T) genotypes. The mean BMI under the additive model CC
(reference) vs. TT (risk genotype) of GCKR (780094 C>T) was significantly lower in
the TT genotype, around 26.56 compared to 29.72 in CC (reference) genotype of GCKR
(p=0.082) (Table 3.9). In addition, in the same Samoan cohort, a significant difference
of mean BMI and LRRC16A (rs742132 A>G) genotypes were found under additive and
recessive models. The mean BMI of the AA genotype of the LRRC16A additive model
was about 27.47 lower compared to the GG genotype of 28.65 (reference) (p=0.033).
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Also, the mean BMI of the AA genotype of the LRRC16A recessive model was lower,
around 27.47, compared to AG+GG (reference), about 30.31 (p=0.031). (Table 3.9).
Numerous risk factors, both genetic and non-genetic, contribute to the increased
risk of cardiometabolic disorders. From a genetic perspective, women of Asian
ancestry, mainly Filipino pregnant women, had a higher frequency of HU risk alleles
that could partially match their risk of developing metabolic disorders. On the other
hand, apart from non-genetic risk factors, both Samoan and Filipino pregnant women
show significant non-genetic risk factors, including age and BMI, associated with
metabolic disorders.
Limitations
This study is retrospective, so we were limited to a certain number of genetic
and nongenetic risk factors. We conducted our investigation between genotypes and
phenotypes only on limited UA genetic polymorphisms from the genetic side.
Meanwhile, on the nongenetic side, we only assessed age and BMI as predictors
associated with developments of CMDs. We believe that other factors associated with
CMDs are lifestyle, diet, physical activity, smoking, and alcohol use. The average age
of pregnant women in this study was 28 years old, and at this age, the proportion of
comorbid disorders is lower than in older age. In addition, the frequency of some UA
risk alleles in the presence of diseases was very low, which may have affected the exact
results and the exact association between genetic/nongenetic risk factors and
cardiometabolic disorders. Finally, the data was convenient, selected from one
geographical location and one hospital on the same average age. Further studies should
be conducted on a more representative and larger sample size to validate our results.

81

Conclusion
Our analysis found that HU/gout risk alleles and other factors such as age and
BMI are associated with the development of CMDs in the selected Asian-Pacific
Islander populations. These study findings are consistent with already published studies
that explain the biological function of UA gene heritability and other demographic
factors in CMDs development. Genetically, our results have found both Filipinos and
Samoans may be at a higher risk of CMDs due to HU risk alleles in ABCG2 (rs2231142
G>T) and SLC22A11 (rs17300741 A>G).
Other factors, including age and BMI, are reported as high-risk factors
associated with the development of CMDs across both Samoan and Filipino
populations. We believe that further studies across different populations will support
our hypothesis. Finally, we would say that the difference in the prevalence of comorbid
diseases across populations could partially be explained by different genetic
backgrounds. Hence, this study suggests that the Asian population in the Filipino
subgroup is at a higher risk of CMDs due to numerous risk factors, including both
genetic and nongenetic, resulting in potentially serious outcomes in pregnant women.
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Table 3.1: Demographic Characteristics across Filipino and Samoan populations
Characteristics
Total population Filipino
Samoan
cohort (n= 1059) (n= 229)
(n= 200)
Mother’s age (years)
28.8±6.3
29.8±6.1*
26.3±5.7*

p-value (Filipino vs
Samoans)
1.391e-09

Gestational age (weeks)

38.0±2.27

37.82±2.27**

38.4±2.0*

0.004

Preterm (<37 weeks)
Full term (≥37 weeks)
Body mass index (kg/m2)

182 (17.3%)
871 (82.2%)
26.3±6.9

44 (19.4%)**
183 (80.63%)**
25.0±6.0*

27 (13.5%)**
173 (86.5%)**
30.1±7.5*

0.17
0.58
4.758e-12

Pre- gravida weight (Ibs)

151.2±46.5

132.7±28.4*

203.7±44.7*

<2.2e-16
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Table 3.2: Clinical and Social Characteristic among Filipino and Samoan Ethnicities
Characteristics

Total population
cohort (n=1059)
Premature labor
169 (15.9%)
Gestational diabetes mellitus 137 (12.9%)
Diabetes mellitus
19 (1.8%)
Gestational hypertension
38 (3.6%)
Chronic hypertension
50 (4.7%)
Mild preeclampsia
41 (3.9%)

Filipino
(n= 229)
36 (15.7%)**
48 (20.9%)*
4 (1.7%)**
6 (2.6%)**
21 (9.1%)*
10 (4.3%)**

Severe preeclampsia

8 (3.5%)*

15 (1.4)

Samoan
(n= 200)
27 (13.5%)**
23 (11.0%)**
6 (3.0%)**
9 (4.5%)**
7 (3.5%)**
14 (7.0%)**
4 (2.0%)**

p-value (Filipino vs
Samoans)
0.00001
0.0255
0.401
0.307
0.0259
<0.00001
0.1574

Eclampsia
1 (0.1)
1 (0.4%)**
History of alcohol intake
27 (2.5%)
4 (1.7%)**
4 (2.0%)**
0.01833
History of smoking
162 (15.3%)
17 (7.4%)*
56 (28.0%)**
<0.00001
*Indicates significant value at p <0.05 of Chi-square analysis relative to the total population
**Indicate non-significant value at p<0.05 of Chi-square analysis relative to the total population
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Table 3.3: Clinical and Social Characteristic among Asian and Non-Asian population (NHPIs)
Characteristics

Total population
cohort (n=1059)
Premature labor
169 (15.9%)
Gestational diabetes mellitus 137 (12.9%)
Diabetes mellitus
19 (1.8%)
Gestational hypertension
38 (3.6%)
Chronic hypertension
50 (4.7%)
Mild preeclampsia
41 (3.9%)

Asian
(n= 543)
95 (17.5%)**
90 (16.6%)**
7 (1.3%)**
17 (3.1%)**
36 (6.6%)**
20 (3.6%)**

Severe preeclampsia

10 (1.9%)**

15 (1.4)

Eclampsia
1 (0.1)
History of alcohol intake
27 (2.5%)
History of smoking
162 (15.3%)
*Indicates significant value at p <0.05
**Indicate non-significant value at p<0.05

1 (0.18)**
14 (2.6%)**
39 (7.2%)*
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NHPIs
(n= 516)
74 (14.3)**
47 (9.1%)*
11 (2.3%)**
21 (4.1%)**
14 (2.7%)**
21 (4.1%)**
5 (0.9%)**

p-value (Asian vs
NHPIs)
0.2327
0.0014
0.2972
0.4282
0.0041
0.7538
0.2362

0
13 (2.5%)**
23.8%)*

0.9527
0.0748

Table 3.4: Association of UA Risk Alleles and CMDs Across the Samoan Subgroup- continue
Gene (SNP)
SLC22A12
(rs505802 C>T)
Additive
CC
CT
TT (Ref.)
Dominant
TT (Ref.)
CT+CC
Recessive
CT+TT (Ref.)
CC

Chronic Hypertension
Yes
No
p% (N)
% (N)
value

Gestational Hypertension
Yes
No
p% (N)
% (N)
value

Diabetes Mellitus
Yes
No
% (N) % (N)

33.3 (2)
50 (3)
16.7 (1)

49.4 (88)
38.8 (69)
11.8 (21)

0.59

57.1 (4)
42.9 (3)
0 (0)

48.6 (86)
39.0 (69)
12.4 (22)

0.877

40.0 (2) 49.2 (88)
20.0 (1) 39.7 (71)
40.0 (2) 11.1(20)

0.191

47.6 (10)
38.1 (8)
14.3 (3)

49.0 (80)
39.2 (64)
11.8 (19)

0.895

16.7 (1)
83.3 (5)

11.8 (21)
88.2 (157)

0.539

0 (0)
100 (7)

12.4 (22)
87.6 (155)

1

40.0 (2) 11.2 (20) 0.109
60.0 (3) 88.8 (159)

14.2 (3)
85.8 (18)

11.6 (19)
88.4 (144)

0.721

66.7 (4)
33.3 (2)

50.5 (90)
49.5 (88)

0.682

42.9 (3)
57.1 (4)

51.4 (91)
48.6 (86)

0.716

60.0 (3) 50.9 (91)
40.0 (2) 49.1 (88)

1

52.4 (11)
47.6 (10)

51.0 (83)
49.0 (80)

0.899

6.3 (11)
42.9 (75)
50.8 (89)

0.126

(0)
42.8 (3)
57.2 (4)

6.9 (12)
43.7 (76)
49.4 (86)

1

60.0 (3) 5.1(9)
40.0 (2) 43.7 (77)
0 (0)
51.2 (90)

0.000
4

10.0 (2)
30.0 (6)
60.0 (12)

6.2 (10)
45.4 (73)
48.4 (78)

0.350

6.3 (11)
93.7 (164)

0.341

0 (0)
100 (7)

6.9 (12)
93.1 (162)

1

60.0 (3) 5.1 (9)
0.002
40.0 (2) 94.9 (167)

10.0 (2)
90.0 (18)

6.2 (10)
93.8 (151)

0.625

49.2 (86)
50.8 (89)

0.210

42.8 (3)
57.2 (4)

50.6 (88)
49.4 (86)

0.720

100 (5)
0 (0)

40.0 (8)
60.0 (12)

51.6 (83)
48.4 (78)

0.329

SLC17A1 (rs1183201 T>A)
Additive
AA (Ref.)
16.7 (1)
AT
66.6 (4)
TT
16.7 (1)
Dominant
AA (Ref.)
16.7 (1)
AT+TT
83.3 (5)
Recessive
AA+AT (Ref.)
83.3 (5)
TT
16.7 (1)

86

48.8 (86)
51.2 (90)

pvalue

0.059

Gestational Diabetes Mellitus
Yes
No
p-value
% (N)
% (N)

Table 3.4: Association of UA Risk Alleles and CMDs Across the Samoan Subgroup- continue
Gene (SNP)

Chronic Hypertension

SLC22A11
Yes
(rs17300741 A>G) % (N)
Additive
AA
100 (6)
AG
(0)
GG (Ref)
(0)
Dominant
GG (Ref.)
(0)
AG+AA
100 (6)
Recessive
AG+GG (Ref.)
(0)
AA
100 (6)
ABCG2 (rs2231142 G>T)
Additive
GG (Ref.)
66.8 (4)
GT
16.6 (1)
TT
16.6 (1)
Dominant
GG (Ref.)
66.7 (4)
GT+TT
33.3 (2)
Recessive
GG+GT (Ref.)
83.4 (5)
TT
16.6 (1)

Gestational Hypertension

Diabetes Mellitus

No
% (N)

pvalue

Yes
% (N)

No
% (N)

pvalue

Yes
% (N)

61.2 (106)
32.9 (57)
5.9 (10)

0.193

85.7 (6)
14.3 (1)
(0)

61.6 (106)
32.6 (56)
5.8 (10)

0.618

5.8 (10)
94.2 (163)

0.511

0 (0)
100 (7)

5.8 (10)
94.2 (162)

38.8 (67)
61.2 (106)

0.085

14.3 (1)
85.7 (6)

48.3 (85)
41.0 (72)
10.7 (19)

0.384

48.3 (85)
51.7 (91)
89.2 (157)
10.8 (19)

Yes
% (N)

No
% (N)

p-value

75.0 (3) 62.3 (109) 0.822
25.0 (1) 32.0 (56)
(0)
5.7 (10)

80.9 (17)
19.1 (4)
0 (0)

60.1 (95)
33.6 (53)
6.3 (10)

0.196

0.511

(0)
100 (4)

5.7 (10)
0.622
94.3 (165)

(0)
100 (21)

6.3 (10)
93.7 (148)

0.609

38.4 (66)
61.6 (106)

0.258

25.0 (1) 37.7 (66) 0.603
75.0 (3) 62.3 (109)

19.1 (4)
80.9 (17)

39.8 (63)
60.2 (95)

0.063

28.6 (2)
71.4 (5)
0 (0)

49.7 (87)
38.8 (68)
11.5 (20)

0.314

40.0 (2) 49.2(87)
60.0 (3) 39.6 (70)
0 (0)
11.2 (20)

0.810

45.0 (9)
45.0 (9)
10.0 (2)

49.4 (80)
39.5 (64)
11.1 (18)

0.941

0.436

28.5 (2)
71.5 (5)

49.7 (87)
50.3 (88)

0.444

40.0 (2) 49.1(87)
60.0 (3) 50.9 (90)

0.686

45.0 (9)
55.0 (11)

49.3 (80)
50.7 (82)

0.711

0.507

100 (7)
0 (0)

88.5 (155)
11.5 (20)

0.343

100 (5)
0 (0)

88.8 (157) 0.425
11.2 (20)

90.0 (18)
10.0 (2)

88.9 (144)
11.1 (18)

0.880
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No
% (N)

Gestational Diabetes Mellitus
pvalue

Table 3.4: Association of UA Risk Alleles and CMDs Across the Samoan Subgroup- continue
Gene (SNP)
Chronic Hypertension
Gestational Hypertension
Diabetes Mellitus
SLC16A9
Yes
No
pYes
No
pYes
No
(rs2242206 G>T) % (N)
% (N)
value % (N)
% (N)
value
% (N) % (N)
Additive
GG (Ref.)
33.3 (2)
GT
66.7 (4)
TT
0 (0)
Dominant
GG (Ref.)
33.3 (2)
GT+TT
66.7 (4)
Recessive
GT+GG (Ref.)
100 (6)
TT
0 (0)
LRRC16A (rs742132 A>G)
Additive
AA
16.7 (1)
AG
66.6 (4)
GG (Ref.)
16.7 (1)
Dominant
GG (Ref.)
16.7 (1)
AG+AA
83.3 (5)
Recessive
AG+GG (Ref.)
83.3 (5)
AA
16.7 (1)

33.0 (58)
55.1 (97)
11.9 (21)

0.651

71.4 (5)
28.6 (2)
0 (0)

31.4 (55)
56.6 (99)
12.0 (21)

0.135

40 (2)
60 (3)
(0)

0.708

47.6 (10)
47.6 (10)
4.8 (1)

31.0 (50)
56.6 (91)
12.4 (20)

0.273

33.0 (58)
67.0 (118)

0.984

71.4 (5)
28.6 (2)

31.4 (55)
68.6 (120)

0.0400

40.0 (2) 32.7 (58) 0.665
60.0 (3) 67.3 (119)

47.6 (10)
52.4 (11)

31(50)
69 (111)

0.128

88.1 (155)
11.9 (21)

0.368

100 (7)
0 (0)

88.0 (154)
12.0 (21)

0.329

100 (5)
(0)

95.2 (20)
4.8 (1)

87.6 (141)
12.4 (20)

0.475

25.6 (45)
52.3 (92)
22.1 (39)

0.782

14.2 (1)
42.8 (3)
42.8 (3)

25.7 (45)
53.2 (93)
21.1 (37)

0.510

(0)
26.0 (46)
60.0 (3) 52.6 (93)
40.0 (2) 21.4 (38)

0.333

33.3 (7)
47.6 (10)
19 (4)

24.2 (39)
53.4 (86)
22.4 (36)

0.646

22.1 (39)
77.9 (137)

0.749

42.8 (3)
57.2 (4)

21.1 (37)
78.9 (138)

0.18

40.0 (2) 21.4 (38) 0.302
60.0 (3) 78.6 (139)

19.0 (4)
81.0 (17)

22.3 (36)
77.7 (125)

0.730

74.4 (131)
25.6 (45)

0.621

85.7 (6)
14.3 (1)

74.3 (130)
25.7 (45)

0.772

100 (5)
(0)

66.7 (14)
33.3 (7)

75.8 (122)
24.2 (39)

0.366

88

32.8 (58)
55.4 (98)
11.8 (21)

pvalue

Gestational Diabetes Mellitus
Yes
No
p-value
% (N)
% (N)

88.2 (156) 0.412
11.8 (21)

74.1 (131) 0.332
25.9 (46)

Table 3.4: Association of UA Risk Alleles and CMDs Across the Samoan Subgroup- continue
Gene (SNP)
Chronic Hypertension
Gestational Hypertension
Diabetes Mellitus
GCKR (rs780094
C>T)

Yes
% (N)

No
% (N)

Additive
CC (Ref.)
33.3 (2)
48.6 (86)
CT
66.7 (4)
41.8 (74)
TT
0 (0)
9.6 (17)
Dominant
CC (Ref.)
33.3 (2)
48.6 (86)
CT+TT
66.7 (4)
51.4 (91)
Recessive
CT+CC (Ref.)
100 (6)
90.4 (160)
TT
0 (0)
9.6 (17)
The bold letter indicates the UA risk allele
(Ref.) Reference

pvalue

Yes
% (N)

No
% (N)

pvalue

Yes
% (N)

0.563

28.6 (2)
57.1 (4)
14.3 (1)

48.9 (86)
42.0 (74)
9.1 (16)

0.413

0.683

28.5 (2)
71.5 (5)

48.8 (86)
51.2 (90)

0.425

85.7 (6)
14.3(1)

90.9 (160)
9.1 (16)

89

No
% (N)

Gestational Diabetes Mellitus
pvalue

Yes
% (N)

No
% (N)

p-value

60.0 (3) 47.8 (85)
40.0 (2) 42.7 (76)
(0)
9.5 (17)

0.727

57.2 (12)
38.1 (8)
4.7 (1)

47.0 (76)
43.2 (70)
9.8 (16)

0.736

0.446

60.0 (3) 47.7 (85)
40.0 (2) 52.3 (93)

0.672

57.1 (12)
42.9 (9)

46.9 (76)
53.1 (86)

0.377

0.500

100 (5)
(0)

95.3 (20)
4.7 (1)

90.2 (146)
9.8 (16)

0.697

90.5 (161) 1
9.5 (17)

Table 3.5: Association of UA Risk Alleles and CMDs Across the Filipino Subgroup
Gene (SNP)

Chronic Hypertension

SLC22A12
(rs505802
C>T)
Additive
TT (Ref.)
CT
CC

Yes
% (N)

No
% (N)

pYes
value % (N)

No
% (N)

pYes
value % (N)

No
% (N)

p-value

Yes
% (N)

No
% (N)

pvalue

0 (0)
27.2 (3)
72.8 (8)

4.7 (8)
34.8 (60)
60.5 (104)

0.848 20.0 (1)
20.0 (1)
60.0 (3)

3.9 (7)
34.8 (62)
61.3
(109)

0.247 25.0(1)
(0)
75.0 (3)

3.9 (7)
35.2 (63)
60.9 (109)

0.108

0 (0)
45.7 (16)
54.3 (19)

5.4 (8)
31.8 (47)
62.8 (93)

0.162

Dominant
TT (Ref.)
CT+CC

0 (0)
100 (11)

4.6 (8)
95.4 (164)

0.464 20.0 (1)
80.0 (4)

3.9 (7)
96.1
(171)

0.202 25.0 (1)
75.0 (3)

3.9 (7)
96.1 (172)

0.165

0 (0)
100 (35)

5.4 (8)
94.6
(140)

0.356

Recessive
CT+TT (Ref.)
CC

27.2 (3)
72.8 (8)

39.5 (68)
60.5 (104)

0.533 40.0 (2)
60.0 (3)

38.7 (69)
61.3
(109)

0.955 25.0 (1)
75.0 (3)

39.1 (70)
60.9 (109)

0.947

45.7 (16)
54.3 (19)

37.2 (55)
62.8 (93)

0.440

SLC17A1 (rs1183201 T>A)
Additive
AA (Ref.)
0 (0)
4.4 (7)
AT
36.4 (4)
33.5 (55)
TT
63.6 (7)
62.1 (102)

1

(0)
60.0 (3)
40.0 (2)

4.1 (7)
33.0 (56)
62.9
(107)

0.467 (0)
75.0 (3)
25.0 (1)

4.1 (7)
32.7 (56)
63.2 (108)

0.257

(0)
35.3 (12)
64.7 (22)

5.0 (7)
33.3 (47)
61.7 (87)

0.579

Dominant
AA (Ref.)
AT+TT

1

(0)
100 (5)

4.1 (7)
95.9

1

4.1 (7)
95.9 (164)

1

(0)
100 (34)

4.9 (7)
95.1

0.348

(0)
100 (11)

4.3 (7)
95.7 (157)

Gestational Hypertension

Diabetes Mellitus

(0)
100 (4)
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Gestational diabetes Mellitus

(163)
Recessive
AA+AT (Ref.)
TT

63.4 (4)
63.6 (7)

37.8 (62)
62.2 (102)

1

60.0 (3)
40.0 (2)

37.1 (63)
62.9
(107)

(134)

0.366 75.0(3)
25.0 (1)

36.8 (63)
63.2 (108)

Table 3.5: Association of UA Risk Alleles and CMDs Across the Filipino Subgroup- continue
Gene (SNP)
Chronic Hypertension
Gestational Hypertension
Diabetes Mellitus
SLC22A11
Yes
No
pYes
No
pYes
No
(rs17300741
% (N)
% (N)
value % (N) % (N)
value % (N)
% (N)
A>G)
Additive
AA
81.8 (9)
AG
18.2 (2)
GG (Ref.)
(0)
Dominant
GG (Ref.)
(0)
AG+AA
100 (11)
Recessive
AG+GG (Ref.) 18.2 (2)
AA
81.8 (9)
ABCG2 (rs2231142 G>T)
Additive
GG (Ref.)
18.2 (2)
GT
54.5 (6)
TT
27.3 (3)
Dominant

0.151

p-value

35.2 (12)
64.8 (22)

38.3 (54)
61.7 (87)

0.844

Gestational diabetes Mellitus
Yes
No
p-value
% (N)
% (N)

73.0 (119)
23.9 (39)
3.1 (5)

0.744 75.0 (3) 73.5 (125)
25.0 (1) 23.5 (40)
(0)
3.0 (5)

0.940 75.0 (3)
25.0 (1)
0 (0)

73.5 (125)
23.5 (40)
3(5)

0.940

70.5 (24)
29.5 (10)
0 (0)

74.3 (104)
22.2 (31)
3.5 (5)

0.525

3.0 (5)
97.0 (158)

1

1

(0)
100 (4)

3.0 (5)
97.0 (165)

0.727

(0)
100 (34)

3.5 (5)
96.5 (135)

0.584

27.0 (44)
73.0 (119)

0.729 25.0 (1) 26.4 (45)
75.0 (3) 73.6 (125)

0.947 25.0 (1)
75.0 (3)

26.5 (45)
73.5 (125)

0.947

29.5 (10)
70.5 (24)

25.8 (36)
74.2 (104)

0.661

29.2 (49)
51.2 (86)
19.6 (33)

0.656 (0)
29.3 (51)
60.0 (3) 51.2 (89)
40.0 (2) 19.5 (34)

0.279 25.0 (1)
(0)
75.0 (3)

28.5 (50)
52.6 (92)
18.9 (33)

0.016

32.4 (11)
50.0 (17)
17.6 (6)

27.6 (40)
51.7 (75)
20.7 (30)

0.834

(0)
100 (4)

2.9 (5)
97.1 (165)
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GG (Ref.)
GT+TT
Recessive
GG+GT (Ref.)
TT

18.2 (2)
81.8 (9)

29.2 (49)
70.8 (119)

0.731 0)
100 (5)

29.3 (51)
70.7 (123)

0.323 25.0 (1)
75.0 (3)

28.5 (50)
71.5 (125)

0.8757

32.3 (11)
67.7 (23)

27.5 (40)
72.5 (105)

0.579

72.7 (8)
27.3 (3)

80.4 (135)
19.6 (33)

0.464 60.0 (3) 80.4 (140)
40.0 (2) 19.6 (34)

0.263 25.0 (1)
75.0 (3)

81.1 (142)
18.9 (33)

0.026

82.4 (28)
17.6 (6)

79.4 (115)
20.6 (30)

0.6904
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Table 3.5: The Association of UA Risk Alleles and CMDs Across the Filipino Subgroup- continue
Gene (SNP)
Chronic Hypertension
Gestational Hypertension
Diabetes Mellitus
SLC16A9
(rs2242206
G>T)
Additive
GG (Ref.)
GT
TT
Dominant
GG (Ref.)
GT+TT

Gestational diabetes Mellitus

Yes
% (N)

No
% (N)

p-value

Yes
% (N)

No
% (N)

pvalue

Yes
% (N)

No
% (N)

pvalue

Yes
% (N)

No
% (N)

p-value

54.5 (6)
45.5 (5)
0 (0)

31.6 (53)
44.0 (74)
24.4 (41)

0.090

20.0 (1)
40.0 (2)
40.0 (2)

33.3 (58)
44.3 (77)
22.4 (39)

0.718

25.0 (1)
50.0 (2)
25.0 (1)

33.2 (58)
44.0 (77)
22.8 (40)

0.942

44.1 (15)
29.4 (10)
26.5 (9)

30.4 (44)
47.6 (69)
22 (32)

0.143

54.5 (6)
45.5 (5)

31.6 (53)
68.4 (115)

0.181

20.0 (1)
80.0 (4)

33.3 (58)
66.7 (116)

0.531

25.0 (1)
75.0 (3)

33.2 (58)
66.8 (117)

1

44.1 (15)
55.9 (19)

30.4 (44)
69.6
(101)

0.124

Recessive
GT+GG (Ref.) 100 (11)
TT
0 (0)

75.6 (127)
24.4 (41)

0.071

60.0 (3)
40.0 (2)

77.6 (135)
22.4 (39)

0.3226 75.0 (3)
25.0 (1)

77.2 (135)
22.8 (40)

0.919

73.5 (25)
26.5 (9)

78.0
(113)
22.0 (32)

0.582

9.5 (16)
42.0 (71)
48.5 (82)

0.902

(0)
20.0 (1)
80.0 (4)

9.7 (17)
42.3 (74)
48.0 (84)

0.500

25.0 (1)
50.0 (2)
25.0 (1)

9.1 (16)
41.5 (73)
49.4 (87)

0.298

5.9 (2)
41.2 (14)
52.9 (18)

10.3 (15)
41.8 (61)
47.9 (70)

0.755

9.5 (16)
90.5 (153)

1

(0)
100 (5)

9.7 (17)
90.3 (158)

1

25.0 (1)
75.0 (3)

9.1 (16)
90.9 (160)

0.329

5.9 (2)
94.1 (32)

10.3 (15)
89.7
(131)

0.744

LRRC16A (rs742132 A>G)
Additive
GG (Ref.)
9.1 (1)
AG
36.4 (4)
AA
54.5 (6)
Dominant
GG (Ref.)
9.1 (1)
AG+AA
90.9 (10)
Recessive
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AG+GG
(Ref.)
AA

45.5(5)
54.5 (6)

51.5 (87)
48.5 (82)

0.698

20.0 (1)
80.0 (4)

52.0 (91)
48.0 (84)

0.203
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75.0 (3)
25.0 (1)

50.6 (89)
49.4(87)

0.621

47.1 (16)
52.9 (18)

52.1 (76)
47.9 (70)

0.599

Table 3.5: Association of UA Risk Alleles and CMDs Across the Filipino Subgroup- continue
Gene (SNP)

Chronic Hypertension

GCKR
(rs780094 C>T)

Yes
% (N)

No
% (N)

pvalue

Additive
CC (Ref.)
27.2 (3)
32.6 (55) 0.435
CT
36.4 (4)
46.7 (79)
TT
36.4 (4)
20.7 (35)
Dominant
CC (Ref.)
27.2 (3)
32.6 (55) 1
CT+TT
72.8 (8)
67.4 (114)
Recessive
CT+CC (Ref.)
63.6 (7)
79.3 (134) 0.256
TT
36.4 (4)
20.7 (35)
The Bold letter Indicates the UA risk allele
(Ref.) Reference

Gestational Hypertension

Diabetes Mellitus

Yes
% (N)

No
% (N)

pvalue

Yes
% (N)

No
% (N)

pvalue

Yes
% (N)

No
% (N)

pvalue

60.0 (3)
20.0 (1)
20.0 (1)

31.4 (55)
46.9 (82)
21.7 (38)

0.368

25.0 (1)
50.0 (2)
25.0 (1)

32.4 (57)
46.0 (81)
21.6 (38)

0.950

29.4 (10)
58.8 (20)
11.8 (4)

32.9 (48)
43.2 (63)
23.9 (35)

0.176

60.0 (3)
40.0 (2)

31.4 (55)
68.6 (120)

0.33

25.0 (1)
75.0 (3)

32.4 (57)
67.6 (119)

0.754

29.4 (10)
70.6 (24)

32.8 (48)
67.1 (98)

0.697

80.0 (4)
20.0 (1)

78.3 (137)
21.7 (38)

0.926

75.0 (3)
25.0 (1)

78.4 (138)
21.6 (38)

0.87

88.2 (30)
11.8 (4)

76.1 (111) 0.119
23.9 (35)
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Gestational diabetes Mellitus

Table 3.6: Hardy Weinberg Equilibrium (HWE) Assessment of
Targeted SNPs
Gene/SNP

Filipino

Samoan

SLC17A1 (rs1183201)
0.7789
PDZK1(rs12129861)
0.0000**
SLC22A11(rs17300741) 0.4439
ABCG2 (rs2231142)
0.6376
SLC16A9 (rs2242206)
0.1473
SLC22A12 (rs505802)
0.8183
SLC2A9 (rs734553)
0.8788
LRRC16A (rs742132)
0.8602
GCKR (rs780094)
0.3981
** Indicates for deviated from HWE p<0.05
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0.3326
0.0000**
0.4465
0.3942
0.0275**
0.2042
0.8211
0.4492
0.9620

Table 3.7: Association of BMI & Age (non-genetic factors) with Cardiometabolic Diseases (CMDs) in Filipino and Samoan

Global
hypothesis test
(p-value)
BMI
Age
R2

Chronic Hypertension
Filipino
Samoan
(OR
(OR
CI 95%
CI 95%
P-value)
P-value)
0.008
0.11

Gestational Hypertension
Filipino
Samoan
(OR
(OR
CI 95%
CI 95%
P-value)
P-value)
0.51
0.07

Diabetes Mellitus
Filipino
Samoan
(OR
(OR
CI 95%
CI 95%
P-value)
P-value)
0.35
0.10

Gestational diabetes mellitus
Filipino
Samoan
(OR
(OR
CI 95%
CI 95%
P-value)
P-value)
-04
8.03
9.48-04

(1.06
0.99- 1.13
0.06)
(1.11
1.02- 1.22
0.013)
7.0%

(1.07
0.93-1.19
0.19)
(1.01
0.85- 1.20
0.86)
3.0%

(0.98
0.77- 1.16
0.88)
(1.16
0.949- 1.53
0.190)
6.0%

(1.01
0.96- 1.07
0.512)
(1.11
1.05- 1.19
0.45)
6.0%

(1.08
0.98-1.20
0.10)
(1.06
0.93- 1.21
0.30)
7.0%

(1.10
1.01-1.22
0.031)
(0.93
0.79- 1.06
0.34)
7.0%
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(1.05
0.98- 1.28
0.32)
(1.12
0.98- 1.28
0.07)
8.0%

(1.03
1.063- 1.254
0.380)
(1.15
1.06- 1.25
0.0006)
11.0%

Table 3.8: Association between Uric Acid Risk Alleles and BMI across the Filipino
Population.
Gene/SNP

Bartlett
Sum
Mean
test
p-value
SLC22A11(rs17300741A>G) (Additive)
AA
0.247
109
25.34
AG
37
24.26
GG (Ref.)
5
23.06
SLC22A11 (Dominant)
GG (Ref.)
0.157
5
25.34
AG+AA
146
25.06
SLC22A11(Recessive)
AG+GG
0.217
42
24.11
(Ref.)
AA
109
25.34
SLC22A12 (rs505802 C>T)
CC
0.1704
94
25.16
CT
58
25.03
TT (Ref.)
6
22.95
SLC22A12 (Dominant)
TT (Ref.)
0.119
6
25.16
CT+CC
152
25.11
SLC22A12 (Recessive)
CT+TT
0.450
64
24.83
(Ref.)
CC
94
25.16

SD

95% CI

ANOVAp-value

6.74
5.97
3.47

24.06-26.62
22.27-26.25
18.74-27.37

0.371

6.74
6.55

24.06-26.62
28.33-30.76

0.496

5.71

21.71-35.13

0.299

6.74

24.06-26.62

6.12
6.91
3.46

22.71-25.85
23.62-26.45
22.80-28.72

0.388

6.12
6.41

22.71-25.85
24.08-26.14

0.413

6.67

19.31-26.58

0.754

6.12

22.71-25.85
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Table 3.8: Association between Uric Acid Risk Alleles and BMI across the Filipino
Population - continue
Gene/SNP
Bartlett Sum
Mean
SD
95% CI
ANOVAtest
p-value
p-value
ABCG2 (rs2231142 G>T) (Additive)
GG (Ref.)
0.00243 45
26.88
8.12
24.44-29.32
0.1204
GT
79
24.17
5.64
22.91-25.44
TT
31
24.04
4.82
22.27-25.81
ABCG2 (Dominant)
GG (Ref.)
0.00075 45
26.88
8.12
24.44-29.32
0.041
GT+TT
110
24.14
5.40
23.12-25.16
ABCG2 (Recessive)
GG+GT
0.030
124
25.16
6.74
19.31-26.58
0.295
(Ref.)
TT
31
24.04
4.82
22.27-25.81
SLC16A9 (rs2242206 G>T) (Additive)
GG (Ref.)
0.448
56
30.18
7.78
23.28-26.87
0.982
GT
85
29.47
6.82
23.34-26.47
TT
16
27.7
8.20
22.63-27.04
SLC16A9 (Dominant)
GG (Ref.)
0.403
56
30.18
7.78
23.28-26.87
0.416
GT+TT
101
29.19
7.04
27.80-30.58
SLC16A9 (Recessive)
GG+GT
0.486
141
29.75
7.20
28.55-30.95
0.287
(Ref.)
TT
16
27.7
8.20
22.63-27.04
GCKR (rs780094) (Additive)
CC (Ref.)
0.04043 53
24.28
5.69
22.71-25.85
0.614
CT
71
25.04
5.98
23.62-26.45
TT
32
25.76
8.20
22.80-28.72
GCKR (Dominant)
CC (Ref.)
0.180
53
24.28
5.69
22.71-25.85
0.365
CT+TT
103
25.26
6.72
23.95-26.58
GCKR (Recessive)
CT+CC
0.011
124
24.71
5.85
23.67-25.75
0.500
(Ref.)
TT
32
25.76
8.20
22.80-28.72
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Table 3.8: Association between Uric Acid Risk Alleles and BMI across the Filipino
Population- continue
Gene/SNP
Bartlett
SUM
Mean
SD
95% CI
ANOVAtest
p-value
p-value
LRRC16A (rs742132 A>G) (Additive)
AA
0.04307 78
25.78
7.22
24.15-27.41
0.2523
AG
62
24.23
5.38
22.86-25.60
GG (Ref.)
15
23.54
5.43
20.53-26.55
LRRC16A (Dominant)
GG (Ref.)
0.393
15
23.54
5.43
20.53-26.55
0.374
AG+AA
140
25.1
6.50
24.01-26.18
LRRC16A (Recessive)
AG+GG
0.0100
77
24.10
5.36
22.88-25.32
0.101
(Ref.)
AA
78
25.78
7.22
24.15-27.41
SLC17A1 (rs1183201 A>T) (Additive)
AA (Ref.)
0.003144 6
23.71
3.39
20.15-27.27
0.469
AT
47
25.95
8.05
23.58-28.31
TT
98
24.61
5.56
23.50- 25.73
SLC17A1 (Dominant)
AA (Ref.)
0.105
6
23.71
3.39
20.15-27.27
0.618
AT+TT
145
25.04
6.47
23.98-26.11
SLC17A1 (Recessive)
AA+AT
0.006
53
25.69
7.68
23.57-27.81
0.368
(Ref.)
TT
98
24.61
5.56
23.50- 25.73
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Table 3.9: Association between Uric Acid Risk Alleles and BMI across the Samoan
Population.
Gene/SNP

Bartlett
Sum
test
p-value
SLC22A11 (rs17300741 A>G) (Additive)
AA
0.877
97
AG
48
GG (Ref.)
8
SLC22A11 (Dominant)
GG (Ref.)
0.759
8
AG+AA
145
SLc22A11 (Recessive)
AG+GG (Ref.)
0.711
56
AA
97
SLC22A12 (rs505802 C>T) (Additive)
CC
0.7864
79
CT
61
TT (Ref.)
18
SLC22A12 (Dominant)
TT (Ref.)
0.490
18
CT+CC
140
SLC22A12 (Recessive)
CT+TT (Ref.)
0.859
79
CC
79
ABCG2 (rs2231142 G>T) (Additive)
GG (Ref.)
0.1618
75
GT
64
TT
17
ABCG2 (Dominant)
GG (Ref.)
0.574
75
GT+TT
81
ABCG2 (Recessive)
GG+GT (Ref.)
0.05
139
TT
17

Mean

SD

95% CI

ANOVAp-value

29.61
29.42
28.42

7.53
7.13
8.02

24.06-26.62
22.27-26.25
18.74-27.37

0.921

28.42
29.55

8.02
7.38

18.74-27.37
28.33-30.76

0.676

29.28
29.61

7.20
7.53

28.09-31.12
24.06-26.62

0.792

28.88
30.38
30.14

7.38
7.48
6.52

23.91-26.41
23.21-26.84
19.31-26.58

0.471

30.14
29.53

6.52
7.43

19.31-26.58
28.29-30.78

0.718

30.33
28.88

7.23
7.38

26.90-33.38
23.91-26.41

0.214

29.22
30.11
29.57

7.04
6.90
9.69

24.44-29.32
22.91-25.44
22.27-25.81

0.760

29.22
30

7.04
7.51

24.44-29.32
28.33- 31.66

0.508

29.63
29.57

6.97
9.69

26.90-33.38
22.27-25.81

0.981
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Table 3.9: Association between Uric Acid Risk Alleles and BMI across the Samoan
Population- continue
Gene/SNP Bartlett
SUM
Mean SD
95% CI
ANOVAtest
p-value
p-value
GCKR (rs780094 C>T) (Additive)
CC (Ref.)
0.171
77
29.72 7.83
22.71-25.85
0.082
CT
66
30.28
TT
14
26.56
GCKR (Dominant)
CC (Ref.)
0.201
77
29.72
CT+TT
80
29.63
GCKR (Recessive)
CT+CC
0.119
143
29.98
(Ref.)
TT
14
26.56
LRRC16A (rs742132 A>G) (Additive)
AA
0.414
41
27.47
AG
84
30.92
GG (Ref.)
31
28.65
LRRC16A (Dominant)
GG (Ref.)
0.291
31
28.65
AG+AA
125
29.79
LRRC16A9 (Recessive)
AG+GG
0.976
115
30.31
(Ref.)
AA
41
27.47

6.92
5.19

23.62-26.45
22.80-28.72

7.83
6.77

22.71-25.85
28.12-31.13

0.936

7.40

28.75-31.20

0.094

5.19

22.80-28.72

7.21
6.73
8.18

24.15-27.41
24.15-27.41
22.86-25.60

0.033

8.18
7.05

22.86-25.60
28.54-31.04

0.437

7.18

28.98-31.64

0.031

7.21

24.15-27.41
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Table 3.9: Association between Uric Acid Risk Alleles and BMI across the
Samoan Population- continue
Gene/SNP Bartlett
SUM
Mean
SD
95% CI ANOVAtest
p-value
p-value
SLC17A1 (rs1183201 A>T) (Additive)
AA (Ref.) 11
29.79
8.76
20.15-27.27
0.393
AT
64
30.46
7.49
23.58-28.31
TT
81
28.75
7.00
23.50-25.73
SLC17A1 (Dominant)
AA (Ref.) 11
29.79
8.76
20.15-27.27
0.902
AT+TT
145
29.50
7.24
28.31-30.69
SLC17A1 (Recessive)
AA+AT
75
30.36
7.63
28.60-32.12
0.172
(Ref.)
TT
81
28.75
7.00
23.50-25.73
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Table 3.10: Abbreviations
NHPI
CMDs
DM
GDM
CHTN
GHTN
SU
PE
IR
NO
PKC
PI3K
BMI
IUGR
IUD

Native Hawaiian and Pacific Islander population
Cardiometabolic diseases
Diabetes Mellitus
Gestational Diabetes Mellitus
Chronic hypertension
Gestational hypertension
Serum uric acid
Preeclampsia
Insulin resistance
Nitric oxide
Phosphokinase-c
Phospho inositol-3 kinase
Body Mass Index
Intrauterine growth restriction
Intrauterine death
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Figure 3.1: The prevalence of comorbid diseases across Asian and native HawaiianPacific Islanders population
The prevalence of GDM and CHTN were significantly higher in Asian versus non-Asian
groups (NHPIs) (16.6% versus 9.1%, P=0.001 and 6.6% versus 2.7%, P=0.004, respectively)
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Figure 3.2: The prevalence of comorbid diseases across Filipino and Samoan
populations
The prevalence of GDM and CHTN were significantly higher in Filipino versus Samoan
(20.9% versus 11%, P=<0.025 and 9.1% versus 3.5%, P=0.025, respectively)
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P-value= 0.04
Figure 3.3: Mean of BMI in the dominant model of ABCG2/rs2231142 among the
Filipino population
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P-value=0.082
Figure 3.4: Mean of BMI in the additive model of GCKR/rs2780094 among the Samoan
population
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P-value=0.033
Figure 3.5: Mean of BMI in the additive model of LRRC16A/rs742132 among the
Samoan population
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P-value=0.031
Figure 3.6: Mean of BMI in the recessive model of LRRC16A/rs742132 among the
Samoan population
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Chapter 4: Overall conclusion
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The prevalence of hyperuricemia and gout disease among the US population
varies due to differences in genetic backgrounds. Many studies conducted on several
racial groups reported that individuals of those racial groups experience a higher rate of
hyperuricemia (HU)/gout conditions when compared with Europeans. Participants in
this study were selected from the Hawaii area and were of diverse races, confirming that
the prevalence of disease variability was not similar between subgroups. The Asian and
Pacific Islander groups are two of the largest minorities living in the US; the Filipino
minority group is the second largest Asian sub-population after the Chinese sub-group,
and the Samoan sub-group is the largest minority group across Pacific Islanders.
This study found that the Asian subgroups, including Filipinos, Koreans, and
Japanese, had the highest UA risk alleles relative to other minorities. Moreover, they
also had a high prevalence of comorbidities, such as hypertension and diabetes mellitus.
Our cross-sectional study was retrospective, and we were limited to specific uric acid
(UA) gene/SNPs pairs associated with the development of HU/gout. That limitation
provides potential direction in terms of further research opportunities across several UA
genes. After analyzing our preliminary findings, we can partially confirm that the Asian
population living in the US is at higher risk of rheumatological diseases, particularly
HU/gout.
Genetic investigations among different populations could assess and aid
knowledge as to why some diseases present higher in some ethnicities when compared
to others. These differences detected might provide insights to allow clinicians and
clinical researchers to think about the best ways of diagnosing and treating patients.
Hence, our results may improve patient and health care outcomes by investigating
diseases and selecting the proper drug at the proper dose for individual patients. Also,
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genetic testing could enhance both the health care system and patients’ treatment
options through decreased healthcare costs associated with incorrect prescribing.
Physiologically, the UA transportome genes show a role in metabolic diseases
through specific pathological mechanisms. These mechanisms might explain the
relationship between UA genes loss of function or polymorphism, and why they can
result in some disorders like insulin resistance or elevated blood pressure. Mendelian
randomization, for example, suggests that not all patients who have a high UA level
would have gout disease, though a high percentage of them might develop
cardiometabolic-related complications. UA risk alleles should be considered a
predictive diagnostic parameter in metabolic diseases together with other risk factors.
Consistent with the epidemiology of gout, women of child-bearing age are
unlikely to develop gout, despite their having the genetic risk factors for HU/gout. The
presence of hormones like estrogen plays an essential role in UA excretion in females,
particularly premenopausal women. Estrogen is a nuclear hormone and has a role in
urate efflux through the increased expression of the ABCG2 gene, which is responsible
for urate excretion. Additionally, the estrogen hormone suppresses the URAT1 genes
like SLC22A12, causing changes in urate reabsorption activity. Therefore, further
studies involving women and men of different ages are needed to compare UA levels
more accurately.
In summary, this study’s findings add clarity to the prevalence of UA risk alleles
among the different populations. The difference in the genetic background across
populations could explain a part of HU/gout risk factors and why a prevalence of these
conditions vary among different ethnicities. Several investigational studies are essential
to validate these results.
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Genetic polymorphisms, particularly UA risk alleles, have a role in the
development of cardiometabolic syndromes. In the final chapter, we reported on genetic
polymorphisms associated with developing different metabolic disorders like diabetes
mellitus, gestational diabetes mellitus, and chronic hypertension. The forementioned
comorbidities are considered significant risk factors for the maternal preeclampsia (PE),
affecting both the mother and fetus. The pathophysiology of PE could partially happen
indirectly through metabolic syndromes, and there is a role played by the UA
transporter in the progression of metabolic traits. That, in turn, leads to an investigation
of the association between UA risk alleles and the development of cardiometabolic
diseases (CMDs). Several studies have reported the prevalence of PE in some ethnic
groups such as African Americans. On the other hand, limited studies have reported risk
factors or causes of PE on different ethnicities. Our study findings add feasibility and
clarify information on the diverse populations that have a high risk of developing PE.
These results assess and provide more knowledge on health inequalities between
different racial groups.
The risk of PE has been reported to have increased up to six-fold between 1980
and 2003 in the US population. Specifically, the Asian-Pacific Islander population
living in Hawaii has a higher prevalence of PE. Filipino and Samoan American
subgroups have the highest prevalence of comorbidities like gestational diabetes
mellitus, which ultimately leads to an increased risk of PE by around 30%. Moreover,
PE disease increases the risk of maternal and fetus defects, significantly increasing the
associated cost of health care by about $2.18 billion.
These results have shown that Filipinos living in Hawaii are at a higher risk of
developing metabolic diseases, particularly diabetes mellitus, due to UA genetic
polymorphisms as compared to the Samoan subgroup. This study finding is to be
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partially consistent with other studies that reported that Filipino American women in the
US had the highest incidence of PE when compared to Chinese and Samoan Pacific
Islander women. More studies investigating the relationship between UA genetic defect
and prevalence of metabolic disorders will help validate and generalize our results,
contributing to personalized medicine in diagnostic and treatment disease approaches.
From a non-genetic perspective, there are many risk factors associated with the
development of PE. Examples of these factors include younger/advanced age and body
mass index above the normal range. Our findings have shown that the Asian/Pacific
Islander population is at a higher risk of cardiometabolic disorders, and that could be
partially due to age and BMI, in addition to other risk factors. Besides these risk factors,
we believe that other factors associated with PE development include lifestyle,
socioeconomic status, and psychological disorders.
These preliminary findings have shown both genetic and non-genetic risk factors
associated with developing cardiometabolic disorders. The Asian population, for
instance, had significantly higher UA risk alleles and cardiometabolic diseases relative
to the native Hawaiian and Pacific Islander populations. Furthermore, the Filipino subAsian population had the highest prevalence of both UA risk alleles and
cardiometabolic syndromes such as gestational diabetes and chronic hypertension as
compared to the Samoan population. Future prospective cross-sectional studies should
be conducted on different ages and ethnicities, and large representative sample sizes
should be included to validate our results findings.
Future prospective
The risk factors contributing to HU/gout diseases vary across different ethnicities
and between males and females. Investigational tools, particularly from a genetic
perspective, greatly help detect possible genetic differences between minorities. This
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study was retrospectively conducted on only pregnant women. A prospective
investigational study on different racial and age groups is necessary to more fully
develop our findings. Moreover, the current study was limited to specific UA
gene/SNPs from Genome-Wide Association Studies performed on EUR ancestry.
Additionally, the sample size was drawn from a limited location with a younger age
average.
We believe that these findings could achieve in the creation of personalized
treatment options under individual genetic profiles. Detecting genetic polymorphisms
that have physiological and pathological roles in diseases could minimize the health
disparities between minorities. Conducting community-based research will help engage
different populations at higher risks of certain diseases, particularly gout. To our
knowledge, this research project is the first study performed on pregnant women from
different genetic backgrounds. This study is also the first study that reported the genetic
association between UA risk alleles and cardiometabolic complications in pregnant
women across different races. These findings could expand the clinical research
paradigm to determine ethnicity/race-specific risk factors in regard to patients
developing preeclampsia.
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Chapter 6
Appendix
In this section, we would mention how we got these results after doing different
statistical analyses. First, we tried to build the logistic regression model to detect an
association between phenotypes and UA risk alleles in the different genetic models,
adjusting for other covariates, including age and body mass index across the whole
sample size. In this test findings, we did not get an exact result because if we aggregated
the population into one group, we assume that the variability around whatever covariate,
such as SNPs or genotype, is similar across all subgroups. Nevertheless, this is not true
because the variability is different around the UA-genotype. Furthermore, we reported
that in the appendix (Section 6.A) as an example.
Then we decided to focus our hypothesis test on the Filipino population as one
group of Asian minorities and Samoan population as one group of Pacific Islander
population. Our selection depended on the several factors involved in those ethnicities
known as major minorities in the US. It is also they have the largest sample size of
participants amongst other populations in the data. In addition, they reported the highest
prevalence of both metabolic and maternal conditions in our dataset. (Table 3.2). We
started to test our hypothesis that aimed to detect an association between
cardiometabolic diseases (CMDs) and both genetic (uric acid (UA) risk alleles) and
non-genetic (age/BMI) using logistic regression analysis. In the first step, we conduct a
simple logistic model to detect an association between metabolic diseases and BMI
covariate, then we add to the model age/BMI. In this analysis, we decided to select both
age/BMI as covariates associated with phenotypes (Section 6.B). The selection was
based on the global hypothesis test and R2 results, which explain how close the data are
to the fitted regression in both models. (Table 3.7).
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Then we were built a model adding other covariates involve UA genotypes
besides age/BMI using multiple logistic regression analysis. Unfortunately, the results
were uninterpretable because they were biologically and directionally inconsistent with
some UA genes toward cardiometabolic diseases (Section 6.C). We assumed that might
partly be due to the low frequency of the outcomes. Although the multiple logistic
regression results were uninterpretable with some genes, it gave us a signal about nongenetic risk factors associated with CMDs developments. These findings led us to think
about doing other statistical analyses to figure out the association between
cardiometabolic phenotypes and UA genotypes.
We moved to use chi-square or Fisher exact test as appropriate. We found an
interesting significant result in several UA genes that are biologically associated with
cardiometabolic diseases developments across both Filipino and Samoan populations. It
should be noted that these results consistent with the previous study that we found
Asians overall and Filipino, in particular, had the highest prevalence of UA risk alleles
compared to Pacific Islanders population. (Table 2.5) Moreover, in characteristic
clinical information, our results have shown Asian population had a significantly higher
metabolic diseases relative to Native Hawaiian and Pacific Islanders. The same analysis
has found Filipino population had a significant prevalence of metabolic diseases.
In the final analysis, we conducted univariate (ANOVA) to assess the mean of BMI
across the different UA genes. First, we selected equal or unequal ANOVA depend on
the Bartlett’s test results, which assess the homogeneity of variance (Table 3.8 & Table
3.9). We found mean BMI in some genes consistent with biology and literature amongst
the Filipino subgroup, but there was insufficient evidence to support that association.
On the other hand, we found a significantly lower mean of BMI in some UA genes in
both Filipino and Samoan.
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Overall, this study discussed both genetic and genetic risk factors associated with
metabolic syndromes in Filipino and Samoan populations using different statistical
analyses. These findings were found Asian overall, and Filipino subgroup in particular
at high risk of metabolic syndromes due to both UA risk alleles and age/BMI compares
to Pacific Islanders population generally and Samoan.
Section 6.A: The logistic regression analysis results across the whole population
Table1. Association between chronic hypertension and UA risk alleles across the
whole population sample (Simple Logistic regression)
Gene/SNP
Test model
Odds
95% CI
p-value
Ratio
SLC17A1(rs1183201
Additive
T>A)
AA (Reference)
0.87
0.541- 1.475 0.614
AT
TT
Dominant
AA (Reference)
1.68
0.5000.477
Vs.
10.532
AT+TT
Recessive
AA+AT
0.69
0.350- 1.356 0.287
(Reference)
Vs.
TT
SLC22A12(rs505802
Additive
C>T)
TT (Reference)
0.73
0.449-1.236 0.225
CT
CC
Dominant
TT (Reference)
0.53
0.204-1.853 0.258
Vs.
CT+CC
Recessive
CT+TT(Reference) 0.72
0.370-1.424 0.342
Vs.
CC
GCKR (rs780094
Additive
C>T)
CC (Reference)
1.40
0.885-2.228 0.147
CT
TT
Dominant
CC (Reference)
1.27
0.632-2.723 0.515
Vs.
CT+TT
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SLC16A9 (rs2242206
G>T)

LRRC16A (rs742132
G>A)

Recessive
CT+CC
(Reference)
Vs.
TT
Additive
GG (Reference)
GT
TT
Dominant
GG (Reference)
Vs.
GT+TT
Recessive
GT+GG
(Reference)
Vs.
TT
Additive
GG (Reference)
AG
AA
Dominant
GG (Reference)
Vs.
AG+AA
Recessive
AG+GG
(Reference)
Vs.
AA

1.98

0.9228-4.032 0.0647

0.74

0.455-1.189

0.22

0.87

0.436-1.888

0.729

0.40

0.120-1.048

0.096

0.99

0.613-1.655

0.984

1.05

0.409-3.610

0.916

0.96

0.488-1.888

0.924

Table 1.A. CHTN vs. dominant models of UA genotypes + BMI+ age across the
whole population
Measurements
OR
95% CI
p-value
BMI

1.07

1.027-1.118

0.000984 ***

Mother age

1.13

1.070-1.213

5.37e-05 ***

SLC17A1 (rs1183201
T>A)
GCKR (rs780094
C>T)

1.48

0.382-10.106

0.619781

1.20

0.563-2.730

0.641019
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SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)

0.48

0.165-1.769

0.215692

0.80

0.382-1.787

0.578133

0.80

0.277-3.023

0.722494

Table 1.B. CHTN vs. recessive models of UA genotypes + BMI+ age across the
whole population
Measurements
OR
95% CI
p-value
BMI

1.07

1.028-1.120

0.000893 ***

Mother age

1.15

1.081-1.229

1.74e-05 ***

SLC17A1 (rs1183201
T>A)

0.38

0.166-0.865

0.023208 *

GCKR (rs780094
C>T)

1.74

0.726-3.880

0.189174

SLC22A12 (rs505802
C>T)

0.63

0.302-1.320

0.220837

SLC16A9 (rs2242206
G>T)

0.34

8.190963e-02 1.024

0.091488

LRRC16A (rs742132
G>A)

1.17

0.516-2.650

0.697015

Table2. Association between GHTN and UA risk alleles across the whole
population (Logistic regression)
Gene/SNP
Test model
Odds
95% CI
p-value
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Ratio
SLC17A1(rs1183201
T>A)

SLC22A12 (rs505802
C>T)

GCKR (rs780094
C>T)

SLC16A9 (rs2242206
G>T)

Additive
AA (Reference)
AT
TT
Dominant
AA (Reference)
Vs.
AT+TT
Recessive
AA+AT
(Reference)
Vs.
TT
Additive
TT (Reference)
CT
CC
Dominant
TT (Reference)
Vs.
CT+CC
Recessive
CT+TT(Reference)
Vs.
CC
Additive
CC (Reference)
CT
TT
Dominant
CC (Reference)
Vs.
CT+TT
Recessive
CT+CC
(Reference)
Vs.
TT
Additive
GG (Reference)
GT
TT
Dominant
GG (Reference)
Vs.
GT+TT
Recessive
GT+GG
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1.77

0.967-3.580

0.0825

3.00

0.63053.855

0.283

1.89

0.901- 4.236

0.103

0.68

0.408- 1.193

0.165

0.34

0.135- 1.038

0.0341 *

0.78

0.384- 1.647

0.521

1.08

0.655- 1.781

0.743

1.17

0.557- 2.623

0.688

1.05

0.385- 2.445

0.913

0.96

0.577- 1.617

0.904

0.90

0.421- 2.106

0.805

1.02

0.402- 2.312

0.952

LRRC16A (rs742132
G>A)

(Reference)
Vs.
TT
Additive
GG (Reference)
AG
AA
Dominant
GG (Reference)
Vs.
AG+AA
Recessive
AG+GG
(Reference)
Vs.
AA

0.99

0.587- 1.738

0.985

0.85

0.324- 2.936

0.773

0.85

0.324- 2.936

0.773

Table 2.A. GHTN vs. dominant models of UA genotypes +BMI+ mother age
across the whole population
Measurements
OR
95% CI
p-value
BMI

1.07

1.025-1.121

0.001431 **

Mother age

1.03

0.968-1.105

0.307908

SLC17A1 (rs1183201
T>A)

2.82

0.530-52.824

0.329488

GCKR (rs780094
C>T)

1.36

0.576-3.498

0.497834

SLC22A12 (rs505802
C>T)

0.49

0.152-2.205

0.280605

SLC16A9 (rs2242206
G>T)

0.70

0.307-1.700

0.411459

LRRC16A (rs742132
G>A)

0.55

0.193-2.004

0.307878
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Table 2.B. GHTN vs. recessive models of UA genotype +BMI+ mother age across
the whole population
Measurements
OR
95% CI
p-value
BMI

1.07

1.025-1.121

0.00151 **

Mother age

1.03

0.965-1.103

0.35517

SLC17A1 (rs1183201
1.89
T>A)
GCKR (rs780094 C>T) 0.85

0.780-4.924

0.16884

0.240-2.381

0.78913

SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)

0.92

0.411-2.150

0.85971

0.89

0.291-2.292

0.83196

0.80

0.335-1.917

0.63180

Table3. Association between DM and UA risk alleles across the whole population
sample (Logistic regression)
Gene/SNP
Test model
Odds
95% CI
p-value
Ratio
SLC17A1
Additive
(rs1183201 T>A)
AA (Reference)
0.35
0.1750.00299 **
AT
0.702
TT
Dominant
AA (Reference)
0.28
0.0950.032 *
Vs.
1.029
AT+TT
Recessive
AA+AT
0.19
0.0450.012 *
(Reference)
0.620
Vs.
TT
SLC22A12
Additive
(rs505802 C>T)
TT (Reference)
0.77
0.3780.507
CT
1.738
CC
Dominant
TT (Reference)
0.19
0.0660.00621 **
Vs.
0.722
142

GCKR
(rs780094 C>T)

SLC16A9(rs2242206
G>T)

LRRC16A (rs742132
G>A)

CT+CC
Recessive
CT+TT(Reference)
Vs.
CC
Additive
CC (Reference)
CT
TT
Dominant
CC (Reference)
Vs.
CT+TT
Recessive
CT+CC
(Reference)
Vs.
TT
Additive
GG (Reference)
GT
TT
Dominant
GG (Reference)
Vs.
GT+TT
Recessive
GT+GG
(Reference)
Vs.
TT
Additive
GG (Reference)
AG
AA
Dominant
GG (Reference)
Vs.
AG+AA
Recessive
AG+GG
(Reference)
Vs.
AA

1.45

0.5234.639

0.493

0.56

0.2491.162

0.139

0.42

0.1501.149

0.091

0.62

0.0962.248

0.53

0.75

0.3641.522

0.441

0.85

0.3072.732

0.771

0.47

0.0741.723

0.329

0.50

0.2481.005

0.0498 *

0.56

0.1782.495

0.379

0.27

0.0620.857

0.0445 *

Table 3.A. DM vs. dominant models of UA genotypes +BMI+ mother age across
the whole population
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Measurements

OR

95% CI

p-value

BMI

1.07

1.000-1.151

0.035402 *

Mother age

1.21

1.099-1.367

0.000362 ***

SLC17A1 (rs1183201
T>A)
GCKR (rs780094
C>T)
SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)

0.18

4.334797e-02-0.911

0.025620 *

0.47

0.142-1.533

0.208353

0.24

6.489311e-02-1.137

0.050988

0.91

0.279-3.551

0.887322

1.00

0.218-6.625

0.992782

Table 3.B. DM vs. recessive models of UA genotypes+ BMI+ mother age across the
whole population sample
Measurements
OR
95% CI
p-value
BMI

1.07

0.998- 1.148

0.041939 *

Mother age

1.21

1.105-1.360

0.000162 ***

SLC17A1 (rs1183201
T>A)
GCKR (rs780094
C>T)
SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)

0.20

4.008983e-02-0.749

0.027274 *

0.79

0.118-3.190

0.773659

1.54

0.497-5.422

0.463180

0.29

0.155-1.585

0.247074

0.49

9.984576e-02-1.897

0.336590

Table4. Association between GDM and UA risk alleles across the whole population
sample (Logistic regression)
Gene/SNP
Test model
Odds
95% CI
p-value
Ratio
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SLC17A1
(rs1183201 T>A)

SLC22A12(rs505802
C>T)

GCKR (rs780094
C>T)

SLC16A9 (rs2242206
G>T)

Additive
AA (Reference)
AT
TT
Dominant
AA (Reference)
Vs.
AT+TT
Recessive
AA+AT
(Reference)
Vs.
TT
Additive
TT (Reference)
CT
CC
Dominant
TT (Reference)
Vs.
CT+CC
Recessive
CT+TT(Reference)
Vs.
CC
Additive
CC (Reference)
CT
TT
Dominant
CC (Reference)
Vs.
CT+TT
Recessive
CT+CC
(Reference)
Vs.
TT
Additive
GG (Reference)
GT
TT
Dominant
GG (Reference)
Vs.
GT+TT
Recessive
GT+GG
(Reference)
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1.42

1.029-2.000

0.0374 *

1.28

0.634- 2.958 0.521

1.64

1.090- 2.498 0.0188 *

1.04

0.756- 1.453 0.813

1.96

0.785- 6.584 0.201

0.92

0.623- 1.396 0.723

0.90

0.680- 1.192 0.476

0.861

0.574- 1.304 0.476

0.88

0.512- 1.473 0.663

0.84

0.635- 1.117 0.238

0.65

0.432- 0.999 0.0464 *

1.03

0.635- 1.632 0.89

LRRC16A (rs742132
G>A)

Vs.
TT
Additive
GG (Reference)
AG
AA
Dominant
GG (Reference)
Vs.
AG+AA
Recessive
AG+GG
(Reference)
Vs.
AA

1.25

0.931- 1.717 0.141

1.57

0.810- 3.436 0.214

1.27

0.855- 1.898 0.232

Table 4.A. GDM vs. dominant models of UA genotype + BMI+ age across the
whole population
Measurements
OR
95% CI
p-value
BMI

1.04

1.011-1.070

0.00588 **

Mother age

1.10

1.064-1.144

9.12e-08 ***

SLC17A1 (rs1183201
T>A)
GCKR (rs780094 C>T)

1.20

0.526-3.271

0.68266

0.75

0.481-1.185

0.21606

SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)

2.00

0.756-6.957

0.20840

0.62

0.395-0.982

0.03914 *

1.95

0.862-5.268

0.14114

Table 4.B. GDM vs. Recessive models of UA genotype + BMI+ age across the
whole population
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Measurements

OR

95% CI

p-value

BMI

1.03

1.008-1.068

0.00894 **

Mother age

1.10

1.062-1.142

2.02e-07 ***

SLC17A1 (rs1183201
1.35
T>A)
GCKR (rs780094 C>T) 0.69

0.842-2.189

0.21441

0.373-1.219

0.22306

SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)

1.04

0.675-1.633

0.84342

1.16

0.692-1.906

0.55293

1.04

0.656-1.649

0.86408
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Section 6.B: The simple model between phenotype versus BM and phenotype versus
both age/BMI
Association of BMI + Age (non-genetic factors) with Cardiometabolic diseases
(CMD) in Filipino and Samoan (Simple model)
A. Filipino subgroup
Chronic hypertension
Filipino, CHTN, (Global test)
CHTN vs. BMI
Adjusted R-square
Global statistic
0.0214
2.797

BMI

DF
1

Filipino, CHTN, (second hypothesis test)
OR
SE
95% CI
1.05
0.032
0.98- 1.12

Filipino, CHTN, (Global test)
CHTN vs. BMI + mother age
Adjusted R-square
Global statistic
0.07
9.602

BMI
Age

DF
2

Filipino, CHTN, (second hypothesis test)
OR
SE
95% CI
1.06
0.033
0.99- 1.13
1.11
0.044
1.02- 1.22
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P-value
0.094

p-value
0.081

P-value
0.008

p-value
0.06
0.01 *

Gestational hypertension
Filipino, GHTN, (Global test)
GHTN vs. BMI
Adjusted R-square
Global test
0.0334
1.311

BMI

DF
1

P-value
0.252

Filipino, GHTN, (second hypothesis test)
OR
SE
95% CI
1.07
0.055
0.93- 1.18

Filipino, GHTN, (Global test)
GHTN vs. BMI + mother age
Adjusted R-square
Global test
0.034
1.34
GHTN, (second hypothesis test)
OR
BMI
1.07
Mothers Age
1.01

DF
2

SE
0.056
0.084
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p-value
0.193

P-value
0.511

95% CI
0.93-1.19
0.85- 1.20

p-value
0.193
0.860

Diabetes Mellitus
Filipino, DM, (Global test)
DM vs. BMI
Adjusted R-square
Global test
0.0008
1.34

BMI

DF
1

P-value
0.246

Filipino, DM, (second hypothesis test)
OR
SE
95% CI
0.98
0.103
0.76- 1.14

Filipino, DM, (Global test)
DM vs. BMI + mother age
Adjusted R-square
Global Test
0.067
2.09

DF
2

Filipino, DM, (second hypothesis test)
OR
SE
BMI
0.98
0.101
Mothers Age
1.16
0.118
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p-value
0.877

P-value
0.351

95% CI
0.77- 1.16
0.94- 1.53

p-value
0.880
0.190

Gestational diabetes mellitus (GDM)
Filipino, GDM, (Global test)
GDM vs. BMI only
Adjusted R-square
Global test
0.0017
0.381

BMI

DF
1

Filipino, GDM, (second hypothesis test)
OR
SE
95% CI
1.01
0.026
0.96- 1.07

Filipino, GDM, (Global test)
GDM vs. BMI + mother age
Adjusted R-square
Global test
0.86
14.25

BMI
Mothers Age

DF
2

Filipino, GDM, (second hypothesis test)
OR
SE
95% CI
1.01
0.027
0.96- 1.07
1.11
0.031
1.05- 1.19
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P-value
0.536

p-value
0.532

P-value
8.03e-04

p-value
0.512
0.457

B. Samoan sub-group
Chronic hypertension
CHTN, (Global test)
CHTN vs. BMI only
Adjusted R-square
0.055

BMI

Global statistic
3.243

DF
1

Samoan, CHTN, (second hypothesis test)
OR
SE
95% CI
1.09
0.051
0.99- 1.21

Samoan, CHTN, (Global test)
CHTN vs. BMI + mother age
Adjusted R-square
Global statistic
0.07
4.25

BMI
Age

DF
2

Samoan, CHTN, (second hypothesis test)
OR
SE
95% CI
1.08
0.051
0.98-1.20
1.06
0.064
0.93- 1.21

152

P-value
0.071

p-value
0.075

P-value
0.119

p-value
0.103
0.304

Gestational hypertension
Samoan, GHTN, (Global test)
GHTN vs. BMI only
Adjusted R-square
Global statistic
0.0598
4.241

BMI

DF
1

Samoan, GHTN, (second hypothesis test)
OR
SE
95% CI
1.09
0.045
1.004- 1.205

Samoan, GHTN, (Global test)
GHTN vs. BMI + mother age
Adjusted R-square
Global statistic
0.073
5.242

BMI
Age

DF
2

Samoan, GHTN, (second hypothesis test)
OR
SE
95% CI
1.10
0.048
1.01- 1.22
0.93
0.071
0.79- 1.06
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P-value
0.039

p-value
0.042 *

P-value
0.072

p-value
0.031 *
0.341

Diabetes mellitus
Samoan, DM, (Global test)
DM vs. BMI only
Adjusted R-square
Global statistic
0.026
1.39

DF
1

Samoan, DM, (second hypothesis test)
BMI
OR
SE
1.06
0.053
Samoan, DM, (Global test)
DM vs. BMI + mother age
Adjusted R-square
Global statistic
0.086
4.49

P-value
0.237

95% CI
0.95- 1.18

DF
2

Samoan, DM, (second hypothesis test)
OR
SE
BMI
1.05
0.054
Age
1.12
0.066
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p-value
0.236

P-value
0.105

95% CI
0.94- 1.17
0.98- 1.28

p-value
0.328
0.074

Gestational diabetes mellitus
Samoan, GDM, (Global test)
GDM vs. BMI only
Adjusted R-square
Global statistic
0.014
1.71

DF
1

Samoan, GDM, (second hypothesis test)
BMI
OR
SE
1.04
0.031

Samoan, GDM, (Global test)
GDM vs. BMI + mother age
Adjusted R-square
Global statistic
0.116
13.92

P-value
0.189

95% CI
0.97- 1.11

DF
2

Samoan, GDM, (second hypothesis test)
OR
SE
BMI
1.03
0.033
Age
1.15
0.041
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p-value
0.189

P-value
9.48e-04

95% CI
0.96- 1.10
1.06- 1.25

p-value
0.380
0.0006 ***

Table1. A. Shows the global hypothesis test results of multiple logistic
regression (additive model) of chronic hypertension (CHTN) vs. BMI +
Mother’s age + uric acid (UA) genes across the Filipino population
Adjusted R-square
Test statistic
DF
pvalue
0.17
12.69
9
0.177
Section 6.C. multiple logistic regression analyses conducting on the separate groups

Table 1.A.1 Shows the secondary hypothesis results of multiple logistic
regression of CHTN vs. BMI+ mother age+ Additive model of UA genes
across the Filipino population
Measurements
OR
95% CI
p-value
BMI
1.03
0.92-1.14
0.490
Mother age
1.14
1.01-1.31
0.047*
SLC17A1 (rs1183201
T>A)
GCKR (rs780094
C>T)
SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)
SLC22A11(rs17300741

0.87

0.24-3.88

0.848

0.94

0.35-2.48

0.913

1.31

0.39-6.75

0.713

0.33

0.08-0.99

0.070

1.21

0.40-4.30

0.741

2.05

0.50-15.04

0.385

ABCG2(rs2231142
G>T)

1.27

0.44-3.66

0.648
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Table 1.B. Shows the global hypothesis test results of multiple logistic
regression (dominant model) of CHTN vs. BMI + Mother’s age + UA genes
across the Filipino population
Adjusted R-square
Test statistic
DF
p-value
0.16
12.23
9
0.200
Table 1.B.1. Shows the secondary hypothesis results of multiple logistic
regression of CHTN vs. BMI+ mother age+ Dominant models of UA genes
across the Filipino population
Measurements
OR
95% CI
p-value
BMI
1.03
0.93- 1.13
0.489
Mother age
1.15
1.02- 1.32
0.032 *
SLC17A1 (rs1183201
T>A)
GCKR (rs780094
C>T)
SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)
SLC22A11(rs17300741
A>G)
ABCG2(rs2231142
G>T)

1.06e+07

2.86e-90-NA

0.995

7.84e-01

018- 4.08

0.751

7.10e+06

5.81e-81-NA

0.995

0.36

8.28e-02- 1.49

0.162

0.70

9.01e-021.51e+01
4.899638e-64NA
0.36-14.23

0.769

8.35e+06
1.82

0.995
0.500

Table 1.C. Shows the global hypothesis test results of multiple logistic
regression of CHTN vs. BMI + Mother’s age + UA genes across the
Filipino population
Adjusted R-square
Test statistic
DF
pvalue
0.19
12.36
9
0.193
Table 1.C.1 Shows the secondary hypothesis results of multiple logistic
regression of CHTN vs. BMI+ mother age+ Recessive models of UA genes
across the Filipino population
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Measurements
BMI
Mother age

OR
1.06
1.15

95% CI
0.95- 1.16
1.01- 1.36

p-value
0.233
0.049*

SLC17A1 (rs1183201
T>A)
GCKR (rs780094
C>T)
SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)
SLC22A11(rs17300741
A>G)
ABCG2(rs2231142
G>T)

0.68

0.14- 3.59

0.641

2.06

0.25- 1.32

0.449

1.58

0.35- 8.60

0.562

2.90e-08

NA - 7.40e+49

0.99

1.21

0.24- 6.33

0.810

2.30

0.43-18. 82

0.367

1.12

0.14- 6.18

0.896

Table 2.A. Shows the global hypothesis test results of multiple logistic
regression of diabetes mellitus (DM) vs. BMI + Mother’s age + UA genes
across the Filipino population
Adjusted R-square
Test statistic
DF
p-value
0.17
5.19
9
0.816

Table 2.A.1 Shows the secondary hypothesis results of DM vs. BMI+ mother
age+ Additive models of UA genes across the Filipino population
Measurements
OR
95% CI
p-value
BMI
0.99
0.78- 1.21
0.970
Mother age
1.16
0.92-1.64
0.260
SLC17A1
(rs1183201 T>A)
GCKR (rs780094
C>T)
SLC22A12
(rs505802 C>T)
SLC16A9
(rs2242206 G>T)
LRRC16A
(rs742132 G>A)
SLC22A11
(17300741 A>G)
ABCG2(rs2231142
G>T)

0.74

8.51e-02 - 7.51

0.778

1.04

0.19- 5.57

0.958

0.48

5.74e-02 - 4.40

0.482

0.56

6.05e-02 - 3.98

0.574

0.37

4.35e-02 - 2.38

0.306

1.00

0.10 - 27.68

0.995

2.39

0.38 - 20.50

0.362

Table 2.B. Shows the global hypothesis test results of multiple logistic regression
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of DM vs. BMI + Mother’s age + UA genes across Filipino population
Adjusted R-square
Test statistic
DF
p-value
0.36
10.59
9
0.304
Table 2.B.1 Shows the secondary hypothesis results of logistic regression of DM vs.
BMI+ mother age+ Dominant models of UA genes across the Filipino population
Measurements
OR
95% CI
p-value
BMI
0.97
0.74 - 1.21
0.858
Mother age
1.32
1.01- 2.06
0.091
SLC17A1
(rs1183201 T>A)
GCKR (rs780094
C>T)
SLC22A12
(rs505802 C>T)
SLC16A9
(rs2242206 G>T)
LRRC16A
(rs742132 G>A)
SLC22A11
(17300741 A>G)
ABCG2(rs2231142
G>T)

1.154e+08

5.24e-192 – NA

0.996

2.00

0.10 - 78.61

0.659

3.98e-03

1.46e-06 - 0.34

0.038 *

0.67

4.11e-02 - 17.83

0.775

9.95e-03

1.72e-06 - 0.86

0.097

4.51e+06

3.13e-234 – NA

0.997

0.10

1.19e-04 - 5.31

0.314

Table 2.C. Shows the global hypothesis test results of multiple logistic regression of
DM vs. BMI + Mother’s age + UA genes across the Filipino population
Adjusted R-square
Test statistic
DF
p-value
0.26
7.64
9
0.570

Table 2.C.1 Shows the secondary hypothesis results of DM vs. BMI+
mother age+ Recessive models of UA genes across the Filipino population
Measurements
OR
95% CI
p-value
BMI
0.90
0.71- 1.18
0.708
Mother age
1.15
0.91- 1.61
0.279
SLC17A1 (rs1183201 0.23
T>A)
GCKR (rs780094
1.63
C>T)
SLC22A12 (rs505802 1.97

8.14e-03 - 3.47

0.303

6.53e-02 – 24.40

0.717

0.14 – 54.02

0.624
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C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)
SLC22A11(17300741
A>G)
ABCG2(rs2231142
G>T)

7.92e-08

NA - 1.08e+160

0.995

0.57

2.27e-02 - 7.83

0.685

0.62

3.56e-02 – 15.79

0.731

6.97

0.581 - 1.73e+02 0.139

Table 3.A. Shows the global hypothesis test results of multiple logistic
regression of gestational hypertension (GHTN) vs. BMI + Mother’s age +
UA genes across Filipino population
Adjusted R-square
Test statistic
DF
pvalue
0.71
15.00
9
0.090

Table 3.A.1 Shows the secondary hypothesis results of GHTN vs. BMI+
mother age+ Additive models of UA genes across Filipino population
Measurements
OR
95% CI
p-value
BMI
0.69
0.21 - 1.60
0.518
Mother age
013
1.55e-03 – 0.52
0.358
SLC17A1
(rs1183201 T>A)
GCKR (rs780094
C>T)
SLC22A12
(rs505802 C>T)
SLC16A9
(rs2242206 G>T)
LRRC16A
(rs742132 G>A)
SLC22A11
(17300741 A>G)
ABCG2(rs2231142
G>T)

7.59e+13

0.00 - NA

0.998

4.60e-02

0.654

1.73e-02

4.95e-12 5.08e+03
2.03e-24 2.15e-02
1.03e-05 - 1.34

5.52e+20

0.0000 – NA

0.996

2.82e+12

0.0000 - NA

0.998

1.81e+10

1.64e+03 5.07e+33

0.368

2.09e-07
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0.411
0.261

Table 3.B. Shows the global hypothesis test results of multiple logistic
regression of GHTN vs. BMI + Mother’s age + UA genes across the Filipino
population
Adjusted R-square
Test statistic
DF
p-value
0.33
6.97
9
0.639

Table 3.B.1 Shows the secondary hypothesis results of GHTN vs. BMI+
mother age+ Dominant model of UA genes across Filipino population
Measurements
OR
95% CI
p-value
BMI
1.23
0.97 - 1.686
0.098
Mother age
0.82
0.54 - 1.142
0.264
SLC17A1 (rs1183201
T>A)
GCKR (rs780094
C>T)
SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)
SLC22A11(17300741
A>G)
ABCG2(rs2231142
G>T)

4.65e+06

0.0000 – NA

0.999

0.28

0.007 - 9.126

0.425

1.96e+07

0.0000 - NA

0.999

0.37

0.009 - 19.681

0.573

4.22e+07

0.000 - NA

0.998

1.26e+08

0.000 - NA

0.999

3.18e+09

0.000 - NA

0.996

Table 3.C. Shows the global hypothesis test results of multiple logistic
regression of GHTN vs. BMI + Mother’s age + UA genes across the
Filipino population
Adjusted R-square
Test statistic
DF
pvalue
0.64
13.66
9
0.134

Table 3.C.1 Shows the secondary hypothesis results of multiple logistic
regression of GHTN vs. BMI+ mother age+ Recessive model of UA genes
across the Filipino population
Measurements
OR
95% CI
p-value
BMI
1.09
0.52-2.16
0.760
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Mother age

0.57

7.85e-02 - 1.10

0.326

SLC17A1 (rs1183201
T>A)
GCKR (rs780094
C>T)
SLC22A12 (rs505802
C>T)
SLC16A9 (rs2242206
G>T)
LRRC16A (rs742132
G>A)
SLC22A11(17300741
A>G)
ABCG2(rs2231142
G>T)

9.68e+08

0.0000 – NA

0.998

3.05e-06

NA - INF

0.999

3.37e-02

8.782e- 07 - 6.06 0.356

2.38e-10

NA – INF

0.999

3.29e+10

0.000 – NA

0.998

2.54e+11

0.000 – NA

0.998

8.52e+02

0.17 - 3.69e+14

0.371

Table 4.A. Shows the global hypothesis test results of multiple logistic
regression of gestational diabetes (GDM) vs. BMI + Mother’s age + UA
genes additive model across the Filipino population
Adjusted R-square
Test statistic
DF
p-value
0.06
9.72
9.0
0.37
Table 4.A.1 Shows the secondary hypothesis results of multiple logistic
regression of GDM vs. BMI+ mother age+ dominant models of UA genes
across the Filipino population
Measurements
OR
95% CI
p-value
BMI
1.00
-0.05-0.07
0.799
Mother age
1.09
.027-0.16
0.007
SLC17A1
(rs1183201 T>A)
GCKR
(rs780094 C>T)
SLC22A12
(rs505802 C>T)
SLC16A9
(rs2242206 G>T)
LRRC16A
(rs742132 G>A)
ABCG2(rs2231142
G>T)
SLC22A11
(17300741 A>G)

1.11

-0.67-0.95

0.787

0.71

-0.91-0.23

0.254

0.98

-0.73-0.75

0.978

0.82

-0.76-0.38

0.521

1.02

-0.63-0.70

0.936

0.80

-0.79-0.38

0.508

1.22

-0.54-1.04

0.607
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Table 4.B. Shows the global hypothesis test results of multiple logistic
regression of GDM vs. BMI + Mother’s age + UA genes in dominant
model across the Filipino population
Adjusted R-square
Test statistic
DF
pvalue
0.12
19.38
9.0
0.022

Table 4.B.1 Shows the secondary hypothesis results of multiple logistic
regression of GDM vs. BMI+ mother age+ dominant model of UA genes
across the Filipino population
Measurements
OR
95% CI
p-value
BMI
9.9-01
-0.07-0.05
0.985
Mother age
1.09
0.02-0.16
0.009
SLC17A1
(rs1183201 T>A)
GCKR (rs780094
C>T)
SLC22A12
(rs505802 C>T)
SLC16A9
(rs2242206 G>T)
LRRC16A
(rs742132 G>A)
ABCG2(rs2231142
G>T)
SLC22A11
(17300741 A>G)

1.70+07

-147.13-NA

0.992

8.67-01

-1.03-0.78

0.758

1.52+07

-161.88-NA

0.992

5.49-01

-1.44-0.26

0.168

1.47

-1.10-2.34

0.643

7.77-01

-160-0.68

0.589

1.58+07

3.12-

0.992

Table 4.C. Shows the global hypothesis test results of multiple logistic
regression of GDM vs. BMI + Mother’s age + uric acid genes across
Filipino population (recessive)
Adjusted R-square
Test statistic
DF
pvalue
0.08
12.7
9.0
0.173
Table 4.C.1 Shows the secondary hypothesis results of GDM vs. BMI+
mother age+ Recessive models of UA genes across the Filipino population
Measurements
OR
95% CI
p-value
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BMI
Mother age

1.01
1.10

-0.05-0.07
0.03-0.17

0.699
0.004

SLC17A1
(rs1183201 T>A)
GCKR (rs780094
C>T)
SLC22A12
(rs505802 C>T)
SLC16A9
(rs2242206 G>T)
LRRC16A
(rs742132 G>A)
ABCG2(rs2231142
G>T)
SLC22A11
(17300741 A>G)

1.00

-0.91-0.96

0.994

0.31

-2.46—0.08

0.051

0.97

-0.86-0.84

0.957

1.42

-0.65-1.30

0.478

0.91

-0.96-0.80

0.851

0.74

-1.41-0.70

0.582

0.90

-0.98-0.83

0.829
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